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ABSTRACT 
 
The use of combination antiretroviral therapy (cART) in individuals infected by 
human immunodeficiency virus type 1 (HIV-1) resulted in substantial reductions in 
morbidity and mortality in many countries worldwide.  
Successful treatment increases levels of CD4+ T cells and suppresses virus 
replication. However, persistent immune activation and inflammation remained 
significantly elevated in these individuals. Several studies associated chronic immune 
activation with an increased risk of non-AIDS associated morbidity and mortality during 
treated HIV infection, such as cardiovascular disease, metabolic disorders, 
neurocognitive abnormalities, liver and renal diseases, osteoporosis and neoplasias. 
The exact mechanisms responsible for persistent immune activation in HIV-1 
infected individuals are not entirely understood. Some studies proposed ongoing viral 
replication in anatomical sites such as the gastrointestinal tract, where antiretroviral 
therapy may not reach inhibitory levels. Others, however, suggested that microbial 
translocation through damaged gut mucosa was the main driver mechanism of 
inflammation and immune activation via secretion of pro-inflammatory cytokines. While 
others highlighted the influence of frequent HIV-1 coinfections, such as with hepatitis C 
virus (HCV), as key potential determinants of persistent immune activation.  
The aim of the study was to further investigate which factors could contribute to 
chronic immune activation and disease progression in HIV-1 infected individuals. 
Microbial translocation, inflammation, immune activation, coinfection with Leishmania 
and the influence of HTLV-2 coinfection frequently found in HIV-1/HCV coinfected and 
HIV-1-monoinfected patients, were analyzed. 
HIV-1 infected patients with regular medical appointments in the Hospital Ramón 
y Cajal, in Madrid, Spain, were analyzed in this study. All participants were grouped 
based on immunological and virological characteristics into three well-differentiated 
scenarios. Within the first scenario, the effect of treatment intensification was evaluated 
on HIV-1 infected individuals with good immune recovery. The second scenario 
included patients with leishmaniasis compared to two control groups that encompassed 
both immunological discordant responders and concordant patients to cART. Finally, 
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the third scenario included the influence of HTLV-2 infection on HIV-1/ HCV 
coinfected and HIV-1 monoinfected individuals.  
Results showed reduced immune activation in HIV-1 infected individuals ongoing 
treatment intensification. However, no parallel decrease was found on microbial 
translocation, which in fact increased during the maraviroc intensification follow-up 
period. There was good correlation between the techniques employed to measure 
microbial translocation, including levels of LPS, LBP and sCD14, though no correlation 
was found between these measurements and immune activation in long term 
suppressed patients.  
HIV-1 infected individuals coinfected with Leishmania showed higher levels of 
activated CD8+ T cells, IL-6, sCD14 and activated CD8+ T cell senescence when 
compared to immunological non-responders to antiretroviral treatment. 
HTLV-2 infection in HIV-1 infected individuals showed lower plasma HIV RNA 
levels before starting antiretroviral therapy, and higher levels of CD8+ T cell count when 
compared to individuals non infected by HTLV-2. Moreover, HIV-1/HCV coinfected 
individuals also infected by HTLV-2 showed decreased levels of activated CD8+ T cells, 
and also lower levels of both alanine transaminase and liver fibrosis.  
In conclusion, this study demonstrated that microbial translocation is associated 
with inflammation and immune activation in HIV-1 infected patients. However, this 
association was not so evident in long-term suppressed individuals with relatively good 
immune recovery on treatment intensification. Besides, coinfection with Leishmania 
aggravated the HIV-1-associated immunosuppression with immune characteristics 
worse than those found in immunological non-responders to antiretroviral treatment. 
And finally, we corroborated the protective role of HTLV-2 infection on HIV-1 infection 
and disease progression, and evidenced further beneficial role of HTLV-2 infection in 
HIV-1/HCV coinfected individuals, reducing immune activation and decreasing risk of 
HCV-associated liver diseases.  
 
 
 
Abstract 
3 
 
RESUMEN 
 
La implantación de tratamiento antirretroviral de alta eficacia (TARGA) en 
pacientes infectados por el virus de la inmunodeficiencia humana tipo 1 (VIH-1) ha 
reducido considerablemente la morbilidad y mortalidad de estos pacientes a nivel 
mundial. La terapia antirretroviral controla la replicación viral y contribuye a la 
recuperación inmunológica del individuo. 
No obstante, a pesar de disminuir los niveles de inflamación y activación 
inmunológica, estos niveles permanecen significativamente elevados. Varios estudios 
han relacionado la expresión de marcadores de inflamación con un peor pronóstico 
clínico y eventos no-SIDA como enfermedades cardiovasculares, neurocognitivas, 
metabólicas, osteoporosis, enfermedades hepáticas y renales, y cáncer. 
Los mecanismos responsables de la activación inmune en individuos infectados 
por VIH-1 continúa siendo tema de controversia. Algunos estudios señalan continuos 
ciclos de replicación viral como posible factor desencadenante de una activación 
crónica generalizada. Esta replicación viral, a niveles indetectables por métodos 
convencionales, podría estar sucediendo en lugares anatómicos como el tejido linfoide 
asociado al intestino, donde el tratamiento antirretroviral podría no alcanzar los niveles 
inhibitorios óptimos. Otros estudios, en cambio, proponen la translocación bacteriana 
como un proceso desencadenante de inflamación local y activación inmune mediante 
la secreción de citoquinas proinflamatorias. Estos fenómenos se agravarían en 
presencia de coinfecciones, frecuentemente producidas en individuos infectados por 
VIH-1, entre las que destaca el virus de la hepatitis C (VHC). 
La finalidad de este estudio es contribuir a clarificar los efectos que pueden tener 
varios factores biológicos en la activación inmune persistente asociada a la infección 
por VIH-1, en particular, la translocación bacteriana y subsecuente expresión de 
citoquinas proinflamatorias, y la influencia de algunas coinfecciones frecuentes en este 
tipo de pacientes, ya sea parasitaria, como la infección por Leishmania., o víricas 
como la infección por  VHC y el virus linfotrópico de células T humanas (HTLV). 
En este estudio se incluyeron individuos infectados por VIH-1 que acuden 
periódicamente a revisiones médicas en el Hospital Ramón y Cajal, en Madrid. Los 
pacientes se analizaron de manera separada atendiendo a características 
inmunológicas y virológicas en un total de tres grupos claramente diferenciados. El 
Abstract 
4 
 
primero de ellos incluía individuos con una buena recuperación inmunológica que 
comenzaron intensificación con tratamiento como estrategia para reducir la replicación 
viral residual. El segundo grupo lo componen individuos con leishmania visceral cuyos 
parámetros analizados los comparamos con dos grupos control formados por 
individuos con respuesta concordante o discordante a tratamiento. Finalmente, el 
último grupo de estudio se compone de una gran cohorte de individuos infectados por 
VIH-1 coinfectados por HTLV-2 y VHC.  
Los resultados muestran una reducción en la activación inmune de individuos 
infectados que se someten a intensificación de tratamiento con maraviroc o raltegravir. 
Sin embargo, sólo en aquellos pacientes que recibieron maraviroc  se observó  un  
incremento en los niveles de translocación bacteriana. Las técnicas utilizadas para 
medir el grado de translocación bacteriana correlacionan entre sí, sin embargo no se 
observa correlación entre la translocación bacteriana y la activación inmune. 
Los individuos coinfectados por Leishmania muestran niveles de activación 
inmune, inflamación, translocación bacteriana y senescencia celular superiores a los 
individuos inmunológicamente discordantes a tratamiento. 
Por otro lado, la coinfección por HIV-1/HTLV-2 muestra menores niveles de 
carga viral por VIH-1 previo inicio de tratamiento, además de mayores niveles de 
células T CD8+ en comparación con individuos negativos para HTLV-2. En individuos 
coinfectados por HIV-1/HCV, la infección por HTLV-2 muestra menores niveles de 
activación celular, alanina transaminasa y fibrosis hepáticas que aquellos individuos no 
infectados por HTLV-2. 
En conclusión, este estudio demuestra que los niveles de translocación 
bacteriana se asocian con la inflamación y activación inmune en individuos infectados 
por VIH-1. Sin embargo, esta asociación no se evidencia en individuos virológicamente 
suprimidos en tratamiento bajo un largo periodo de tiempo. Por otro lado, la 
coinfección por Leishmania acelera el nivel de inmunosupresión relacionado con la 
infección por VIH-1 con características inmunológicas peores que individuos 
inmunológicamente discordantes a tratamiento. Por último, la infección por HTLV-2 
ejerce una función protectora en la infección por VIH-1 ralentizando la progresión a 
SIDA, y se evidencia por primera vez que esta función protectora  es extensible a la 
infección por VHC, disminuyendo la hepatotoxicidad asociada.  
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ANTIRETROVIRAL THERAPY: SUCCESSES AND CHALLENGES 
 
 
Thirty decades after the recognition of acquired immunodeficiency syndrome 
(AIDS) in United States, HIV-1 has spread throughout the world, with growing 
heterogeneity. In 2010, the estimated number of people with HIV-1 world-wide was 
over 34 million people1, more than 95% living in low-and middle-income countries. The 
number of people infected by HIV-1 is expected to increase, mostly because of 
inadequate access to prevention and treatment2. 
 
1.1 From lethal disease to chronic pathology: 1996 
 
The AIDS mortality in 1993 was the leading cause of death among persons ages 
25 to 44 years3. However, after 1996, the number of deaths among people with AIDS 
drops every year since then. According to the Centers for Disease Control and 
Prevention (CDC), AIDS mortality fell from more than 51,000 in 1995 to about 16,000 in 
2002 (Figure 1.1). These dramatic declines in AIDS mortality rate were due largely to 
the availability of combination antiretroviral therapy4-5, although with differences among 
demographic areas6.  
In this way, the development of antiretroviral therapy (ART) has been one of the 
greatest accomplishments of basic and translational research of the late 20th century. 
Combination ART (cART) with at least three drugs has resulted in substantial 
reductions in morbidity and mortality in many countries worldwide7.  
Successful cART increases levels of CD4+ T cells and reduces HIV-1 viral load 
indefinitely to undetectable levels (below 40 HIV-1 RNA copies/ml)8. Besides, cART 
has proven efficacious in HIV prevention, reducing the risk of HIV-1 viral transmission 
from mother-to-child and serving as post-exposure prophylaxis for individuals exposed 
to HIV-19-10.  
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Figure 1.1 The estimated AIDS mortality from 1981 until 2008 in United States 
(www:cdc.gov) 
 
 
 
1.2 Limitations of antiretroviral therapy 
 
 Although lifelong suppression of HIV-1 replication with cART should be possible 
in adherent patients, as soon as treatment is stopped, HIV-1 viremia rapidly 
rebounds11-12. 
Additionally, despite the inherent potency of cART to suppress virus replication, 
full life expectancy for patients living with HIV-1 has not been restored, remaining 
significantly less than population controls. Although ongoing refinements to improve the 
increased risk of morbidity and mortality, HIV-1-associated complications persist, 
including increased risk of cardiovascular disease, metabolic disorders, neurocognitive 
abnormalities, liver and renal disease, osteoporosis, and cancer 13-21. 
The exact mechanisms responsible for this increased risk are not entirely 
understood, however, toxic effects of long-term antiretroviral treatment22 or persistence 
of immune activation and inflammation emerged as key potential determinants of non-
AIDS associated morbidity and mortality during treated HIV-1 infection23. 
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PERSISTENT INMUNE ACTIVATION 
 
Chronic immune activation is a characteristic feature of progressive HIV-1 
disease24-25. Generalized immune activation contribute to the inefficiency of the HIV-1 
immune response and to the impairment of the regenerative potential of the entire 
immune system, including deleterious effects on  generation of effective immune 
responses and on T-cell homeostasis and changes in the composition of lymphoid 
tissues that impede immune function26. The increase in immune activation and 
inflammation is also accompanied by HIV-1 specific exhaustion of CD4+ and CD8+ T 
cells, defined by decreased proliferative and effector functions, alterations in homing 
receptor expression patterns consistent with migration to sites of inflammation and 
increased expression of inhibitory receptors such as PD-1, or CTLA-4 on T cells27-28.  
The most widely accepted evidence that immune activation plays a major role in 
HIV-1 immunopathogenesis is the nonpathogenic outcome of SIV infection in its natural 
host. SIV-infected sooty mangabeys (SM) have strikingly low levels of immune 
activation in the chronic stage of infection and almost never develop immunodeficiency 
despite high levels of SIV viremia29. Conversely, SIV infection of rhesus macaques 
(RM) and other non-natural hosts results in high levels of systemic immune activation 
despite having lower or similar levels of SIV viremia, CD4+ T cell depletion, and rapid 
progression to clinical manifestations similar to AIDS30-31. It remains unclear, however, 
how the natural hosts of SIV infection are able to maintain low levels of immune 
activation despite high levels of viral replication. 
 
1.3  Immunological non-response  to cART 
 
Abnormally high levels of T cell activation persist despite years of ART-mediated 
viral suppression compared to uninfected individuals32. Control of HIV-1 replication 
reduces CD4+ T cell loss from direct cytolysis33-34, and partially restores T cell 
homeostasis35, increasing the number of CD4+ T cell count. Although many patients 
continue to have CD4+ T cell recovery for several years after receiving ART36, from 6% 
to 30% patients known as immunological non-responders (INR) or immunologic 
discordant patients (ID) failed to increase their absolute counts of CD4+ T cells37-39, 
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having increased risk of non-AIDS-related complications40-41 and detrimental clinical 
consequences42-43.  
Elevated immune activation has been established as a marker of disease 
progression in untreated patients44-45. Even though its role during viral suppression may 
be less significant46, compelling evidences for decreased thymic production47 and 
increased CD4+ T cell hyperactivation that undergo rapid proliferation and subsequent 
cellular apoptosis seems to have a significant effect on CD4+ T cell recovery during 
ART48-49 (Figure 1.2).  
These findings were consistent with other studies in which elevated CD4+ T cell 
activation was observed in patients with idiopathic CD4 lymphopenia (ILC) who have 
low CD4+ T cells counts in the absence of HIV-145, suggesting that CD4+ T cell 
activation may be at least partly related to lymphopenia-driven T cell proliferation50-51. 
Although highlighting the possible pathogenic role of enhanced CD4+ T cell activation 
in well suppressed HIV-1-infected individuals, these findings also raise the questions 
on the driver mechanisms of persistently elevated CD4+ T cell activation52. 
 
 
 
 
 
 
 
 
Figure 1.2 Activated CD4+ T cells undergo proliferation and 
apoptosis having a significant effect on CD4+ T cell recovery 
during HAART.  (Modified from Gazzola et al, 2008 52). 
Full immunological 
response 
Immunological non-
responders 
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1.4  Immunosenescence 
 
Ongoing HIV-1-related immune dysfunction and inflammation during ART 
underlies premature aging in HIV-1-infected individuals53-55. Several physiological 
alterations and comorbidities related to old ages, such as osteoporosis, 
atherosclerosis, and neurocognitive decline, occurs in HIV-1 disease56-59.  
During aging, a reduction in T cell renewal together with progressive enrichment 
of terminally differentiated T cells occurs. Remarkably similar, HIV-1 reduces the 
capacity of the thymus to produce new cells60-62. Continuous stimulation of the immune 
system in HIV-1 disease with loss of CD4+ T cells by activation-induced cell death 
coupled with poor T-cell restoration due to lower thymic function results in an impaired 
T-cell homeostasis. The naïve T-cell pool cannot be replenished efficiently, and 
therefore old senescent CD8+ T cell clones or depleted CD4+ T cells cannot either be 
replaced, leading to an imbalance in T-cell phenotypes, similar to that observed in the 
elderly63-65. 
HIV-1 infection induces premature aging of naïve CD4+ T cells and both memory 
CD4+ and CD8+ T cells. Levels of cellular activation (CD38+ HLA-DR+)66-68 are the 
major driving factor of proliferation and T-cell differentiation, resulting in the generation 
of antigen-experienced cells with limited proliferative potential that eventually lose 
expression of CD28 and increase the expression of CD57, which is a key predictor of 
immune incompetence in the elderly and HIV-1-infected individuals69-71. 
The association of HIV-1-related immune dysfunction and non-AIDS defining co-
morbidities and premature aging is represented in the figure 1.3. The accelerated aging 
model in HIV-1 infection would start with ongoing HIV-1-related immune activation 
despite cART as the central event in the senescent pathway. Activated T cells undergo 
clonal expansion due to circulating antigen, resulting in differentiation and accumulation 
of nonfunctional end stage senescent cells that cannot be replenished due to the loss 
of thymic function altering T cell homeostasis increasing the risk of developing non-
AIDS morbidities associated to HIV-1-associated immune activation and 
inflammation72. 
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Figure 1.3 Accelerated aging model in HIV-1 infection (Modified from Desai et al, 201065). 
 
 
PERSISTENT IMMUNE ACTIVATION: CAUSES 
 
The underlying causes of persistent immune activation during cART-mediated 
viral suppression are likely multifactorial but remain incompletely defined. Several 
potential causes have been proposed, highlighting HIV-1 ongoing replication, microbial 
translocation and co-infections, as continuous trigger mechanisms of immune 
activation73.  
 
RESIDUAL VIREMIA: ONGOING VIRAL REPLICATION 
 
First, the effectiveness of current therapeutic regimens has been monitored by 
using HIV-1 RNA assays which have a sensitivity of 40 to 50 copies/ml. Suppression of 
plasma viremia below detectable levels can be sustained in HIV-1 infected individuals 
by antiretroviral regimens currently in use74-75. Nevertheless, replication-competent cell-
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free virions can be found for many years in the plasma of most patients on cART, and 
viremia rapidly rebounds when antiretroviral suppression is interrupted76-79. 
Still infected individuals remain clinically stable on cART, persistent virus 
expression may contribute to long-term complications53. Using recently developed real-
time HIV-1 RNA assay, with sensitivity below one HIV-1 RNA copy per ml, allows a 
more detailed analysis of the viral decay kinetics in patients on suppressive cART80,81. 
Several studies revealed persistent low-level viremia of around 3-5 copies/ml in plasma 
of most patients on cART and persists in patients even after years of therapy82. 
The source and dynamics of this residual viremia are currently unknown, 
representing a challenge to future attempts to induce a drug-free remission of HIV-1 
disease and eradication of the infection83. Viremia could arise from ongoing cycles of 
viral replication in a sanctuary site where there is suboptimal drug penetration, from 
long-lived productively infected cells, or from activation of virus expression from latently 
infected cell reservoirs84-87. 
 
1.5 Generation of 2-LTR circles: recent infection events 
 
Efforts to characterize the extent of ongoing viral replication in suppressed 
individuals have been hampered by a lack of convenient surrogates of ongoing viral 
replication88. Viral episomes containing one or two long terminal repeats (1-LTR or 2-
LTR-containing episomes) are formed after completion of viral cDNA synthesis and 
translocation to the host cell nucleus, where recombination and direct ligation lead to 
the formation of episomes containing one and two LTRs, respectively. These episomal 
cDNA forms are labile and, as such, their presence is indicative of recent infection 
events89-91. 
 
1.6 Anatomical sites: HIV-1 reservoirs 
 
Persistent ongoing viral replication may remain in anatomical sites 
immunologically sheltered from the blood and lymphoid systems with low antiretroviral 
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drug penetration92-93. These anatomical sites, including the lymphoid tissue, central 
nervous system, respiratory, gastrointestinal and genitourinary tracts, may act as 
reservoirs of HIV-1 replication94-96. 
 
 
 
Figure 1.4 Generation of 2-LTR and 1-LTR circles after intensifying 
suppressive regimen with raltegravir (Buzon et al, 2010110). 
 
1.7  Antiretroviral treatment intensification: maraviroc and raltegravir  
 
Several studies have looked at the intensification treatment with an additional 
antiretroviral drug, not previously used by the patients, as a possible strategy to reduce 
low-level viremia and subsequent immune activation whether ongoing new cycles of 
viral replication were contributing to residual viremia97. Additionally, the emergence of 
new antiretroviral drugs with different mechanisms of action, such as CCR5 
antagonists and integrase inhibitors, provides new opportunities to assess the viral 
reservoirs and residual viremia that persist in suppressed individuals99-100. 
Particularly, these new antiretroviral drugs referred are; maraviroc (MVC), a 
potent new antiretroviral agent approved for the treatment of HIV-1 infection that blocks 
interaction between the virus and the CCR5 co-receptor, targeting HIV-1 entry process, 
a crucial step in the HIV-1 life cycle101-102, and raltegravir (RAL), the first-in-class 
integrase inhibitor approved for the treatment of HIV-1 infection. It blocks integration of 
linear viral cDNA that is subsequently circularized by host DNA repair enzymes to form 
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episomes containing two copies of 2-LTR circles or undergoes recombination to form a 
1-LTR circle103-104, as represented above (Figure 1.4). 
Disappointingly, the vast majority of treatment intensification trials to date have 
failed to show any decline in low-level viremia or cell-associated HIV-1 DNA105-107, 
highlighting two studies that showed no change in the gastrointestinal tract108 or in the 
cerebrospinal fluid109. Nevertheless, the addition of raltegravir lead to an increase in 2-
LTR circles within two weeks in one-third of the suppressed HIV-1-infected individuals, 
consistent with evidence of residual viral replication, and a significant reduction on T 
cell activation after 48 weeks intensifying with RAL, although there was still no change 
in persistent low-level HIV-1 RNA or cell-associated DNA, following intensification110. 
 
MICROBIAL TRANSLOCATION 
 
Secondly, microbial translocation has been pointed as a possible mechanism 
underlying immune activation and non-AIDS-associated morbidity in HIV-1 disease 
during suppressive regimen111-112. 
 
1.8  Gut-associated lymphoid: anatomical viral reservoir 
 
The gastrointestinal (GI) tract continues to serve as an important viral reservoir of 
HIV-1-infected cells even during long-term cART and contributes to viral persistence113-
114
. The GI tract harbors most of the total lymphoid tissue in the body and an 
abundance of activated effector memory CD4+ T cells that are CCR5+ and their 
predominantly activated state make them highly sensitive to HIV-1 infection115-117. Of 
these CD4+ CCR5+ T cells, Th17 cells, which also expressed the gut homing marker 
CCR6, are even more susceptible to HIV-1 infection and subsequent cellular 
depletion118-119.  
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1.9  Intestinal epithelium: HIV-1 associated CD4+ T cell depletion 
 
HIV-1 infection cause massive depletion of CD4+ T cells from the gut-associated 
lymphoid (GALT) tissue in the first few weeks of the infection, attributable to the 
cytopathic effects of the viral infection or the activation-induced uninfected CD4+ T cell 
death120-121. Insufficient production and tissue delivery of CD4+ memory T cells may 
contribute to sustained CD4+ T cell depletion during disease progression122. The loss of 
CD4+ T cells was coincident with increased prevalence of CD8+ T cells in GALT and 
the subsequent marked changes in the T-cell subset distribution in GALT, that were not 
adequately reflected in peripheral blood123. This dysregulation in T-cell homeostasis 
leads to increased levels of pro-inflammatory cytokine124-125, increased apoptosis of 
epithelial cells, and altered tight junction protein composition126 resulting in a functional 
degradation of the intestinal barrier127. The mucosa damage leads to a process known 
as microbial translocation, whereby microbial products from the intestinal lumen cross 
the disrupted mucosal barrier into the systemic circulation in the absence of overt 
bacteraemia128-129.   
Additionally, the cytokines IL-17 and IL-22 produced by Th17 cells enhance 
epithelial regeneration and defend against microbial translocation by recruiting 
neutrophils to the GALT to clear microbial products and by stimulating epithelial cell 
proliferation and antibacterial defensin expression130-132. Therefore, loss of Th17 cells 
may cause impaired mucosal healing increasing intestinal permeability and the 
subsequent microbial translocation133-134. Hence, both HIV-1-infected individuals and 
SIV-infected rhesus macaques have preferential significant depletion of gut Th17 CD4+ 
T cells with a sequential increase in Th1 CD4+ T cells, contributing to epithelial injury 
and enhance local inflammation and immune activation135. However, SIV-infected sooty 
mangabeys and African green monkeys, the natural hosts for SIV infection that do not 
have increased microbial translocation and do not develop AIDS, maintain, strikingly, 
Th17 cells in the gut despite mucosal CD4+ T cell losses136 -137. 
Taking together all data, intestinal epithelium in HIV-1 infected individuals is 
characterized by massive CD4+ T cell depletion, particularly Th17 cells138-140, abnormal 
enterocyte differentiation141, enterocyte apoptosis and destruction of the tight 
junctions142 caused by increased production of interferon-γ (IFN-γ) and tumor necrosis 
factor (TNF), contributing to increased microbial translocation143 (Figure 1.5).  
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Figure 1.5.  Intestinal epithelium in HIV-1-infected individuals (Sandler et al, 2012). 
 
 
1.10 Microbial translocation 
 
Increased levels of circulating microbial products in HIV-1-infected individuals, 
such as lipopolysaccharide (LPS), peptidoglycan, bacterial CpG DNA, flagellae, and 
viral genomes, molecules that can directly stimulate the innate immune system through 
Toll-like receptors (TLRs), are strongly associated with increased immune activation144-
146
 (Figure 1.6). 
Several parameters have been indistinctly used to determine bacterial 
translocation147-149, though LPS and soluble CD14, have been the most commonly 
used150. Lipopolysaccharides (LPS) are the major component of gram-negative 
bacteria cell walls and a potent immunostimulatory product151. Circulating LPS 
promotes hepatic synthesis of LBP, a plasma protein that increases the binding of LPS 
to CD14/TLR4 receptor complex on monocyte/macrophages152-153, triggering monocyte 
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activation and resulting in the release of soluble CD14 (sCD14) and the production of 
inflammatory cytokines, such as interleukin-6 (IL-6), interleukin-1β (IL-1β), Tumor 
Necrosis Factor (TNF) and type I Interferons (IFN-I)154-155, contributing to HIV-1-
associated immune activation (Figure 1.6). 
 
 
 
Figure 1.6.  Intestinal epithelium in HIV-1-infected individuals (Sandler et al, 2012). 
 
 
1.11 Possible driver mechanism of HIV-1 associated immune activation 
 
The association between microbial translocation and immune activation were 
reported in several studies in the first years of chronic HIV-1 infection or in the most 
advance stages of HIV-1/AIDS156-160. 
Due to the ongoing viral replication in GALT and elevated chemokine production, 
there is a recruitment of CD4+ T cells from the periphery into the gut via α4β7, an 
integrin that mediates migration of lymphocytes to the gut161. Engagement of α4β7 on 
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CD4+ T cells by gp120 viral envelope protein leads to activation of lymphocyte function-
associated molecule 1 (LFA-1) or αLβ2, facilitating formation of virologic synapses and 
increasing the efficiency of HIV-1 infection providing new targets for the virus162. 
 
1.12  Recovery of gut mucosa integrity 
 
On the other hand, studies utilizing the SIV model showed that the major 
mechanism of early and near complete CD4+ T cell restoration in GALT, involved 
trafficking of CD4+ T cells from the periphery to gut mucosa during primary SIV 
infection163-165. Moreover, longitudinal follow-up studies revealed that the kinetics of 
restoration of the gut mucosal immune system in patients with HIV-1 infection during 
cART was substantially delayed and incomplete compared with that observed in the 
peripheral blood compartment and was independent of the time of initiation of cART166. 
This delay in mucosal immune restoration was attributed to incomplete suppression of 
viral replication in GALT during therapy and increased levels of local inflammation and 
immune activation167. 
Noteworthy, viral replication was detected in GALT of HIV-1-infected patients 
receiving cART despite undetectable viral loads in the peripheral blood168. The lack of 
complete viral suppression with the subsequent loss of CD4+ T cells in the mucosa 
may contribute to discordant CD4+ T cell restoration and viral suppression between 
GALT and peripheral blood169. 
 
HIV-1 COINFECTIONS 
 
Thirdly, and finally, the vast majority of HIV-1-infected individuals are coinfected 
with other chronic viral infections or parasitic diseases, many of which get worse as a 
consequence of immunodeficiency during untreated HIV-1 disease, and may continue 
to contribute to systemic immune activation during treated HIV-1 infection73. 
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1.13  Visceral leishmaniasis: Leishmania infantum 
 
Visceral leishmaniasis (VL) caused by Leishmania infantum is a frequent disease 
among HIV-1 infected patients in countries of the Mediterranean basin170-171 
(Leishmania lifecycle in Figure 1.7). Despite cART, which indeed led to a reduction of 
its incidence, this disease still constitutes the third most frequent parasitic opportunistic 
infection in Europe172. Even in treated patients VL has case-fatality rates of 10-20%173, 
especially in HIV-1-co-infected patients174. 
Leishmania and HIV-1 share some of the same target cells, namely 
macrophages and dendritic cells175-176, and similar immune compromising mechanisms, 
most notably pro-inflammatory responses177-178 and CD4+ T cell lymphocyte depletion 
making immunosuppression as the hallmark of both Leishmania-HIV-1 pathogens179.  
The parasite infection in HIV-1-infected individuals is thought to induce chronic 
immune activation, viral replication and HIV-1 disease progression180-181, diminishing 
their life expectancy175; whereas immunological disturbances caused by HIV-1, despite 
cART, are particularly favorable for the uncontrolled multiplication of the parasite182, 
with increased parasite burden, drug resistance and frequent relapses183-184. 
Studies addressing microbial translocation in infectious diseases are scarce. 
Considering the involvement of microbial translocation in activation mechanisms in 
HIV-1-infected individuals115, and the similar pathogenic features shared between VL 
and HIV/AIDS185, it was also expected that gut parasitation by Leishmania amastigotes 
lead to mucosal barrier breach predisposing to microbial translocation in these patients. 
This phenomenon was, in fact, detected in VL186-187, and may potentiated in co-infected 
patients contributing to the activation status by enhancing the plasma cytokine storm, 
aggravating the disease´s clinical outcome in Leishmania/HIV-1 co-infected 
individuals188.  
The contribution of microbial translocation to the pathogenesis of different 
infectious diseases with persistent immune activation is likely to vary. Thus, microbial 
translocation per se has been proposed as a common pathway causing disease 
progression that is shared by different pathogens, such as HIV-1, Leishmania, and 
HCV189. 
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Figure 1.7 Leishmania life cycle (Centers for Disease Control and 
Prevention). Considering human stages, the female phlebotomies sandflies 
inject the promastigote form of Leishmania phagocytized by macrophages 
that reach the puncture wound. Promastigotes transform into amastigotes 
form within these cells, where they multiply and infect other mononuclear 
phagocytic cells and affect different tissues causing clinical manifestations 
of visceral leishmaniasis. 
 
 
1.14  Hepatitis C virus (HCV) 
 
The overall burden of HIV-1/HCV coinfection is estimated at 4 or 5 million people 
worldwide190, finding the highest prevalence of HCV infection in HIV-1 infected 
individuals with a history of intravenous drug use, with a rate reported to be 82% to 
93%191-193. In Europe, liver disease has emerged as a leading cause of death among 
HIV-1-infected individuals, mostly due to chronic viral hepatitis194, increasing mortality 
from liver in coinfected individuals with the consumption of alcohol195-196. The increased 
mortality of coinfected individuals over that of HCV-monoinfected ones reflects 
accelerated progression of chronic liver disease with HIV-1-related 
immunosuppression197-198. 
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The determinants of progression to cirrhosis and liver failure are poorly defined. 
One contributor to chronic inflammation and fibrosis in chronic HCV monoinfection is 
microbial translocation199-202. Microbial translocation may promote liver fibrosis either by 
direct interaction with Kupffer cells and hepatic stellate cells upregulating pro-
inflammatory and pro-fibrogenic cytokines such as tumor necrosis factor TNF-α, IL-1, 
IL-6, and IL-12  or indirectly via induction of systemic immune activation and activation-
induced apoptotic cell death203-204. 
 
 
 
 
Figure 1.8 Microbial translocation due to HIV-1-related CD4+ 
lymphocyte depletion contributes to both immune activation and 
progression of liver disease in HIV/ HCV coinfected individuals 
(Balagopal 2008209). 
 
 
 
In addition, HIV-1/HCV seems to augment the local and systemic effects of 
microbial translocation caused by CD4+ T lymphocyte depletion and immune activation, 
accelerating liver disease consistent with the chronic hepatic inflammation observed in 
chronic HCV infection205-209 (See model below, Figure 1.8). 
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1.15  Human T-lymphotropic virus (HTLV) 
 
 
During the 1980s and 1990s, Spain had one of the highest prevalence of drug 
injection in Europe210. Sharing needles practice led to the spread of different viruses 
among injection drug users (IDUs) and their sex partners, such as HIV-1, HCV and 
HTLV211. While the prevalence of HTLV-1 infection in Spain is low, there is a high 
prevalence of HTLV-2 infection   specially in injecting drug users, reaching prevalence 
rates around 18% in prisoners, and around 5% outside the prison212-214. The molecular 
characterization of HTLV-2 isolates from North America and Europe demonstrated that 
HTLV-2a subtype was the predominant circulating variant in North America215 and 
northern Europe216, while HTLV-2b subtype was almost exclusive in southern Europe, 
particularly Spain and Italy217-218, where co-infection with HCV and HIV-1 is frequent. 
Up today, there is still no clear evidence that HTLV-2 causes any human disease, 
although it has been occasionally linked to neurological and lymphoproliferative 
disorders219-221. Several studies analyzing the effects of HTLV-2 on HIV-1 pathogenesis 
in dually infected HIV-1/ HTLV-2 individuals, revealed delayed progression of HIV-1 to 
AIDS222-223 linked, in some cases, to a long-term nonprogressor phenotype224-225.  
This protective role is thought to be due to maintenance of CD4+ T cells, lowering 
levels of HIV-1 replication and immune activation in dually infected HTLV-2/HIV-1 
individuals compared to patients infected with HIV-1 only226-228. Additionally, several 
IDU long-term non-progressors (LTNPs) with stable CD4 counts, in the absence of 
ART, have been reported to be infected with HTLV-2229, and the median value of 
HTLV-2 proviral loads (pVL) tended to be higher in the LTNP coinfected group 
compared to those who required antiretroviral treatment230. 
The possible mechanism underlying the milder HIV-1 disease course has been 
attributed to the modulation of cytokine and chemokine networks by HTLV-2 that would 
modify innate host immune responses. In this way, HTLV-2 induces the expression of 
three CC-chemokines, natural ligands for CCR5 from PBMCs and monocytes; 
Macrophage inflammatory protein 1-alpha (MIP-1α)/CC-Chemokine ligand-3 (CCL3); 
MIP-1β/ CCL4; and RANTES (Regulated upon activation normal T-cell expressed and 
secreted (RANTES)/CCL5 inhibiting HIV-1 entry by binding to CCR5231-233, and the 
concomitant downregulation of the CCR5 receptor on lymphocytes234-235, interfering 
with HIV-1 infection process (Figure 1.9). 
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Notably, different viruses have specific cytokine and chemokine requirements for 
maintenance in vivo. What appears to be optimal for one strain may be detrimental for 
another236-238. Therefore, the reported upregulation of granulocyte-macrophage colony-
stimulating factor (GM-CSF) and IFN-γ secretion239, which can also inhibit CCR5 
expression contributing to slow HIV-1 disease progression240. In fact, it has been 
demonstrated in a clinical trial conducted on AIDS patients that GM-CSF decreases 
viral replication and increases the number of circulating CD4+ T cells, the primary target 
of HIV-1241. In addition, IFN-γ is the pivotal cytokine triggering a phagocyte-dependent 
Th1 response leading to CTL response against invading pathogens242.  
In this regard, a poor Th1 response and a dominant Th2 response have been 
implicated in the pathogenesis and progression of HIV-1 infection243-244. Thus, HTLV-2 
infection may exert protective effect on HIV-1 disease progression inducing Th1 
response against invading pathogens via up-regulating IFN-γ expression239,242. 
 
 
 
Figure 1.9 Scheme illustrating how HTLV-2 may interfere on 
HIV-1 pathogenesis. The HTLV-2 infected CD8+ T cells and their 
expansion induces the secretion of CC-chemokines, which can 
reinforce the cytotoxic T lymphocyte response against CD4+ HIV-
1 infected cells (Casoli 2007227). 
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On the other hand, clinical features of coinfected individuals have been 
overlooked, despite its high frequency among injecting drug users245. Only higher 
frequencies of severe fibrosis has been found among HCV/HTLV-2 individuals 
compared to HCV-monoinfected group, although no significant246. Consistent with the 
fact that hepatic measures were reported to be worse in HTLV-1/ HCV coinfected 
individuals with more severe immunosuppression247, cellular immune response should 
be analyzed in HCV/HTLV coinfected individuals to elucidate the effects on HTLV-2 on 
HCV infection and progression of liver disease248. 
From public health perspective, prevention of HTLV-1/2 is crucial as there is no 
current treatment for this infection. Several studies analyzed the effects of antiretroviral 
agents widely used for treating HIV-1 infection on HTLV virus expression, showing no 
effects on HTLV proviral burden or HTLV mRNA expression249-251.  
Raltegravir was an integrase inhibitor approved for HIV-1 infection treatment. 
Given the similarities between HIV-1 and HTLV integrases, raltegravir was thought to 
be effective against HTLV-1. Furthermore, two studies reported a decrease HTLV-1 
pVL in vitro and also ex vivo252-253. Despite these promising in vitro results, no decrease 
on HTLV-1 pVL was reported in the unique in vivo study254, attributed to the lack of new 
rounds of viral replication that is mainly maintained through cell division255.    
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AIMS OF THE STUDY 
 
Despite viral suppression and partially immune recovery, persistent increased 
immune activation continues in HIV-1-infected individuals. Microbial translocation and 
the subsequent pro-inflammatory cytokines expression has been proposed as the 
major driver mechanisms of HIV-1-associated immune activation and inflammation, 
also influenced by frequent HIV-1-coinfections. 
The aim of the study was to analyze microbial translocation, cytokines profile, 
and immune activation in different scenarios, involving, HIV-1-infected individuals on 
treatment intensification, HIV-1-infected individuals with different immune response to 
antiretroviral therapy, and HIV-1-infected individuals with other coinfections, such as 
Leishmania, HCV and HTLV. 
 
Objective 1. To evaluate in a longitudinal study the effects of treatment intensification 
with maraviroc or raltegravir and further intensifying drug discontinuation on immune 
activation, microbial translocation and dynamics of T cell subsets including expression 
of gut homing β7 receptor on T cells. 
 
Objective 2. To determine correlations between different techniques employed to 
measure microbial translocation, including levels of LPS, sCD14, LBP and 16S rDNA, 
and between all these techniques and immune activation in HIV-1 infected patients on 
treatment intensification.  
 
Objective 3. To investigate in a cross-sectional study how visceral leishmaniasis 
impacts immune activation compared to two control groups consisted of HIV-1 infected 
both immunological concordant and non-responders to antiretroviral therapy, and which 
factors could impair immune response in these individuals, including inflammation, 
microbial translocation and immunosenescence. 
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Objective 4. To investigate in a cross-sectional study how HTLV-2 infection influences 
both HIV-1 disease progression and liver disease associated to HCV infection. Immune 
activation, microbial translocation, cytokine profile and HTLV-2 proviral load are 
determined for this purpose. 
 
Objective 5. Evaluation of HTLV-2 proviral load in coinfected HIV-1/HTLV-2 individuals 
ongoing treatment intensification with raltegravir.  
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FLOW CYTOMETRY STAINING 
 
Many immunologically important cells can be defined based on proteins present 
on their membrane. Human clusters of differentiation (CD) are used to classify many 
epitopes on the cell surface of leukocytes. The study of cellular characteristics using 
flow cytometry involves the use of fluorescent molecules such as fluorophore-labeled 
antibodies that binds to a specific molecule on the cell surface or inside the cell. In 
further analysis through flow cytometer, when laser light of the right wavelength strikes 
the fluorophore, a fluorescent signal is emitted and detected by the flow cytometer, 
demonstrating the presence of both superficial and intracellular proteins. The 
combination of several immunological markers is used to define cellular immune 
functions or properties.  
The commercial antibodies used to study cellular characteristics using flow 
cytometry are shown in Table 2.6. These antibodies had the following fluorochromes 
FITC (Fluorescein Isothiacyanate), PE (Phycoerythrin), PerCP (Peridinin Chlorophyll 
Protein Complex), PE-Cy7 (Phycoerythrin-Cyanin7), APC (Allophycocyanin), APC700 
(Allophycocyanin 700), APC-Cy7 (Allophycocyanin-Cyanin 7), eF450 (eFluorTM 450) 
and KO (KromeTM Orange) directly conjugated to the antibodies used as described 
above. Fluorocrhome peack excitation and emission wavelengths are also shown in 
Table 2.1. All antibodies against different CDs were purchased from Becton Dickinson 
(Becton Dickinson, NJ, USA). 
 
CELL STAINING AND FLOW CYTOMETRY 
 
Briefly, 100 µl of blood were lysed with 200 µl of FACS lysing solution (Becton 
Dickinson, NJ, USA) for 30 min at room temperature, incubated with the corresponding 
superficial antibodies during 20 min at 4ºC, washed twice with phosphate-buffered 
saline (PBS) containing 1% azida, fixed with BD CytofixTM (Becton Dickinson, NJ, USA) 
for 10 min at 4ºC and finally washed and resuspended in PBS containing 1% azida. An 
unstained control was performed for all samples. 
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Table 2.1 Fluorochrome-conjugated antibodies used for flow cytometry staining. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cells stained with fluorochrome-conjugated antibodies were visualized using flow 
cytometry using a Gallios flow cytometer (Beckman-Coulter, California, US). Flow 
cytometry allows the analysis of multiple parameters of individual cells within 
hererogeneous populations. The flow cytometer analysis is performed by passing 
thousands of cells through a laser beam and capturing the light that emerges from 
each cell as it passes through one at a time. As a cell passes through the laser, it will 
refract or scatter light at all angles.  
Forward scatter (FSC), or low-angle light scatter, is the amount of light that is 
scattered in the forward direction as the laser light strikes the cell. The magnitude of 
forward scatter is roughly proportional to the size of the cell.  
Light scattering at larger angles, to the side (SSC), is caused by granularity and 
structural complexity inside the cell. The generation of two-dimensional dot or scatter 
plots, using forward and side scatter, allow us to distinguish between cell populations.  
The scatter plot from a peripheral blood cell run is shown below (Figure 2.1). The 
populations that emerge include lymphocytes which are small cells possessing low 
internal complexity; monocytes which are medium-sized cells with slightly more internal 
Excitation 
Laser Antibody Fluorocrhome 
Excitation 
Max (nm) 
Emission 
Max (nm) 
638 nm 
Red 
HLA-DR APC-Cy7 650 774 
CD38 APC700 696 719 
β7 APC 645 660 
488 nm        
Blue 
CCR7 PE-Cy7 496, 565 774 
CD8 PerCP 482 675 
CD45RA PE 496, 565 575 
CD57 FITC 493 525 
405 nm       
Violet 
CD3 eF450 410 455 
CD4 KO 398 528 
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complexity, and neutrophils and other granulocytes which are large cells that have a lot 
of internal complexity.  
A threshold was set to avoid information coming from a very large number of 
minute particles, like platelets and debris. Thereby, the majority of events that the 
cytometer collects are the cells of interest, despite small particles are still passing 
through the instrument.  
Gallios flow cytometer can analyze 12 parameters, FSC, SSC and 10 different 
channels simultaneously, allowing to gather statistical data on large number of cells 
and to use that information to correlate multiple parameters within a cell population. 
 
 
 
 
Figure 2.1 Populations emerged from a peripheral blood run defined by 
Forward and Side scatter. 
 
 
At least 105 CD3+ T cells were collected for each sample and analyzed up to nine 
different parameters with Kaluza software v.1.1 (Beckman coulter) by initially gating 
lymphocytes according to morphological parameters. Gating was always the same 
between the different time points. At least 20000 events were gated for the T cell 
subsets. 
Granulocytes 
Lymphocytes 
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MICROBIAL TRANSLOCATION 
 
CD14 is a glycoprotein that mediates the interaction of lipopolysaccharide (LPS, 
endotoxin) with cells, thereby signaling the presence of gram-negative bacteria. The 
binding of LPS to CD14 requires an acute phase protein, LPS-binding protein (LBP). 
These three factors appear to participate in a complex feedback mechanism of immune 
regulation involving both up-regulation and down-regulation of the inflammatory 
process triggered by LPS. The 16S ribosomal RNA, however is a component of the 
30S small subunit of prokaryotic ribosomes, and thus, presented in all bacteria, gram-
negative and gram-positive. 
 
LIPOPOLYSACCHARIDE (LPS) 
 
Lipopolysaccharides (LPS) are found in the outer membrane of Gram-negative 
bacteria. Levels of LPS are determined in duplicated 50 µl of plasma samples using a 
quantitative test QCL-1000 Limulus Amebocyte Lysate (Lonza®, Basel, Switzerland). 
This method utilizes lyophilized lysated prepared from the circulating amebocytes of 
the horseshoe crab Limulus polyphemus which was an extremely sensitive indicator of 
the presence of endotoxin. This technique requires to be used with appropriate 
precautions to avoid microbiological or endotoxin contamination.  
 
SOLUBLE CD14 (SCD14) 
 
CD14 is expressed mainly by macrophages, neutrophils and dendritic cells. 
CD14 acts as a co-receptor with Toll-like receptor-4 (TLR4) for the detection of 
bacterial lipopolysaccharide (LPS), to which it binds in the presence of 
lipopolysaccharide-binding protein (LBP). The soluble form of the receptor (sCD14) is 
secreted mainly by monocytes. 
Levels of soluble CD14 were measured in duplicated 200-fold diluted plasma 
samples using the Quantikine® Human sCD14 Immunoassay (R&D Systems, 
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Minneapolis, Minnesota, US). This assay employs the quantitative sandwich enzyme 
immunoassay technique (ELISA), in which a monoclonal antibody specific for sCD14 
has been pre-coated onto a microplate.  
 
LIPOPOLYSACCHARIDE-BINDING PROTEIN (LBP) 
 
Lipopolysaccharide-binding protein (LBP) is a soluble protein that binds to 
bacterial lipopolysaccharide (LPS) to elicit immune responses by presenting the LPS to 
the receptor CD14 and the pattern recognition receptor TLR4.  
Levels of LBP were determined in 800-fold diluted plasma samples, run in 
duplicate, using the Enzyme Immunoassay for Quantification of free human LBP kit 
(Enzo Life Siences, Farmingdale, NY). 
However, LBP levels were only determined at baseline, at week 48 after 
treatment intensification, and at weeks 12 and 24 after intensifying drug 
discontinuation. 
 
BACTERIAL 16S RIBOSOMAL DNA (16S rDNA) 
 
Because LPS is a component of cell wall of gram-negative bacteria, present on a 
proportion of enteric bacterial microbiota, the well-conserved 16S ribosomal DNA (16S 
rDNA) subunit common to most bacteria was also quantified during the follow-up 48 
weeks of treatment intensification. 
The bacterial 16S rDNA was quantified from the DNA extracted from 200 µl of 
plasma using QIAamp DNA kit (Qiage, Hilden, Germany). DNA concentrations were 
determined using ND-1000 spectrophotometer, according to manufacturer´s protocol. 
DNA was kept at -20ºC until further use. 
Standard plasmids were generated through the amplification of partial 171bp 16S 
rDNA gene. Reaction mixtures were performed in a total volume of 25 µl containing 
PCR Buffer II (AccuPrime Taq High Fidelity, Bioline, London, UK), 0,5 U Taq 
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polymerase (AccuPrime Taq High Fidelity, Bioline, London, UK), 200 ng of genomic 
DNA from the plasma of diagnosed HIV-1-infected individual, and 20 pmol of the 
following primer pairs were used, (16S-1/ 16S-2) for partial bacterial 16S rDNA gene, in 
the Table below (Table 2.2). Thirty-five cycles of denaturation at 95ºC for 15s, 
annealing at 56ºC for 10s, and extension at 68ºC for 20s, followed by a final extension 
at 68ºC for 2min were performed. 
 
Table 2.2 List of oligonucleotides used for generating the 16S rDNA 
standard plasmids. 
 
 
 
 
 
 
Standard plasmids were generated by cloning PCR amplicon products in a 
pUC19 plasmid DNA following the instructions provided by TOPO® Cloning reactions 
(TOPO TA Cloning® kits, Invitrogen, Life Technologies, US) according to 
manufacturer´s protocol. Subsequently, competent One Shot® Escherichia coli were 
transformed and diluted bacteria were spread plated with Ampicillin (100 µg/ml) and 
incubated at 37ºC overnight (See Molecular Cloning 2.6.2). 
The presence of the cloned amplicon was verified in some colonies by colony 
PCR using the same amplification conditions for 171 bp 16S rDNA gene explained 
above. The selected colonies were grown in 2 ml of LB liquid medium overnight, and 
plasmid DNA was extracted from transformed bacteria using the QIAprep Spin 
Miniprep kit (Qiagen GmbH, Hilden, Germany). 
A standard curve for copy number quantification were generated in each run 
using six 5-fold serial dilutions of each plasmid specific amplicon template.   
The bacterial 16S rDNA levels in plasma of HIV-1-infected patients were 
determined by real time PCR assay, with newly designed primers and probe are 
described in Table 2.3. A TaqMan® Probe (Sigma-Aldrich, Missouri, US) was used with 
6-FAMTM and TAMRA as a fluorophore and a quencher, respectively. 
Primer Sequence  Length (bp) 
16S-1 5´-TAGCGATTCCGACTTCATGGA-3´ 
171bp 
16S-2 5´-ACACACGTGCTACAATGGC-3´ 
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Since any contaminating DNA is likely to be co-amplified and could interfere with 
quantification, we considered to perform a DNase treatment of commercial 
amplification FastSart Buffer kit prior to proceed with the real-time quantification. Thus, 
LightCycler FastStart DNA Master PLUS HybProbe 5X (Roche Diagnostics) was 
treated with DNase I (Invitrogen, Life Technologies, US) at 37ºC for 10 min followed by 
10 min at 95ºC to inhibit the enzyme activity, according to manufacturer´s indications. 
 
 
Table 2.3  Primers and probes used for partial 16S rDNA gene quantification  
by RT- PCR. 
 
 
 
 
 
 
Since any contaminating DNA is likely to be co-amplified and could interfere with 
quantification, we considered to perform a DNase treatment of commercial 
amplification FastSart Buffer kit prior to proceed with the real-time quantification. Thus, 
LightCycler FastStart DNA Master PLUS HybProbe 5X (Roche) was treated with 
DNase I (Invitrogen, Life Technologies, US) at 37ºC for 10 min followed by 10 min at 
95ºC to inhibit the enzyme activity, according to manufacturer´s indications. 
The amplification reaction was carried out in triplicate using the capillary-based 
LightCycler® 2.0 (Roche). Standards curves were preparared for each amplification and 
analyzed at each PCR-run, including negative and positive controls. Reactions were 
carried out in triplicate in a total volume of 20 µl containing LightCycler FastStart DNA 
Master PLUS HybProbe 5X (Roche), 200 ng of DNA, 50 pmol of each primer, 16S-3/ 
16S-4 along with 2 pmol of the following 16S Taqman probe. The cycling parameters 
included a hot start at 95ºC 10 min, and continued with 40 cycles of denaturation at 
95ºC for 10s, annealing at 55ºC for 10s and extension at 72ºC for 15s. 
  Primer Sequence  Length (bp) 
  16S-3 5´-TTGCAGACTCCAATCCGGACT-3´ 
122bp 
  16S-4 5´-GCATAGAAAGAGAAGCGACCT-3´ 
  16S Taqman  
  Probe 5´-CAGCGTCAAAGGTGAGGAGTGGGTGTCG-3´ 
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The Ct values were converted into template quantity using the standard curve 
method, with PCR efficiency >90% and R2 correlation superior to 0.9, avoiding 
replicates that have more than 0.5 Ct of difference. Levels of 16S rDNA were 
calculated and the final results were expressed as 16S rDNA DNA copies per microliter 
of plasma sample. 
 
ANTIRETROVIRAL TREATMENT INTENSIFICATION 
 
 
In the frame of two pilot open-label phase II clinical trials, we analyzed the effects 
and dynamics of treatment intensification and intensified treatment discontinuation on 
immune activation, T cell subsets, expression of gut homing β7 receptor on T cells and 
microbial translocation in 16 HIV-1-infected patients of whom seven intensified with 
maraviroc, a CCR5 antagonist, and the other nine patients with raltegravir, an integrase 
inhibitor. We also analyzed the correlations between different measurements of 
microbial translocation including lipopolysaccharides (LPS), soluble CD14 (sCD14), 
lipopolysaccharide-binding proteins (LBP) and quantification of 16S ribosomal DNA 
(16S rDNA), and also the association between microbial translocation and either 
immune activation, T cell subsets or expression of gut homing β7 receptor on T cells. 
 
2.1 Study design and ethic statement 
 
Two independent pilot prospective open-label clinical trials were performed to 
evaluate the effect of maraviroc (MVC), a CCR5 antagonist (developed and provided 
by Pfizer, Inc., US) or raltegravir (RAL), an integrase inhibitor (developed and provided 
by Merck, New Jersey, US) on the HIV-1 latent reservoir in 16 HIV-1 infected patients. 
Both clinical trials (NCT00795444 and NCT00807443) were conducted at the Hospital 
Universitario Ramón y Cajal, in Madrid, Spain, between 2008 and 2011 with an 
intensification period of 48 weeks and a follow-up of 24 weeks after drug 
discontinuation. Biochemical, immunological and virological parameters were assessed 
at baseline and at weeks 12, 24, 36 and 48 of treatment intensification, and at weeks 
12 and 24 weeks after intensifying drug discontinuation. 
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The study was carried out according to the recommendations of the Declaration 
of Helsinki and current Spanish legislation on clinical trials. It was approved by the 
AEMPS (Spanish Agency for Medications and Health Products) and our local 
Independent Ethics Committee (Hospital Ramón y Cajal, Madrid, Spain). All patients 
provided written informed consent for participation, sample collection, and laboratory 
determinations. 
 
 2.2 Patients and specimen collection 
 
Sixteen patients (seven from MVC trial and 9 from RAL trial) completed the 
intensification phase of the study; however one individual from RAL trial declined to 
participate in the follow-up 24 weeks after intensifying drug discontinuation, so finally 
fifteen patients completed the follow-up period of 24 weeks.  
Plasma viral load was measured by quantitative RT-PCR with a detection limit of 
40 copies/ml (Roche Taqman HIV-1 test; Roche Molecular Systems), and T-
lymphocyte counts were determined by flow cytometry. 
The main inclusion criteria were as follows: HIV-1 infected adults receiving 
antiretroviral treatment for at least 2 years; undetectable plasma viral load (below 40 
copies HIV-1 RNA/ml) for at least two years; CD4+ T-cell count above 350 cells/mm3; 
and no previous experience with MVC or RAL. Patients were excluded if they had 
experienced virological failure, received any immunosuppressive or immunomodulatory 
therapy, were or planned to become pregnant, or planned to interrupt treatment for any 
reason. A total of 50 ml of whole blood with ethylenediaminetetraacetic acid (EDTA) 
was drawn for plasma and isolation of peripheral blood mononuclear cells (PBMCs). 
Plasma samples were stored at -80ºC and PBMCs in liquid nitrogen until further use. 
 
2.3  Immune activation 
 
Fresh EDTA anticoagulated whole blood was used to analyze CD4+ and CD8+ T 
cell activation with the following antibody combination: CD3-eFluorTM 450 (eF450), 
CD4-KromeTM Orange (KO), CD8-peridinin chlorophyll protein complex (PerCP), CD38-
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Allophycocyanin-700 (APC-700), and HLA-DR-allophycocyanin-Cy7 (APC-Cy7). Also 
staining with β7-allophycocyanin (APC) to analyze the expression of gut homing β7 on 
both T cells or activated T cells, respectively. All the antibodies (Becton Dickinson, NJ, 
USA) are shown in Table 2.1. 
 
2.4  T cell subsets 
 
Lymphocyte subpopulations were defined as naïve (CD45RA+CCR7+), T central 
memory (CD45RA+CCR7+, TCM), T effector memory (CD45RA+CCR7+, TEM),  and T 
effector memory RA+ (CD45RA+CCR7+, TemRA). To analyze lymphocyte subsets this 
antibody combination was used: CD3-eFluorTM 450 (eF450), CD4-KromeTM Orange 
(KO), CD8-peridinin chlorophyll protein complex (PerCP), CD45RA-phycoerythrin (PE) 
and CCR7-allophycocyanin (APC). Additionally, staining with β7-allophycocyanin 
(APC) was used to analyze the expression of gut homing β7 on both T cells or 
activated T cells, respectively. All the antibodies (Becton Dickinson, NJ, USA) are 
shown in Table 2.1. 
 
2.5  Microbial translocation 
 
Microbial trnalocation was measured in plasma by two commercial kit assays 
according to the manufacturer´s protocol. Plasma bacterial LPS was measured using 
QCL-1000 Limulus Amebocyte Lysate (Lonza, Basel, Switzerland), plasma sCD14 was 
quantified using the Quantikine Human sCD14 Immunoassay (R&D Systems, 
Minneapolis, MN) and plasma LBP was measured by LBP soluble ELISA kit (Enzo Life 
Sciences, Farmingdale, NY). Real-time quantification was used to perform the bacterial 
16SrDNA. 
 
2.6 Statistical analysis 
 
Continuous variables were expressed as median and interquartile range (IQR) 
and discrete variables as percentages. The t test for independent samples was used to 
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compare normally distributed continuous variables and the Mann-Whitney U test to 
compare non-normally distributed continuous variables. Categorical variables were 
described as proportions. The association between categorical variables was evaluated 
using the chi-square test. The Spearman correlation coefficient was used to analyze 
the correlations between continuous variables. Statistical analysis was performed using 
IBM SPSS software 21.0 (IBM, Chicago, Illinois, USA).Graphs were generated using 
GraphPad Prism 5.01 (La Jolla, California, USA).  
 
 
COINFECTION WITH LEISHMANIA COMPARED TO 
IMMUNOLOGICAL DISCORDANT RESPONSE                                     
TO ANTIRETROVIRAL THERAPY 
 
 
In this cross-sectional comparative study, we analyzed levels of microbial 
translocation, immune activation, inflammation through IL-6 levels, and immune 
senescence in HIV-1 infected patients with concordant immunological response to 
antiretroviral therapy, compared to infected individuals with discordant immunological 
response to treatment. We also studied correlations between microbial translocation 
measured by LPS and soluble CD14 levels, and either markers of inflammation or 
immune activation.    
 
2.7  Study design, ethic statement and sample collection 
 
A cross-sectional, descriptive and comparative study was performed in HIV-1 
infected patients at the Hospital Universitario Ramón y Cajal, in Madrid, Spain. A total 
of 29 HIV-1-infected adults with undetectable viral load (lower than 40 HIV-1 copies/ml) 
and receiving antiretroviral therapy for at least one year were analyzed. 15 of these 
HIV-1 infected adults showed concordant immunological response to the therapy, with 
CD4+ T cell count above 400 cells/mm3, while the other 14 HIV-1-infected patients 
showed discordant immunological response with CD4+ T cell count below 200 
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cells/mm3. Whole blood was collected in Vacutainer-EDTA tubes (Becton-Dickinson, 
Madrid, Spain) for plasma and PBMCs isolation. Plasma samples were stored at -80ºC 
while the PBMCs were stored in liquid nitrogen until further use. 
The study was carried out according to the recommendations of the Declaration 
of Helsinki and current Spanish legislation on clinical trials. It was approved by the 
Institution Review Board and Ethics Committee (Hospital Ramón y Cajal, Madrid, 
Spain). All patients provided written informed consent for participation, sample 
collection, and laboratory determinations. 
 
2.8  Immune activation and Immune senescence 
 
Fresh EDTA anticoagulated whole blood was used to analyze CD4+ and CD8+ T 
cell activation with the following antibody combination: CD3-eFluorTM 450 (eF450), 
CD4-KromeTM Orange (KO), CD8-peridinin chlorophyll protein complex (PerCP), CD38-
Allophycocyanin-700 (APC-700) and HLA-DR-allophycocyanin-Cy7 (APC-Cy7). 
Immunosenescence was defined as the expression of CD57-fluorescein isothiacyanate 
(FITC), and the absence of CD28-allophycocyanin-H7. All the antibodies (Becton 
Dickinson, NJ, USA) are shown in Table 2.1. 
 
2.9  Inflammation 
 
Inflammation was measured by plasma interleukin 6 (IL-6) quantification using 
hsIL-6 (Human IL-6 Quantikine High-Sensitive ELISA kit, R&D Systems). IL-6, along 
with TNF-α and IL-1, drives the acute inflammatory response and is important in the 
transition from acute inflammation to either acquired immunity or chronic inflammatory 
disease. 
 
2.10  Microbial translocation 
 
Microbial translocation was measured in plasma by the quantification of both 
lipopolysaccharide (LPS) using QCL-1000 Limulus Amebocyte Lysate (Lonza®, Basel, 
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Switzerland) and soluble CD14 using the Quantikine® Human sCD14 Immunoassay 
(R&D Systems, Minneapolis, Minnesota, US), according to manufacturer´s protocol. 
LPS-bound CD14 signals production of inflammatory cytokines and other inflammatory 
proteins.  
 
2.11 Statistical analysis 
 
Continuous variables were expressed as median and interquartile range (IQR) 
and discrete variables as percentages. The t test for independent samples was used to 
compare normally distributed continuous variables and the Mann-Whitney U test to 
compare non-normally distributed continuous variables. Categorical variables were 
described as proportions. The association between categorical variables was evaluated 
using the chi-square test. The Spearman correlation coefficient was used to analyze 
the correlations between continuous variables. Statistical analysis was performed using 
IBM SPSS software 21.0 (IBM, Chicago, Illinois, USA).Graphs were generated using 
GraphPad Prism 5.01 (La Jolla, California, USA). Multivariate lineal regression analysis 
to identify variables associated with immune activation as dependent variable. 
 
 
COINFECTION WITH HTLV-2 IN BOTH HIV-1/HCV COINFECTED    
AND HIV-1 MONOINFECTED INDIVIDUALS 
 
 
In this cross-sectional comparative study, we evaluated the influence of HTLV-2 
infection in both HIV-1/HCV coinfected and HIV-1 monoinfected individuals. With this 
purpose, immune activation, microbial translocation, cytokine profile, HTLV-2 proviral 
load, among other variables were studied. 
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2.12 Screening for HTLV infection among intravenous drug users infected by 
HIV-1 
 
Following the diagnostic algorithm proposed by the HTLV European Research 
Network (HERN) criteria, the initial screening of HTLV-1/2 infection is based mainly on 
testing for antibodies by enzyme-linked immunosorbent assays (ELISA). Repeatedly 
reactive ELISA samples were confirmed by western blot. However, in some 
indeterminate cases, due to the showed bands pattern it is not possible to confirm 
HTLV-1 or HTLV-2 infection by WB and it is necessary to perform a supplementary 
assay such specific polymerase chain reaction (PCR) in order to further confirm HTLV-
1 or HTLV-2 infection (HERN, 1996). Figure 2.2 summarizes the diagnostic algorithm 
proposed by the HERN for HTLV and other related infections. 
A total of 1673 HIV-1 infected patients with regular medical appointments in the 
Hospital Ramón y Cajal, Madrid, Spain, at the end of the 2010, were analyzed. From 
these patients, 798 individuals had a history of intravenous drug use with undetectable 
viral load (<50 copies/ml) on antiretroviral therapy at least for one year. All these 
patients were included for the screening of HTLV-1/2 infection, following the 
aforementioned diagnostic algorithm proposed by the HTLV European Research 
Network (HERN) criteria. 
 
• ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) 
 
Qualitative detection of various specific IgA, IgG and IgM antibodies against 
HTLV-1 and HTLV-2 found in the collected human plasmas, using a commercial third 
generation direct sandwich immunoassay, BioELISA HTLV I+II 5.0 (Biokit, S.A., 
Barcelona, Spain), that utilizes a combination of recombinant proteins and a tri-fusion 
recombinant protein labeled with horseradish peroxidase.  
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Figure 2.2.  HERN algorithm for the diagnosis of HTLV-1/2 
infections in seroprevalence studies. 
 
 
• WESTERN BLOT (WB) 
 
Repeatedly reactive ELISA samples were confirmed by western blot (WB) 
technique in plasma, using the commercial HTLV blot 2.4 Western Blot assay (MP 
Diagnostic Technology, Singapore). This test is a qualitative enzyme immunoassay for 
the in vitro detection of antibodies to core (gag) and envelope (env) proteins of HTLV-1 
and HTLV-2. 
 
A WB is considered HTLV-1 positive if band for gag proteins p19 with or without 
p24 and env recombinant proteins rgp21 (GD21) and rgp46-I (MTA-1), and it is HTLV-2 
positive if gag proteins p19 with or without p24 and env recombinant proteins rgp46-I 
(K55). It is considered to be indeterminate when HTLV specific bands are detected but 
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does not meet criteria for HTLV-1 or HTLV-2 infection due to its reactivity to any other 
proteins (HERN, 1996) (Figure 2.3). In those cases of indeterminate WB, additional 
specific PCR for HTLV-1 or HTLV-2 has to be performed to obtain conclusive diagnosis 
of HTLV-1 or HTLV-2 infection.  
 
 
 
Figure 2.3.  Interpretation of results based on bands 
pattern by WB technique. The specific bands as 
visualized with a- A HTLV-I/ II dual infection serum, b- 
Strong reactive control I (reactive for HTLV-1 only), c- 
Strong reactive control II (reactive for HTLV-2 only), 
d- Non-reactive control. 
  
 
 
 
 
 
 
2.13 Patients`characteristics 
 
Sixty-one HTLV-2-infected individuals with undetectable HIV-1 viral load on 
suppressive regimen at least for one year, were selected for the study. Forty of them 
were also infected by HCV. 
Ninety HIV-1 infected individuals seronegative for HTLV-2 infection with 
undetectable HIV-1 viral load on suppressive regimen at least for one year, were 
selected as control group for this study. Forty-two of them were also infected by HCV.  
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Anticoagulated-EDTA whole blood drawn for plasma and isolation of peripheral 
blood mononuclear cells (PBMCs). Plasma samples were stored at -80ºC and PBMCs 
in liquid nitrogen until further use. 
The clinical trials from which we obtained DNA samples were approved by the 
Ethics Committee of both Hospitals and all recruited patients signed an informed 
consent form.  
 
2.14 HTLV-2 proviral load 
 
Sixty-one HTLV-2-infected individuals with undetectable HIV-1 viral load on 
suppressive regimen at least for one year, were selected for the study. Forty of them 
were also infected by HCV. 
 
• STANDARD CURVES 
 
Partial 267 bp of HTLV-2 tax and 211 bp of cellular GAPDH genes were amplified 
by PCR. For both amplifications, reaction mixtures were performed in a total volume of 
25 µl containing PCR Buffer II (AccuPrime Taq High Fidelity, Bioline, London, UK), 0,5 
U Taq polymerase (AccuPrime Taq High Fidelity, Bioline, London, UK), 200 ng of 
genomic DNA from a diagnosed HIV-1/ HTLV-2b coinfected individual, and 20 pmol of 
the following primer pairs were used, (GAPDH-1/ GAPDH-2) and (Tx5/ Tx6) for partial 
cellular GAPDH and viral tax genes, respectively, as shown in the Table below (Table 
2.4). For GAPDH gene amplification, thirty-five cycles of denaturation at 95ºC for 15s, 
annealing at 60ºC for 8s, and extension at 68ºC for 20s, followed by a final extension at 
68ºC for 2 min were performed, while for tax gene amplification, thirty-five cycles of 
denaturation at 95ºC for 15s, annealing at 56ºC for 8s, and extension at 68ºC for 20s, 
followed by a final extension at 68ºC for 2 min were used. 
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Table 2.4 List of oligonucleotides used for generating the standard 
plasmids. 
 
 
 
 
 
PCR amplicon products were cloned products in a pUC19 plasmid DNA following 
the instructions provided by TOPO® Cloning reactions (TOPO TA Cloning® kits, 
Invitrogen, Life Technologies, US) according to manufacturer´s protocol. Ligation 
between amplicon and plasmid vector was performed using the T4-DNA ligase enzyme 
(Sigma-Aldrich, Missouri, US). 
Competent One Shot® Escherichia coli were transformed chemically through cells 
heat-shock with both cloning reactions containing one copy of HTLV-2 tax fragment or 
one copy of human genomic GAPDH gene fragment. Each transformation was spread 
in Luria Broth (LB) medium (pancreatic extract to casein, yeast extract, NaCl) plates to 
which Ampicillin (100µg/ml) was added (Invitrogen, Life Techonologies, US) and 
incubated at 37ºC overnight. 
The presence of the cloned amplicon was verified in some colonies by colony 
PCR using the same amplification conditions for 211 bp GAPDH or 267bp tax partial 
genes explained above. The PCR amplicons were run on an agarose gel to check 
whether fragments of interest were amplified and, hence, inserted into the plasmid. The 
selected colonies were grown in 2ml of LB liquid medium overnight.  
Plasmid DNA was extracted from transformed bacteria using the QIAprep Spin 
Miniprep kit (Qiagen GmbH, Hilden, Germany), allowing purification of high-purity 
plasmid DNA. Bacterial cultures are lysed and the lysates are cleared by centrifugation 
and the applied to the unique silica membrane that adsorbs plasmid DNA. Impurities 
are washed away and pure DNA is eluted in a small volume of UltraPure 
DNase/RNase-Free Distilled Water (Life Technologies, New York, US). DNA 
concentrations were determined using the NanoDrop® ND-1000 spectrophotometer. 
Primer Sequence  Length (bp) 
GAPDH-1 5´-GTGGACCTGACCTGCCGT-3´ 
211bp 
GAPDH-2 5´-CCAGAAATGAGCTTGAC-3´ 
Tx-5 5´- ACCCAGAGAACCGCCAAG-3´ 
267bp Tx-6 5´-GTATAAGTGGCCAGGTCA-3´ 
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A standard curve for copy number quantification were generated in each run 
using six 5-fold serial dilutions of each plasmid specific amplicon template.   
 
• PERIPHERAL PBMCS ISOLATION 
 
The Ficoll® density gradient separation (Lymphocytes Isolation Soution, Rafer, 
S.L., Zaragoza, Spain) was used for separation of mononuclear cells, such as 
monocytes and lymphocytes, with the lymphocyte population comprised of T cells, B 
cells and NK cells, from 4ml of heparinized whole blood.  
Differential migration during centrifugation results in the separation of cell types 
into different layers. The bottom layer contains aggregated red blood cells. Immediately 
above this, a Ficoll® layer containing granulocytes and PBMC is found. Due to a slightly 
lower density, PBMCs sediment at the interface between the Ficoll® and the uppermost 
plasma/platelet layer (Figure 2.4). PBMCs were cryopreserved until needed. 
 
 
 
Figure 2.4 Layers after Ficoll®density gradient 
centrifugation. 
 
 
• DNA EXTRACTION 
 
DNA was extracted from cryopreserved PBMCs using the QIAamp DNA Mini kit 
(Qiagen GmbH, Hilden, Germany), allowing purification of high-quality genomic DNA. 
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In this system, DNA binds specifically to the QIAamp silica-gel membrane while 
contaminants pass through. PCR inhibitors, such as divalent cations and proteins, are 
completely removed in thwo efficient wash steps, leaving pure DNA to be eluted in 
UltraPure DNase/RNase-Free Distilled Water (Life Technologies, New York, US). 
DNA concentrations were determined using the NanoDrop® ND-1000 
spectrophotometer by measuring the OD260 according to manufacturer´s protocol. The 
OD260/ OD280 ratio was also calculated for an indication of nucleic acid purity. DNA was 
kept at -20ºC for further use.  
 
• REAL TIME POLYMERASE CHAIN REACTION (RT-PCR) 
 
HTLV-2 proviral load from genomic DNA isolated from cryopreserved PBMCs 
from infected individuals was determinate by real time PCR assay, with newly designed 
primers and probes.  
A TaqMan® Probe (Sigma-Aldrich, Missouri, US) was used for HTLV-2 tax gene 
quantification. The TaqMan method, first reported in 1991 by Holland et al., relies on 
the 5´-3´ exonuclease activity of the Taq DNA polymerase to cleave a dual labeled 
probe when it is hybridized to a complementary target during each annealing step of 
the PCR run. The double-strand-specific 5´-3´ nuclease activity of the Taq enzyme 
displaces the 5´end of the probe releasing the fluorophore (6-FAMTM) from the 
quencher, (TAMRA) and leading to increase in fluorescence from the reporter. 
Otherwise, hybridization probes (Sigma-Aldrich, Missouri, US) developed by 
Roche (Caplin et al., 1999) were used for partial GAPDH gene quantification. Two 
probes were designed to bind adjacent to one another on the amplicon during 
annealing step. One has a donor dye on its 3´end, Fluorescein (Flc), while the other 
has an acceptor dye on its 5´end, LightCycler® Red 705. The reporter is excited and 
passes its energy to the acceptor dye through Fluorescence Resonance Energy 
Transfer (FRET) and the intensity of the light emitted is measured by the second probe. 
All sets of primers and probes for real time PCR quantification of both cellular 161 
bp GAPDH and 171 bp tax genes are described in Table 2.5. 
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The amplification reaction was carried out in triplicate using the capillary-based 
LightCycler® 2.0 (Roche). Standard curves were preparated for each amplification and 
analyzed at each PCR-run, including negative and positive controls. Reactions were 
carried out in triplicate in a total volume of 20 µl containing LightCycler FastStart DNA 
Master PLUS HybProbe 5X (Roche), 200 ng of genomic DNA, 50 pmol of each primer, 
GAPDH-3/ GAPDH-4 or Tx-5/ Tx-6 for partial GAPDH or tax genes, respectively,  along 
with 2pmol of the following fluorescent hybridization GAPDH or Taqman tax probes.  
 
 
 
Table 2.5 Primers and probes used for partial GAPDH and tax genes amplification by RT-
PCR. 
 
The cycling parameters for the both amplifications begun with hot start at 95ºC 10 
min, and continued with 40 cycles of denaturation at 95ºC for 5s, annealing at 62ºC for 
10s and extension at 72ºC for 20s for GAPDH gene, and 40 cycles of denaturation at 
95ºC for 10s, annealing at 62ºC for 15s and extension at 72ºC for 20s for tax gene. 
The Ct value is the PCR cycle in which there is a significant increase in reporter 
signal, above the threshold where signal can be considered not to be background. The 
Ct values were converted into template quantity using the standard curve method. 
Several parameters were evaluated each run to validate the assay performed, such as 
the PCR efficiency given by the slope of the standard curve, showing PCR efficiency 
>90%, R2 correlation coefficients for all the standard curves greater than 0.9, avoiding 
replicates that have more than 0.5 Ct of difference.  HTLV-2 copy number per genome 
Primer Sequence  Length (bp) 
  GAPDH-3 5´-CCTGCCAAATATGATGAC-3´ 
161bp 
  GAPDH-4 5´-GTCGTTGAGGGCAATGC-3´ 
  GAPDH                             
Hybridization 
Probe 
5´-TGGAACCAACCCTCGGGGATCAGCTCCAGC [Flc]-3´ 
5´-[LC640] TCCCTCGCCTTCCCTGAACCTG [Phos]-3´ 
  Tx-5 5´-CACTCCTGTCTCCCCCAAG -3´ 
171bp 
  Tx-6    5´-TACGGTTTTTCCCCAGGTG-3´ 
  Tax Taqman  
  Probe  5´-[6-FAM] CACCCGCCTTCTTCCAATCAATGCGAAAG [TAMRA]-3´ 
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or cell was calculated as the ratio between the quantity of template for tax and GAPDH, 
multiplied by two (diploid genome in each cell). The final results were expressed as 
HTLV-2 DNA copies per million PBMCs. 
 
2.15 Immune activation 
 
Fresh EDTA anticoagulated whole blood was used to analyze CD4+ and CD8+ T 
cell activation with the following antibody combination: CD3-eFluorTM 450 (eF450), 
CD4-KromeTM Orange (KO), CD8-peridinin chlorophyll protein complex (PerCP), CD38-
Allophycocyanin-700 (APC-700) and HLA-DR-allophycocyanin-Cy7 (APC-Cy7). All the 
antibodies (Becton Dickinson, NJ, USA) are shown in Table 2.1. 
 
2.16 Statistical analysis 
 
Continuous variables were expressed as median and interquartile range (IQR) 
and discrete variables as percentages. The t test for independent samples was used to 
compare normally distributed continuous variables and the Mann-Whitney U test to 
compare non-normally distributed continuous variables. Categorical variables were 
described as proportions. The association between categorical variables was evaluated 
using the chi-square test. The Spearman correlation coefficient was used to analyze 
the correlations between continuous variables. Statistical analysis was performed using 
IBM SPSS software 21.0 (IBM, Chicago, Illinois, USA).Graphs were generated using 
GraphPad Prism 5.01 (La Jolla, California, USA). Multivariate lineal regression analysis 
to identify variables associated with immune activation as dependent variable. 
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SUBSTUDY 1 
 
Seventeen HTLV-2 infected individuals coinfected with HCV and HIV-1, and two 
other control groups notinfected by HTLV-2, including eight individuals coinfected by 
HIV-1/HCV and 10 HIV-1-monoinfected individuals, were analyzed. All three groups 
were receiving suppressive cART (HIV-1 viral load lower than 50 RNA copies/ml) with 
CD4+ T cell count superior to 200 cells/mm3. 
 
2.18 Microbial translocation 
 
Microbial translocation was measured in plasma by two commercial kit assays 
according to the manufacturer´s protocol. Plasma bacterial LPS was measured using 
QCL-1000 Limulus Amebocyte Lysate (Lonza, Basel, Switzerland) and plasma sCD14 
was quantified using the Quantikine Human sCD14 Immunoassay (R&D Systems, 
Minneapolis, MN). 
 
2.19 Cytokine profile 
 
Levels of the following cytokines: Inteleukin-6 (IL-6), tumor necrosis factor (TNF), 
interferon-γ (IFN-γ), and interleukin -17A (IL-17A) were measured by Flow cytometry 
using the BDTM CBA Human Th1/ Th2/ Th17 Cytkokine Kit (BD Biosciences, California, 
US). 
 
2.20  Epidemiological characterization of the HTLV-2 isolates 
 
Twelve HTLV-2-infected Spanish IDUs also infected by HIV-1 were 
phylogenetically analyzed through three viral genes, LTR, env and tax and compared 
with other reported isolates.  
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• Nested polymerase chain reaction (nPCR) 
 
Partial LTR, env, and tax genes were amplified by nested PCR, a sensitive and 
selective method based on the amplification of the partial genes of interest followed by 
a second round of internal polymerase amplification for incrementing of the quantity of 
PCR product.  For the first round of PCR, all reaction mixtures were performed in a 
total volume of 25 µl containing PCR Buffer II (AccuPrime Taq High Fidelity, Bioline, 
London, UK), 0,5 U Taq polymerase (AccuPrime Taq High Fidelity, Bioline, London, 
UK), 200 ng of genomic DNA and 20 pmol of the following primer pairs were used, 
(HT2-1/ HT2-2) for LTR, (Ev-2/ Ev-3) for the env gene, and (Tx3/ Tx4) for the tax gene, 
as shown in the Table below (Table 2.6). Thirty-five cycles of denaturation at 94ºC for 
15s, annealing at 58ºC for 15s, and extension at 68ºC for 20s followed by a final 
extension at 68ºC for 2 min were used.  
 
Table 2.6  Oligonucleotides used for partial HTLV-2 LTR, env and tax genes nPR. 
 
Primer Sequence for the First PCR run Target (bp) Length (bp) 
HT2-1 5´-TAAAGGCTCTGACGTCTCC-3´ 
nt (89-684) 596 bp 
HT2-2 5´-GCAGCAAGGGCTAGGGCT-3´ 
Ev-2 5´-GTTCCAATAGCAGTGAGCCTTGT-3´ nt (5113-
6129) 1017 bp Ev-3 5´-AAAGCTGCATGCCCAAGAC-3´ 
Tx-3 5´-CTGGTCTCCTAACGGCAATCTC-3´ nt (7142-
8294) 1153 bp Tx-4 5´-CAAGTAAAGGCTCTGACGTCT-3´ 
Primer Sequence for the Second PCR run Target (bp) Length (bp) 
HT2-1 5´-TAAAGGCTCTGACGTCTCC-3´ 
nt (153-541) 390 bp 
HT2-2 5´-GCAGCAAGGGCTAGGGCT-3´ 
Ev-2 5´-GTTCCAATAGCAGTGAGCCTTGT-3´ nt (5180-
5956) 777 bp Ev-3 5´-AAAGCTGCATGCCCAAGAC-3´ 
Tx-3 5´-CTGGTCTCCTAACGGCAATCTC-3´ nt (7213-
8205) 993 bp Tx-6 5´-CAGACCGTCTCACACAAACAATC-3´ 
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After the first PCR reaction, 2 µl of the amplified products were used for a second 
PCR run in the same amplification conditions, with the following primer pairs were used 
(HT2-1/ HT2-4) for the amplification of 390 bp of LTR, (Ev-2/ Ev-3) for 777bp of the env 
region, and (Tx3/ Tx4) for 993 pb of tax region were used, as also shown in the table 
2.6. Thirty-five cycles of denaturation at 94ºC for 15s, annealing at 58ºC for 15s, and 
extension at 68ºC for 20s followed by a final extension at 68ºC for 2 min were used. 
The sequence positions are listed according to the Mo isolate (GenBank accession 
number M10060). 
 
• Sequencing and phylogenetic analysis 
 
PCR products are purified by ethanol precipitation method, to ensure good quality 
DNA templates for sequencing. After DNA precipitation, where competing ezymes or 
buffer components were eliminated, DNA pellet is air-dried and the DNA is 
resuspended in UltraPure DNase/RNase-Free Distilled Water (Life Technologies, New 
York, US). 
Purified PCR products were sequenced in a final volume of 15µl by using the ABI 
Big Dye Terminator v3.1 cycle sequencing reaction kit (Applied Biosystems, Foster 
City, CA) and processed with the ABI 310 Genetic Analizer (Applied Biosystem).  
Sequences were edited using SeqMan II Software version 5.0.1 (DNASTAR, 
Madison, WI) and aligned with MEGA software v4.0.2 together with reference 
sequences of the HTLV-2a subtype (Mo) and HTLV-2b subtype (G12 and NRA) whose 
GenBank accession numbers are shown in Table 2.7. Sequences from the samples 
studied were submitted to GenBank under the numbers shown in Table 2.7.  
Phylogenetic trees were generated using the unweight pair group method with 
arithmetic mean (UPGMA) by Clustal W v5.8 and MEGA v4.0.2. The neighbor-joining 
method was also used to corroborate them. The topology of the trees was supported 
by 1000 bootstrap replicates. Genetic distance was estimated by Kimura´s two-
parameter method. Some reported sequences from GenBank listed below (Table 2.8) 
were used for comparison purpose, and the simian T cell lymphotropic virus type 2 
(STLV-2) was used as outgroup. 
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Table 2.7  GeneBank accession numbers of previously published HTLV-2 gene fragments used 
for comparison purpose. 
 
 
Table 2.8  GeneBank accession numbers of HTLV-2 samples. 
 
 
 
GeneBank Accession Numbers of reported sequences 
Reference 
sequences 
Mo (M10060),  G12 (L11456), G2(AF07965), NRA (L20734), Gab (Y13051), Efe-
2 (Y14365), STLV-2 (U90557). 
For the LTR 
analysis 
NAV.DS (U10357), SMH2 (Y09148), PH230PCAM (Z46838), LA8A (U10356),  
KAY73 (L42509), BRAZ.A21 (U10253), ATL18 (U10252), Dub805 (AF175467), 
AA (L7738), DP (L7737), JA (L7739), BF (L77236), SPAN129 (U10265), 
SPAN130 (U10266), RVP (L77244), 130 (L77242), 324 (L77243), PortH1 
(AY622977), PortNn (AY622978), PortVs (AY622979), Gu (X89270), I-GI 
(Y09153), I-OV (Y09155), I-OG (Y09154), WYU1 (U12792), BBD_3126 
(FJ911656), BBD_2278 (FJ911644), BBD_2766 (FJ911652), BBD_2286 
(FJ911645). 
For the env 
analysis 
WY100 (S69268), Gu (X89270),  SP-WV (AF139382), RP329 (AF326583), K96 
(AF326584), AF4122314. 
For the tax analysis 
SMH2 (Y09148), Gal (AF292002), SP-WV (AF139382), K96 (AF326584), RP329 
(AF326583), KAY1 (U32874), KAY2 (U32875), SP1 (U32873), SP2 (U32872), 
PR-46 (DQ022075), FUC (U32882), PAR (U32880). 
GeneBank Accession Numbers of samples sequenced 
LTR fragment 
MA_CPE (GU455203), MA_DGE (GU455204), MA_FRM (GU455205), MA_MSC 
(GU455206), MA_JSR (GU455207), MA_CGO (GU455208), MA_GRO 
(GU455209), MA_SPG (GU455210), MA_ROL (GU455211), MA_VMM 
(GU455212), MA_CPE (GU455213), MA_CAS (GU4586121). 
Partial env gene 
MA_BMJ (GU586109), MA_DGE (GU586110), MA_FRM (GU586111), MA_MSC 
(GU586112), MA_JSR (GU586113), MA_CGO (GU586114), MA_GRO 
(GU586115), MA_SPG (GU586116), MA_ROL (GU586117), MA_VMM 
(GU586118), MA_CPE (GU586119), MA_CAS (GU586120). 
Partial  tax gene 
MA_BMJ (GU591294), MA_CGO (GU591295), MA_CPE (GU591296), MA_DGE 
(GU591297), MA_FRM (GU591298), MA_GRO (GU591299), MA_JSR 
(GU591300), MA_MSC (GU591301), MA_ROL (GU591302), MA_SPG 
(GU591303), MA_VMM (GU591304), MA_CAS (GU591305), 
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SUBSTUDY 2 
 
As secondary study, in the frame of two clinical trials, the evolution of HTLV-2 
proviral load was studied among HIV-1/HTLV-2 co-infected patients who intensified 
their cART with an integrase inhibitor (raltegravir) compared to those who did not. In 
this retrospective longitudinal study, DNA was extracted from cryopreserved PBMCs 
and total HTLV-2 proviral DNA was quantified by in-house real-time PCR. For viral and 
cellular gene quantification, two standard curves were generated in each run 
respectively, using recombinant plasmids containing one copy of HTLV-2 tax gene 
fragment or one copy of human genomic GAPDH gene fragment.  
 
3.21 Patients`s characteristics 
 
HTLV-2 proviral load was measured in this retrospective longitudinal study at 
baseline, week 24 and week 48 in HIV-1/ HTLV-2- coinfected patients with intensifying 
treatment with raltegravir compared and those without raltegravir intensifying therapy. 
Four HIV-1/HTLV-2-coinfected patients who intensified their antiretroviral 
treatment with 400 mg of an integrase inhibitor, raltegravir, twice daily, were recruited 
from Hospital Germans Trias I Pujol (Badalona, Barcelona, Spain) and Hospital Ramón 
y Cajal (Madrid, Spain). One of these patients was analyzed in two further time points, 
a second baseline and at week 4. Besides, eleven HIV-1/HTLV-2-coinfected patients 
who did not intensified their cART were also analyzed for 48 weeks as control group. 
The main inclusion criteria were as follows: HIV-1 infected adults receiving 
antiretroviral treatment for at least two years; undetectable plasma viral load (below 40 
copies HIV-1 RNA/ml) for at least two years; CD4+ T-cell count above 350 cells/mm3; 
and no previous RAL in their cART.  
The study was carried out according to the recommendations of the Declaration 
of Helsinki and current Spanish legislation on clinical trials. It was approved by the 
AEMPS (Spanish Agency for Medications and Health Products) and our local 
Independent Ethics Committee (Hospital Ramón y Cajal, Madrid, Spain). All patients 
provided written informed consent for participation, sample collection, and laboratory 
determinations. 
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ANTIRETROVIRAL TREATMENT INTENSIFICATION 
 
3.1 Patients characteristics 
 
 Baseline characteristics of the 16 HIV-1-infected individuals that undergo 
treatment intensification are summarized in Table 3.1. Median age was 46 years (IQR 
41–50) and no significant differences were found between CD4+ and CD8+ T-cell 
counts at baseline [676 cells/mm3 (IQR 522–828) and 678 cells/mm3 (IQR 567–1066), 
respectively, p=0.7] and at the end of 24-week follow-up [642 cells/mm3(IQR 552–722) 
and 647 cells/mm3 (IQR 439–886), respectively, p=0.1]. During follow-up, no changes 
were made in previous ART regimens. Seven of them intensified their treatment with 
maraviroc (MVC), while the other nine intensified with raltegravir (RAL). All individuals 
remained virally suppressed during the period of the study. 
Within the MVC group, the median age was 46 years and six patients were male. 
The median baseline CD4+ and CD8+ T-cell counts were 711 and 784 cells/mm3, 
respectively. All patients were receiving nucleoside reverse transcriptase inhibitor 
(NRTI)–containing regimens combined with non-nucleoside reverse transcriptase 
inhibitors (NNRTIs) in two cases (28%), with protease inhibitors (PIs) in five cases 
(43%), and with a third nucleoside in two cases (22%). The median duration of ART 
before study entry was 75 months with undetectable HIV-1 viral load, below 50 
copies/ml maintained until the end of the study 
While within RAL group, patients were predominantly male with a long history of 
ART (median 12 years). Median CD4 cell count was 655 cells/mm3 and median CD8 
cell count was 636 cells/mm3. Only two patients were coinfected with HCV (22%). All 
patients were receiving nucleoside reverse transcriptase inhibitors combined with 
nonnucleoside reverse transcriptase inhibitors in five cases (55%) and with protease 
inhibitors in four cases (44%) (Table 3.1). 
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Table 3.1: Baseline characteristics of the 16 HIV-1-infected individuals including in 
the treatment intensification according to the intensifying drug administered. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MVC: Maraviroc; RAL: Raltegravir; IDU: Intravenous drug use; HSx, unprotected 
heterosexual contacts; MSM: men who have sex with men; ART: antiretroviral therapy. 
Continuous variables are expressed as median and interquartile range (IQR). 
 
 
 
Variable MVC  (n=7) RAL  (n=9) Total  (n=16) 
Age (years) 46 [31-48] 48 [44-53] 46 [ 41-50] 
Male (%) 85.7% 100% 93% 
Risk factors (%) IDU (42.8%) 
MSM (42.8%) 
HSx (14.2%) 
IDU (25%) 
MSM (50%) 
HSx (25%) 
IDU (33.3%) 
MSM (46.6%) 
HSx (20%) 
Viral Load (copies/mL) < 50 copies/mL  < 50 copies/mL  < 50 copies/mL  
CD4 count (cells/mm3)                                         711 [547-793] 655 [417-877] 676 [522-828] 
CD8 count (cells/mm3) 784 [673-1109] 636 [367-827] 678 [567-1066] 
Duration of ART 
(months) 
75 [38-144] 144 [70-167] 110 [52-144] 
MVC intensification 
(%) 
100% - 46.6% 
RAL intensification 
(%) 
- 100% 53.3% 
CD4+ CD38+HLADR+ 
(%) 
3.1 % 2.4% - 
CD8+ CD38+HLADR+ 
(%) 
5.3% 3.8% - 
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3.2  Effect of treatment intensification on T-cell count 
 
Globally, no differences were observed in CD4+ or CD8+ T-cell counts either 
during follow-up 48 weeks of treatment intensification or after the 24 weeks of 
discontinuation with respect to baseline (Figure 3.1). 
 
 
 
 
 
 
 
Figure 3.1: Effects of maraviroc or raltegravir intensification on CD4+ and 
CD8+ T cell count. 
 
 
 
MVC group 
RAL group 
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3.3  Effect of treatment intensification on T-cell immune activation 
 
The level of CD4+ T cell activation decreased significantly after 12, 23 and 36 
weeks of maraviroc (MVC) intensification (p=0.028, p=0.027, and p=0.028, 
respectively), only to increase after 48 weeks,  although the difference with baseline 
was not significant (p=0.6). Compared to HIV-1-negative subjects, CD4+ T cell 
activation at baseline was significantly higher (p=0.001), with no significant differences 
at weeks 12 and 24 (p=0.950 and p=0.181, respectively). Despite no significant 
decrease in CD4+ T-cell activation was observed at week 48 after intensification in the 
MVC group, these levels were significantly lower at week 24 after discontinuation than 
at baseline (p=0.028). The effect of intensification with MVC in reducing CD8+ T-cell 
activation was maintained at week 12 and 24 after discontinuation compared with 
baseline (p=0.028 and p=0.028, respectively) (Figure 3.2a). 
The level of activation of CD8+ T cells also decreased significantly after 12 weeks 
of MVC intensification compared to baseline and continued diminished until the end of 
the study (p=0.043, p=0.025, p=0.028, and p=0.046, at weeks 12, 24, 36, and 48, 
respectively). The level of CD8+ T cell activation at baseline was higher than in the HIV-
1-negative subjects (p=0.001). And only at week 48 was this difference not significant 
compared to the HIV-1-negative group (p=0.181). Additionally, the effect of 
intensification with MVC in reducing CD8+ T-cell activation was maintained at week 12 
and 24 after discontinuation compared with baseline (p=0.028 and p=0.028, 
respectively) (Figure 3.2b). 
However, within RAL group, CD4+ T cell activation remained stable during 
intensification period or after RAL discontinuation, with no significant differences 
compared to baseline (Figure 3.2c). Nevertheless, CD8+ T-cell activation decreased 
after intensification, the difference being statistically significant at week 36 (p=0.028), 
with a clearly decreasing trend at week 48 (p=0.093) compared with baseline. The 
slight waning effect at week 48 was due to the increase of cell activation in only three 
patients. Besides, only the levels of CD8+ T-cell activation were significantly lower at 
week 24 after  discontinuation than at baseline (p=0.042) (Figure 3.2d). 
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Figure 3.2: Effects of treatment intensification with maraviroc (a, b) or raltegravir (c, d) and 
intensifying drug intensification discontinuation on CD4+ T cell (a, c) and CD8+ T cell (b, d)  
immune activation. 
 
 
 
MVC group 
a b 
RAL group 
c d 
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3.4  Effect of treatment intensification on T cell subsets 
 
Regarding to T cell subsets, a significant increase in CD8+ effector memory and 
TemRA T cell count was found during the first 12 and 24 weeks after MVC 
intensification, respectively. Thereafter, the differences compared to baseline were not 
significant (Figures 3.3c and 3.3d). These increments are balanced by a significant 
decrease in CD8+ central memory T cells at week 12 of MVC intensification (p=0.002), 
again with no differences thereafter compared to baseline (Figure 3.3b). Levels of 
naive CD8+ T cells were similar during follow-up, at all time points (Figure 3.3a). 
Further, no significant differences were observed in any CD4+ T cell subsets during 
follow-up (not shown). 
 
 
 
 
 
Figure 3.3: Effects of treatment intensification with maraviroc and intensifying drug 
discontinuation on naïve, and either central, effector or transitory memory CD8+ T cells. 
a b Naïve Central Memory 
c d Effector Memory TemRA 
Results 
62 
 
However, within RAL group, naïve CD4+ and CD8+ T cells remained stable during 
all time-points studied during treatment intensification and RAL discontinuation. 
Likewise, no other significant differences were found in the counts of either central, 
effector or transitory CD4+ or CD8+ T cells (not shown). 
 
3.5  Effect of treatment intensification on microbial translocation 
 
The effect of treatment intensification on microbial translocation was different 
whether individuals intensified with maraviroc or raltegravir. 
 
 
 
 
 
 
 
 
Figure 3.4: Effects of treatment intensification and drug discontinuation on either LPS 
or sCD14 levels. 
MVC group 
a b 
c d 
RAL group 
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Within MVC group, a significant increase in LPS level was observed after 24, 36 
and 48 weeks of intensification with MVC compared to baseline (p=0.006, p=0.006, 
and p=0.021, respectively). After 12 and 24 weeks of discontinuation, LPS levels 
progressively decreased to levels similar to those found at baseline (Figure 3.4a). 
Besides, sCD14 levels were also significantly higher after 24, 36 and 48 weeks of MVC 
intensification compared to baseline (p=0.015, p=0.028 and p=0.028, respectively). 
However, these levels reverted but remained significantly higher after 12 and 24 weeks 
after drug discontinuation (Figure 3.4b). 
On the other hand, within RAL group, LPS and sCD14 levels remained entirely 
stable during the follow-up period studied, except for the late decline in LPS with levels 
significantly lower at week 48 of intensification than baseline (p=0.008), decrease 
compensated after drug discontinuation with significant increase at week 12 and 24 
compared to week 48 (p=0.025 and p=0.036, respectively), but no significance when 
compared to baseline (Figure 3.5c and 3.5d).  
 
3.6 Effect of treatment intensification on the expression of gut homing β7 
receptor on activated T cells 
 
 
In individuals who received maraviroc intensification, the proportion of activated 
CD8+ T cells expressing β7 receptor also increased in at week 12 compared to 
baseline (p=0.046), and a trend to increase was observed during the rest of the follow 
up 48 weeks of intensification. After MVC discontinuation, the levels of CD8+β7+ T cells 
remained stable at week 12 and 24, but significantly higher when compared to levels at 
baseline (p=0.042 and p=0.043, respectively) (Figures 3.5a). No change in activated 
CD4+β7+ T cells were observed during the analyzed follow-up (Figures 3.5b). 
Contrarily, in individuals intensified raltegravir, the proportion of activated 
CD4+β7+ were stable during intensified period with a no significant decrease late at 
week 48. Those levels significantly increased at week 12 and 24 compared to week 48 
(p=0.012 and p=0.017, respectively), with levels similar to those found at baseline 
(Figures 3.5c). No change in activated CD8+β7+ T cells was observed during the 
analyzed follow-up (Figures 3.5d). 
 
Results 
64 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: Effects of maraviroc or raltegravir intensification on the proportions of the 
expression of gut homing β7 receptor on activated CD4+ or CD8+ T cells. 
 
 
3.7  Good correlation between microbial translocation measurements except for 
16S rDNA quantification 
 
Microbial measurements were performed in seven time points included in the 
study as follows: baseline, weeks 12, 24, 36 and 48 after the inclusion of the 
intensifying drugs, and weeks 12 and 24 after discontinuation of intensifying drugs from 
MVC group 
a b 
RAL group 
c d 
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the 16 patients recruited for the study. A total of 112 determinations performed from 
these patients at different time points were analyzed altogether.  
Plasma LPS determinations positively correlated with levels of sCD14 and LBP 
found (p=0.001 and p=0.042, respectively) (Figures 3.6a,b). Similarly, high levels of 
sCD14 were associated with high levels of LBP detected (p=0.009) (Figure 3.6c). No 
correlation was found, however, between bacterial 16S rDNA either with LPS, sCD14, 
or LBP levels (p=0.346, p=0.405, and p=0.644, respectively) (Figures 3.6d, e,f).  
 
 
 
 
 
Figure 3.6:  Correlation between different measurements of microbial translocation. Only 
significant data (p<0.05) are shown with regression lines and correlation coefficients, using 
Spearman correlation test. 
 
 
 
3.8   16S rDNA levels correlated with activated CD4+ T cells, while no correlation 
with CD8+ T-cell activation was evident 
 
No significant correlation was found between plasma levels of LPS, sCD14, or 
LBP and activated CD4+ T cells (p=0.418, p=0.619, and p=0.728, respectively) (Figure 
a b c 
f e d 
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3.7a) or activated CD8+ T cells (p=0.352, p=0.275, and p=0.124, respectively) (Figure 
3.7b). However, high levels of bacterial 16S rDNA quantified correlated significantly 
with high levels of activated CD4+ T cells (p=0.005) (Figure 3.7a) but not with activated 
CD8+ T cells (p=0.171) (Figure 3.7b).  
 
3.9  Association of microbial translocation and immune activation with T-cell 
subsets 
 
No association between microbial translocation measurements and CD4+ or 
CD8+ T-cell count or CD4/CD8 ratio was observed (not shown). Similarly, T-cell 
immune activation showed no significant correlation either with CD4+ or CD8+ T-cell 
count or CD4/CD8 ratio (not shown). 
No association was found between microbial translocation or immune activation 
with either naïve or memory CD4- or CD8- TCM, TEM or TemRA cells (not shown).  
 
 
 
 
 
Figure 3.7:  Correlation between different measurements of microbial translocation and 
immune activation. Significant data are shown with regression lines and correlation 
coefficients. 
 
 
a b 
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3.10  Association between microbial translocation and the expression of gut 
homing β7 receptor on activated CD4+ and CD8+ T cells 
 
Despite no significant correlation was found between microbial translocation and 
expression of gut homing β7 receptor on activated T cells (not shown), similar trend 
was observed during the follow up period studied. Furthermore, within maraviroc group, 
LPS levels correlated with activated CD4+ or CD8+ T cells 48 weeks after MVC 
intensification. However, this correlation was lost after discontinuation of the drug 
(Figure 3.8). 
 
 
 
 
Figure 3.8:  Correlation between LPS levels and activated CD4+ or CD8+ T cells bearing gut 
homing β7 receptor at baseline, after 48 weeks of MVC intensification and 12 and 24 weeks 
after drug discontinuation. Significant data are shown with regression lines and correlation 
coefficients. 
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COINFECTION WITH LEISHMANIA COMPARED TO 
IMMUNOLOGICAL DISCORDANT RESPONSE TO   
ANTIRETROVIRAL THERAPY 
 
3.11 Patients´ characteristics 
 
 Eight HIV-1-infected individuals with visceral leishmaniasis, 62.5% males, had a 
median age of 45 years, similar to the age of the two control groups with no co-
infection with Leishmania composed of 13 infected individuals with concordant 
response to antiretroviral therapy and 14 immunological non-responders or immune-
discordant patients. All three groups were receiving suppressive cART (HIV-1 viral load 
lower than 50 RNA copies/ml) with similar duration of both cART and viral suppression. 
 
 
 
 
Figure 3.9:  CD4+ T cell count and CD4/CD8 ratio in patients with 
concordant response (CR), discordant response (DR) or with visceral 
leishmaniasis (VL). 
 
 
All patients with VL but one were injecting drug users (IDUs) which is a different 
scenario compared to the risk factor of the other two control groups where patients with 
concordant response were predominantly men who have sex with men (MSM) (60%), 
and similar frequencies of IDUs and MSM were found within patients with discordant 
response (42.8% in both cases). Interestingly, while VL patients had significantly lower 
CD4 count and CD4/CD8 ratio 
a b 
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levels of CD4 count, CD4/CD8 ratio and CD4 nadir compared to CR patients (p<0.001, 
p<0.001, and p=0.001, respectively), they had higher levels of CD4 count and 
CD4/CD8 ratio compared to DR patients (p=0.005 and p=0.038, respectively), while no  
significant differences were found in nadir CD4 count (Figure 3.9). Most of the VL 
patients were infected with VHC (75%) and had a time of diagnosis of VL similar to the 
duration of cART (75%). Clinical and laboratory characteristics are shown in Table 3.2. 
 
3.12  Immune activation 
CD4+ T-cell activation in VL patients was similar to DR patients (p=0.402), but 
significantly higher compared to CR patients (p<0.001). On the other hand, CD8+ T-cell 
activation was significantly higher in VL patients compared to both DR and CR patients 
(p=0.010 and p<0.001, respectively) (Figure 3.10a). 
 
Table 3.2: Baseline characteristics of the HIV-1 infected patients included in the study. HSx, unprotected 
heterosexual contacts; MSM: men who have sex with men. Significant values when p<0.05, comparison 
VL vs CR and VL vs DR shown. 
 VL patients 
N=8 
 CR patients 
N=15 
 
p 
DR patients 
N=14 
 
p 
 
      
Age (years) 45 [43-51]  45 [32-53] 0.728 47 [41-59] 0.664 
Gender (male %) 62.5  86.6  92.8  
Risk factors (%) 
IDU 
MSM 
HSx 
 
87.5 
- 
12.5 
  
13.3 
60 
26.7 
  
42.8 
42.8 
14.3 
 
CD4 count (cells/mm3) 331 [145-667]  680 [527-825] <0.001 143 [88-159] 0.006 
CD8 count (cells/mm3) 679 [546-1029]  675 [544-906] 0.776 691 [569-850] 0.815 
CD4/CD8 ratio 0.42 [0.21-0.96]  1.0 [0.84-1.44] <0.001 0.19 [0.09-0.32] 0.035 
Nadir CD4 (cells/mm3) 34 [16-68]  202 [62-317] 0.001 50 [26-99] 0.441 
cART (months) 172 [74-203]  89 [43-144] 0.065 156 [97-197] 0.799 
HIV-1 suppression 
(months) 
59 [26-125]  63 [43-110] 0.824 69 [28-102] 0.799 
HCV infection (%) 75  13.3  57  
       
VL diagnosis (months) 53 [36-165]  -  -  
Relapses of VL 3 [2-8.5]  -  -  
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3.13  Inflammation and microbial translocation 
 
Plasma IL-6 levels were significantly elevated in VL patients compared to both 
DR (p=0.035) and CR patients (p<0.001) (Figure 3.10b). While LPS levels in VL 
patients had significant higher levels compared to CR patients (p=0.001) and similar 
levels compared to DR patients (p=0.297) (Figure 3.10c), plasma sCD14 levels were 
significantly higher compared to both DR and CR patients (p<0.001 in both) (Figure 
3.10c). Additionally, no association between time of VL diagnosis and number of VL 
relapses with inflammation and microbial translocation was found. 
 
 
 
 
 
 
 
 
 
 
Figure 3.10:  CD4+ and CD8+ T cell immune activation (a), levels of IL-6 immune 
inflammation (b) and microbial translocation measured by LPS and sCD14 levels (c). 
a. Immune activation 
c. Microbial translocation b. Inflammation 
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3.14  Immune senescence 
 
VL patients had similar level of CD4+ T-cell senescence compared to DR 
patients, but significantly higher compared to CR patients (p=0.037), despite similar 
age of the patients in each of the three groups. Similarly, levels of activated CD4+ T-cell 
senescence in VL patients were not different from those in DR patients, but again 
significantly higher compared to CR patients (Figure 3.11a).  
Interestingly, CD8+ T-cell senescence was higher in VL patients compared to DR 
patients, although not significant (p=0.059). However, significantly higher levels were 
found in activated CD8+ T-cells compared to DR patients (p=0.005). Both senescence 
levels were significantly higher compared to CR patients (p<0.001 in both cases) 
(Figure 11b). No association between time of VL diagnosis and number of VL relapses 
with cellular senescence markers was found. 
 
 
 
 
 
 
 
Figure 3.11:  Immune senescence in both CD4+ (a) and CD8+ (b) T cells. 
a. Senescence in CD4+ T cells 
b. Senescence in CD8+ T cells 
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3.15  Factors independently associated with immune activation 
 
Several factors were independently associated with immune activation (both 
CD4+ and CD8+ T-cell activation as dependent variables) to analyze whether HCV 
infection could influence the results of immune activation. As shown in table 3.3, 
CD4/CD8 ratio and sCD14 levels were independently associated with CD4+ T-cell 
activation (p=0.045 and p=0.025, respectively), while leishmaniasis and sCD14 levels 
were independently associated with CD8+ T-cell activation (p=0.046 and p=0.003, 
respectively). Therefore, leishmaniasis rather than HCV greatly contributes to the hyper 
immune activation. No association between both time of VL diagnosis and number of 
VL relapses with immune activation, CD4 count or CD4/CD8 ratio was found. 
 
 
Table 3.3: Multivariate analysis: factors independently associated with immune activation 
(dependent variables CD4+ and CD8+ T cell activation). 
 
 
 
 
 
 
CD4+ T cell activation 
 
CD8+ T cell activation 
 Coefficient (95% CI) p  Coefficient (95% CI) p 
CD4 count 
CD4/CD8 ratio  
Nadir CD4 count 
 
Leishmaniasis 
VHC infection 
 
IL-6 
LPS 
sCD14 
-0.003 (-0.009-0.002) 
-2.470 (-4.881- -0.058) 
0.009 (-0.002-0.020) 
 
-8.810 (-18.029-0.409) 
 1.093 (-1.673-3.859) 
 
0.039 (-1.120-1.198) 
-0.064 (-0.191-0.063) 
4.081 (0.546-7.617) 
0.234 
0.045 
0.105 
 
0.060 
0.424 
 
0.945 
0.308 
0.025 
 
-0.001 (-0.015-0.012) 
-5.216 (-10.817-0.384) 
0.018 (-0.008-0.044) 
 
-21.850 (-43.259- -0.440) 
-2.334 (-8.757-4.090) 
 
0.843 (-1.849-3.535) 
-0.173 (-0.468-0.122 
13.199 (4.988-21.410) 
0.838 
0.067 
0.161 
 
0.046 
0.462 
 
0.525 
0.238 
0.003 
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3.16  Correlation between immune activation, inflammation and microbial 
translocation 
 
Among VL patients, there was a significant positive correlation between both 
CD4+ and CD8+ T-cell activation with sCD14 levels (p=0.048, r=0.711 and p=0.017, 
r=0.801, respectively). Moreover, IL-6 level correlated with LPS and sCD14 levels 
(p=0.001, r=0.935 and p=0.010, r=0.833 respectively), but not with T-cell activation 
(Figure 3.12a).  
On the other hand, among DR patients, a significant correlation between CD4+ T-
cell activation and sCD14 levels (p=0.048, r=0.553), and between IL-6 and LPS levels 
(p=0.023, r=0.601) were found (Figure 3.12b).  
Among CR patients no correlation was found between immune activation and 
inflammation or microbial translocation. Nevertheless, LPS correlated with sCD14 in 
the three groups of patients, i.e., VL (p=0.011, r=0.826), DR (p=0.001, r=0.779), and 
CR patients (p=0.046, r=0.659) (not shown). 
 
 
 
 
Figure 3.12:  Correlation between immune activation or inflammation and microbial 
translocation, in VL patients (a) and immunodiscordant patients (b). Significant data are shown 
with regression lines and correlation coefficients. 
 
a. Visceral Leishmaniasis patients b. Immunodiscordant patients 
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COINFECTION WITH HTLV-2 IN BOTH HIV-1/HCV COINFECTED AND 
HIV-1 MONOINFECTED INDIVIDUALS 
 
 
3.17 Screening for patients infected by HTLV-2 
 
A total of 1673 HIV-1 infected patients with regular medical appointments are 
included in the HIV cohort in the Hospital Ramón y Cajal, Madrid, at the end of the 
2010. Of them, 798 individuals had a history of intravenous drug use (Figure 3.14) and 
were included for the screening of HTLV-1/2 infection, following the diagnostic 
algorithm proposed by the HTLV European Research Network (HERN) criteria. 
A total of 68 virologically suppressed HIV-1 infected patients (below 50 copies/ml) 
on cART, were diagnosed by HTLV-2 coinfection (Figure 3.13), 72% were men while 
28% were women. They had a median age of 45 [IQR 42-49] years old with CD4+ T 
cell count of 490 [IQR 297-599] and CD8+ T cell count of 923 [IQR 625-1305]. From 
these patients, 67% were also infected by HCV, while the other 33% were HCV- (Figure 
3.13).  
 
 
 
Figure 3.13:  HTLV-2 infection among HIV-1 infected IDUs 
In the Hospital Ramón y Cajal HIV cohort. 
. 
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3.18  HTLV-2 infected patients 
 
Sixty-one HTLV-2-infected individuals with undetectable HIV-1 viral load on 
suppressive regimen at least for one year, were selected for the study. Forty of them 
were also infected by HCV, while the other 21 were not. However, no significant 
differences were found in age or T cell count among HTLV-2-infected individuals 
whether they were also infected with HCV or not. General clinical characteristics of 
HTLV-2 infected patients studied are shown in table 3.4 
 
3.19  HTLV-2 proviral load 
 
HTLV-2 proviral load (pVL) was determined in all these sixty-one HTLV-2-
infected individuals. Univariate analysis was performed to evaluate which factors were 
independently and significantly associated to the HTLV-2 pVL. In this case, CD8+ T cell 
count, both CD4+ and CD8+ T cells frequency and the CD4/CD8 ratio. Further, these 
four significant variables were analyzed simultaneously in a multivariate analysis 
showed that only CD8+ T cell count was independently and significantly associated to 
HTLV-2 pVL (Table 3.5). 
Additionally, we observed significantly higher HTLV-2 pVL in patients coinfected 
with HCV compared to those with no HCV infection (Figure 3.14).  However, regarding 
to the gender of the participants, no difference in HTLV-2 pVL was found between male 
and women. 
 
 
Figure 3.14:  HTLV-2 pVL in HIV-1 infected patients regarding to HCV infection (a) 
and HTLV-2pVL variation whether infected individuals are women or men (b). 
a.  b.  
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Table 3.4: Epidemiological and clinical characteristics of the HTLV-2-HIV-1-co-infected patients. 
 
 
             
 
HTLV-2/HIV-1 coinfected individuals  HIV-1 infected individuals  All HCV+   HCV- 
 
All    N=61 HCV+   N=40 HCV-   N=21 p  All    N=90 HCV+  N=48 HCV-  N=42 p  p p p 
Age (years) 46 [42-49] 45 [43-50] 46 [40-49] 0.246  47 [44-50] 47 [43-49] 47 [44-51] 0.967  0.081 0.203 0.144 
Gender (male) 24.6 (75.4%) 27.1 (72.5%) 19 (81%) 0.459  26.7 (72.2%) 25 (75%) 28.6 (69%)   0.745 0.794 0.373 
CD4 count  484 [298-610] 486 [297-599] 484 [276-674] 0.931  498 [299-702] 459 [235-654] 629 [361-727] 0.109  0.329 0.878 0.296 
CD8 count  920 [645-1328] 988 [658-1477] 812 [592-1008] 0.130  821 [560-1041] 843 [621-1060] 709 [549-1041] 0.186  0.041 0.056 0.606 
CD4 frequency  23.2 [14.7-31.6] 21.7 [14.2-30.5] 24.6 [18-34.8] 0.486  24.8 [17.5-32.9] 23.5 [16.9-30.2] 29.8 [19.0-38.3] 0.024  0.418 0.950 0.352 
CD8 frequency  48.6 [37.7-58.3] 52.3 [39.5-59.6] 41.6 [31-57.5] 0.125  42.6 [33.9-51.2] 44.3 [36-54.5] 38.1 [30.1-48.7] 0.013  0.935 0.064 0.521 
CD4/CD8 ratio 0.51 [0.28-0.81] 0.43 [0.26-0.78] 0.60 [0.42-0.84] 0.322  0.58 [0.37-0.98] 0.53 [0.36-0.70] 0.76 [0.40-1.17] 0.011  0.149 0.797 0.161 
Nadir CD4 124 [41-214] 132 [66-189] 84 [37-236] 0.870  144 [65-222] 117 [66-169] 188 [50-244] 0.122  0.733 0.449 0.337 
Time on cART 156 [116-195] 167 [115-195] 153 [117-167] 0.694  179 [118-211] 183 [163-213] 152 [97-196] 0.014  0.096 0.015 0.955 
Time with HIV-1 
suppression  
51 [28-79] 52 [26-76] 48 [36-106] 0.315  85 [46-109] 76 [40-109] 94 [64-108] 0.522  0.003 0.017 0.158 
HCV viral load  - 6.0 [5.5-6.7] - -  - 6.3 [5.4-6.6] -   - 0.829 - 
Pre-ART HIV1 VL 4.7 [3.9-5.2] 4.6 [4.0-5.2] 4.7 [3.6-5.1] 0.992  5.2 [4.7-5.6] 5.3 [4.8-5.6] 5.1 [4.6-5.6] 0.275  <0.001 <0.001 0.005 
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Table 3.5:  Univariate and Multivariate analysis: factors independently associated with immune 
activation (dependent variable HTLV-2 proviral load). 
 
 
 
3.20  HTLV-2 non-infected control groups 
 
Ninety HIV-1 infected individuals seronegative for HTLV-2 infection with 
undetectable HIV-1 viral load on suppressive regimen at least for one year, were 
selected as control group for this study. Forty-two of them were also infected by HCV, 
while the other 21 negative for HCV infection. General clinical characteristics of HIV-1 
infected patients studied are shown in table 3.4. 
 Univariate (p, r2) 
 
Multivariate (p, coefficient)  
HTLV-2 pVL                   
dependent variable 
  All             
N=60 
HCV+       
N=40 
HVC- 
N=21 
 All                                     
N=61 
HCV+                       
N=40 
Age (years) 
Gender 
Time on cART (months) 
Time with undetectable  
    HIV-1 viral load (months) 
Pre cART log HIV-1 viral load      
    (RNA copies/ml) 
0.750 
0.941 
0.506 
 
0.592 
0.837 
0.838 
0.858 
0.539 
 
0.494 
0.215 
0.383 
0.863 
0.604 
 
0.428 
0.096 
 
  
Nadir CD4 (cell/mm3) 
CD4 count (cell/mm3) 
CD8 count (cell/mm3) 
CD4 frequency (%) 
CD8 frequency (%) 
CD4/CD8 ratio 
CD4 T cell activation (%) 
CD8 T cell activation (%) 
Log HCV viral load (IU/ml) 
0.886 
0.930 
0.001, 0.426 
0.020, -0.298 
<0.001, 0.448 
0.002, -0.386 
0.548 
0.852 
0.993 
0.483 
0.399 
<0.001, 0.534 
0.001, -0.499 
0.002, 0.469 
0.002, -0.482 
0.398 
0.716 
 
 
0.458 
0.287 
0.871 
0.615 
0.192 
0.980 
0.393 
0.366 
 
  
 
<0.001, 2.851  
0.469 
0.091 
0.192 
 
 
 
<0.001, 3.057  
0.681 
0.619 
0.662 
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3.21 Characteristics associated to HIV-1 infection modified by HTLV-2 
coinfection 
 
Significant differences mainly in HIV-1 viral load previous treatment with 
antiretroviral therapy and in CD8+ T cell count were found when compared the 61 
HTLV-2/HIV-1 coinfected individuals with the 90 HIV-1-infected individuals (Table 3.4). 
Both differences were maintained among individuals coinfected with HIV-1/ HCV when 
compared based on HTLV-2 coinfection. However, when there was no HCV infection, 
only HIV-1 viral load previous treatment remained significantly different between HIV-
1/HTLV-2 coinfected and those HIV-1-monoinfected individuals (Table 3.4). 
Therefore, CD8+ T cell count were significantly higher in HIV-1 infected 
individuals also infected by HTLV-2 compared to those HTLV-2 seronegative (Figure 
3.15a). Despite HIV-1 viral load before starting antiretroviral therapy was significantly 
lower in HIV-1 who were also infected by HTLV-2 compared to those who were not, 
they had similar nadir CD4+ T cells (Figure 3.15 b,c). 
 
 
 
 
Figure 3.15:  Differences in CD8+ T cell count (a), log HIV-1 viral load (b) and nadir CD4+ T 
cells (c) in HIV-1 infected patients regarding to HTLV-2 coinfection. 
 
 
3.22  Immune activation 
 
Activated CD8+ T cells were significantly elevated in HCV/HIV-1 coinfected 
individuals when compared to HIV-1 monoinfected ones. Strinkingly, those elevated 
b.  Log HIV-1 viral load c.  Nadir CD4+ T cells a.  CD8+ T cell count 
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levels of activated CD8+ T cells were significantly reduced with HTLV-2 infection. We 
further analyzed levels of activated CD8+ T cells stratifying patients according to their 
CD4+ T cell count. The decrease observed in percentage of activated CD8+ T cells 
when HIV-1/HCV coinfected patients were also infected by HTLV-2 was mainly 
generated in individuals whose CD4+ T cell count was above 500 cells/mm3 (Figure 
3.16a). This decrease was also observed in HIV-1/HCV coinfected individuals with  
CD4+ T cells between 200 and 400 cells/mm3, though no significant (Fig. 3.16b) and 
was completely lost in HIV-1/HCV coinfected individuals below 200 CD4+ T cells/mm3 
(Fig. 3.16c). No significant differences were found in levels of activated CD4+ T cells 
among HTLV-2 infection in any group studied based on CD4+ T cell counts (not 
shown). 
 
 
 
 
 
Figure 3.16:  Differences in activated CD8+ T cells among HIV-1-infected individuals 
stratified based on CD4+ T cell count, superior to 500 cells/ mm3 (a), between 200 and 500 
cells/mm3 (b) and below 200 cells/mm3 (c). 
 
3.23  Influence of HTLV-2 over HCV infection 
 
Similar levels of log HCV viral load were found among HIV-1/HCV coinfected 
individuals whether they were coinfected with HTLV-2 or not (Fig. 3.17a).  
However, when transaminase enzymes were analyze, similar levels of aspartate 
transaminase (AST) or glutamic oxoloacetic transaminase (GOT) were detected among 
HCV-infected patients, regardless of whether they were infected by HTLV (Fig. 3.17b). 
Interestingly, levels of alanine transaminase (ALT) or glutamic-pyruvic transaminase 
c.  CD4+ < 200 cells/mm3 a.  CD4+ > 500 cells/mm3 b.  200 ≤ CD4+ cells ≥ 500 
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(GPT) were significantly lower in HCV also infected by HTLV-2 when compared to 
those HCV-infected individuals negative for HTLV-2 (Fig. 3.17c). 
Additionally, the analysis of Fibroscan values from HCV-infected patients showed 
a significantly lower degree of liver fibrosis in HCV-infected patients also infected by 
HTLV-2 than HCV-infected individuals without HTLV-2 infection (Fig. 3.17d). 
 
 
 
 
 
 
 
Figure 3.17:  Log HCV viral load (a), levels of transaminase enzymes 
(b,c) and levels of fibroscan (d) analyzed in HIV-1/HCV-coinfected 
individuals also infected by HTLV-2. 
 
a.  Log HCV viral load b.  AST/GOT transaminase 
c.  ALT/GPT transaminase d.  Liver fibrosis 
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SUB-STUDY 1 
 
3.24  Patients´ characteristics 
 
Seventeen HTLV-2 infected individuals coinfected with HCV and HIV-1 with a 
median age of 47 years, similar to the age of the two control groups non-infected by 
HTLV-2, composed of eight individuals coinfected by HIV-1/HCV and 11 HIV-1-
monoinfected individuals, with a median age of 47 and 48, respectively. All three 
groups were receiving suppressive cART (HIV-1 viral load lower than 50 RNA 
copies/ml) with similar CD4+ T cell count superior to 200 cells/mm3 in all participants 
and similar CD8+ T cell count. 
We also analyzed twelve of the HTLV-2 infected patients studied 
epidemiologically through LTR, env and tax viral genes. All of them belonged to HTLV-
2b subtype, closely related to HTLV-2b strains from Portuguese and Italian IDUs, and 
differentiated from HTLV-2a strains, the main subtype circulating in North Europe 
(Figure 3.18). 
 
 
 
Figure 3.18:  Epidemiological study of HTLV-2 subtypes among HIV-1 infected patients. 
LTR gene (320 bp) env gene (777 bp) tax gene (993 bp) 
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3.25 Microbial translocation 
 
Plasma LPS levels in HIV-1 patients coinfected by HCV and HTLV-2 were 
significantly lower than either HIV-1/HCV coinfected (p=0.014) or HIV-1 monoinfected 
individuals (p=0.04). However, no difference was found in LPS between the HTLV-2-
seronegative groups (Figure 3.19).  
Similarly, levels of sCD14 were significantly lower than HIV-1-infected patients, 
but no significance was found when compared to HIV-1/HCV coinfected individuals 
(p=0.013). No difference was either found among HTLV-2-seronegative individuals. 
 
 
Figure 3.19:  Microbial translocation in HTLV-2-infected individuals compared 
to both HIV-1/HCV-coinfected or HIV-1 monoinfected individuals. 
 
 
3.26 Cytokine profile 
 
Plasma IFN-γ levels were significantly higher in HTLV-2 infected individuals 
compared to both groups not infected by HTLV-2, either HIV-1/HCV infected (p=0.009) 
or HIV-1-monoinfected individuals (p<0.001) (Figure 3.20a). Similar levels of both IL-6 
and TNF pro-inflammatory cytokines were found in plasma from the three groups of 
patients analyzed (Figure 3.20b and 3.20c).  
Levels of IL-17 detected in plasma of HTLV-2-infected individuals were 
significantly higher than both HIV-1/HCV-coinfected (p=0.011) or HIV-1-monoinfected 
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individuals (p<0.001). Again, no significant differences were found among individuals 
not infected by HTLV-2.  
 
 
 
 
 
 
Figure 3.20:  Levels of cytokines in plasma of HTLV-2-infected individuals compared 
to both HIV-1/HCV-coinfected and HIV-1 monoinfected individuals. 
 
 
When analyzed levels of cytokines from HIV-1 patients analyzed all data 
together, only significant correlation was found between levels of IL-17A and IFN-γ (not 
shown). Neither significant correlation was found between levels of cytokines and 
levels of microbial translocation measured by LPS or sCD14 (not shown). 
 
a. IL-6 levels b. TNF levels 
c. IFN-γ levels d. IL-17A levels 
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SUB-STUDY 2 
 
3.27  Patients´ characteristics 
 
Four patients who intensified their suppressive regimen with an integrase inhibitor 
(raltegravir) were analyzed. They had a median age of 51 [48-55], CD4 count of 215 
[97-251] cells/mm3, and CD8 count of 819 [658-929] cells/mm3. Besides, a total of 11 
HTLV-2-HIV-1-coinfected patients who did not intensify their cART with raltegravir were 
also analyzed as control group. The 11 patients from the control group had median age 
of 50 [46-56] years, CD4 count of 524 [307-1060] cells/mm3, CD8 count of 980 [690-
1308] cells/mm3, and nine of them were male (82%). All the patients included in this 
study had undetectable HIV-1 plasma viremia (<50 HIV-1 RNA copies/ml) on cART for 
more than a year (Table 3.18). 
 
3.28  T cell count 
 
Neither CD8 count nor frequency, cells that are the main target for HTLV-2, 
showed any statistical change during the follow up among patients who received 
raltegravir as shown in figure 3.18. Among the control group, no significant variation in 
either CD8 count or frequency was found during the follow up (not shown). 
Regarding CD4+ T cells, other potential target for HTLV-2 infection, no significant 
variation of either counts or frequency was found. Only two patients increased either 
their CD4 counts or frequency (Ral1 and Ral3, table 1) at week 24 compared to 
baseline (Figure 3.22.). Among the control group, no significant variation in either CD4 
count or frequency was found during the follow up (not shown). 
 
3.29  HTLV-2 proviral load 
 
During raltegravir intensification, HTLV-2 pVL significantly increased at week 24 
compared to baseline in all four patients (p=0.003), as shown in figure 3.23a. At week 
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48 compared to week 24 a significant decrease of HTLV-2 pVL was found (p=0.020), 
reaching baseline levels. Among the control group, with no raltegravir in their cART, 
HTLV-2 pVL did not show any significant variation during the follow up, as shown in 
figure 3.23b. 
 
 
 
Figure 3.22: CD4 and CD8 T cell characteristics during the follow up and type of 
treatment of the patients who received raltegravir-based cART.  Cell count in 
cells/mm3; cell frequency in percentage; IQR, interquartile range; Significant when 
p<0.05 (paired samples t test). 
 
 
 
 
Figure 3.23: HTLV-2 pVL during the follow-up in patients with raltegravir-based 
cART (a) and patients with cART (b). Significant when p<0.05. 
a. Raltegravir-based cART b. cART 
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ANTIRETROVIRAL TREATMENT INTENSIFICATION 
 
 
Intensification of successful antiretroviral therapy has been evaluated as a 
strategy to help to eradicate HIV-1. The role of intensification in reducing residual 
replication and cell infection by the replicative virus has been supported by several 
studies256-258. One of them showed that intensification with raltegravir was associated 
with a significant decrease in proviral DNA in gut-associated lymphoid tissue (GALT)108, 
and a decrease in unspliced HIV-1 RNA in CD4+ T cells obtained from the terminal 
ileum259, whereas no significant effect was observed on residual viremia. The 
hypothesis supported in these studies would be that the effect of intensification takes 
place mainly outside plasma sites, such as the GALT, where ART may not reach 
inhibitory levels, with the result that HIV-1 is able to replicate and infect new cells260.  
Activated CD8+ T cells decreased during treatment intensification either with 
maraviroc or raltegravir. Therefore, the effect of treatment intensification seems to be 
not related to specific drug class. Moreover, this effect does not either seem to be due 
to a dilutional effect as a result of cell trafficking from plasma to the gut, because T-cell 
counts were stable during intensification. 
The decrease observed in immune activation does not correlate with a decrease 
in bacterial translocation, which in fact increased in individuals who intensified their 
therapy with MVC, thus supporting increased viral replication and activation in the 
intestine resulting from the release of pro-inflammatory cytokines261. 
Within MVC group, the transient increase in TEM and TemRA CD8+ T cell counts 
parallels the increase in bacterial translocation. These increments are balanced by a 
transient decrease in central memory CD8+ T cell counts, while naive CD8+ T cells 
remained stable262. 
Additionally, levels of microbial translocation increased during maraviroc 
intensification in parallel to levels of activated T cells bearing β7, favouring the idea of 
cells recruitment from peripheral blood to the gut tract as the major mechanism to 
recover the mucosa integrity. Hence, microbial translocation and systemic inflammation 
would be reduced163-164. Interestingly, this cell recruitment is reverted when microbial 
translocation is not longer increasing after 24 weeks of maraviroc discontinuation. 
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In accordance to these findings, within maraviroc group there is a strong 
correlation between both activated CD4+β7+ and activated CD8+β7+ T cells with LPS 
levels at the end of the intensification treatment, when the alteration of microbial 
translocation is the hieghest. 
Within raltegravir group, bacterial translocation, levels of gut homing receptor β7 
and T-cell subpopulations, that is naïve CD4+ or CD8+ T cells, TCM, TEM and TEMRA 
were stable during the follow-up period. No correlation between microbial translocation 
and either homing gut receptor expression on T cells or T-cell subsets were found. 
On the other hand, analyzing patients on treatment intensification all together at 
the different time points, significant correlation between plasma LPS, LBP and sCD14 
levels were found, in agreement with other studies263. Nevertheless, no correlation 
between 16S rDNA and the other measurements of microbial translocation was found 
in our study, although this correlation has been reported by other authors who 
evaluated both treatment-naive and -experienced patients264. The fact that our study 
included only patients on long-term cART who were virologically suppressed and with 
good immunological recovery may explain the discrepancy between our results and 
those of the other studies, including mixed populations. 
Microbial translocation has been proposed as a possible driver mechanism of 
immune activation in HIV-1 infection265-266, supported by the correlation between LPS 
levels and circulating CD8+ T cells expressing CD38+ and HLA-DR+ observed in 
chronically infected HIV-1 patients, elite controllers, and naive patients267. Another 
group found a correlation between 16S rDNA and CD8+ T-cell activation (p=0.047), but 
only when aviremic- and viremic-treated patients were analyzed together145. On the 
other hand, other studies failed to show this correlation during treatment interruption268 
or in patients undergoing raltegravir treatment intensification269. We did not observe 
any correlation between the levels of LPS, LBP, or sCD14 with immune activation.  
Considering these data, we are unable to ensure that microbial translocation 
directly triggers T-cell immune activation, at least among these patients with relatively 
good immune recovery and under treatment intensification, although this process is 
clearly an important component of innate immune inflammation associated to HIV-1 
infection. 
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COINFECTION WITH LEISHMANIA COMPARED TO 
IMMUNOLOGICAL DISCORDANT RESPONSE TO ART 
 
Immunossupressed HIV-1-infected patients showed inefficient T-cell response 
compromising parasite control in Leishmania co-infection, resulting in frequent relapses 
especially in VL, despite antiretroviral therapy270-272. Conversely, Leishmania infection 
can promote HIV-1 replication180 and increases the degree of immune system 
activation273. 
VL patients showed lower levels of CD4 counts compared to CR patients despite 
similar time on suppressive regimen, with levels similar to those observed in DR 
patients. This may be partially explained by the depletion of bone marrow precursor 
cells associated to Leishmania in individuals concomitantly infected with HIV-1 leading 
to deficiencies in the input of new lymphocytes into the periphery, though these values 
still remained superior to DR patients in some cases274. 
Another contribution for this immunosuppression is the elevated levels of T-cell 
activation in VL patients compared to those without leishmaniasis that lead to elevated 
T-cell depletion. This elevated immune activation was independently associated with 
CD4/CD8 ratio, leishmaniasis and sCD14 levels, but not with the presence of HCV 
infection. Therefore, the contribution of leishmaniasis to cell activation in VL patients 
was stronger than that observed in HCV infection.  
Moreover, the elevated immune activation was associated to an increase of T-cell 
senescence, despite similar age of the groups studied, which might accelerate the 
impairment of the immune effector function, and could explain the lack of 
immunological recovery also observed.  
On the other hand, the increased levels of sCD14 in VL patients may indicate 
higher levels of microbial translocation. However, Leishmania infect and may activate 
monocyte/macrophage linage increasing sCD14 secretion. For this reason, sCD14 
levels in this subgroup of patients may is not an adequate indicator of microbial 
translocation, at least as a single measurement. 
In any case, LPS levels in VL patients were higher than levels found in DR 
patients, though no significant. The overactivation of monocyte/macrophage lineage 
produced by Leishmania may impair the phagocitosis of microbial products leading to 
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the increase in LPS levels. Elevated levels of microbial translocation among VL 
patients, similar or even higher to those found in DR patients, suggest further 
deterioration of the mucosal tissue strongly associated to Leishmania infection that 
might increase proinflammatory response and immune activation. According to this 
hypothesis, we observed correlation between microbial translocation and inflammation 
in VL patients, only partially observed among DR patients. And furthermore, sCD14 
correlated with immune activation in VL patients and, again, only partially among DR 
patients.  
Our results show that VL is an independent cause of increased levels of immune 
activation, inflammation and microbial translocation compared to HIV-1 infected 
patients without leishmaniasis despite HIV-1 viral load suppression.  
 
The main limitation in this study is the small number of VL patients although most 
of the published studies are performed with a limited number of patients. 
 
COINFECTION WITH HTLV-2, HEPATITIS C VIRUS (HCV) AND HIV-1 
 
 
HIV-1 and HTLV-2 coinfection is found with relatively high frequency among 
injecing drug users in North America and Western Europe212-214. We found prevalence 
rate for HTLV-2 infection of 8.5% in HIV-1-infected patients with a history of injecting 
drug use in our centre. Twelve of these patients epidemiologically analyzed revealed 
that HTLV-2b remained the prevalent circulating subtype in Spain, closely related to 
Italian and Portuguese IDUs. 
Several studies emphasized the beneficial influence of HTLV-2 infection on HIV-1 
disease progression231-232,275.Even more, coinfection with HIV-1/HTLV-2 was found in 
many long-term non-progressors, where HTLV-2 infection was able to modify innate 
host immune responses by hampering the fusion and entry of the most commonly 
transmitted HIV-1 strains234-235. 
Supporting the protective role of HTLV-2 infection on the pathogenesis of HIV-1 
disease, we found significantly lower plasma HIV-1 RNA levels in HTLV-2 coinfected 
individuals than individuals negative for HTLV-2 infection, despite having similar nadir 
CD4+ T cell count and CD4+ T cell count.  
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Additionally, we found higher levels of CD8+ T cell count in HTLV-2 coinfected 
patients. Moreover, CD8+ T cell count, the main target of HTLV-2 infection, was 
strongly and independently associated to HTLV-2 proviral load.  
Further analysis of HTLV-2-coinfected patients regarding to HCV infection 
revealed that, within HCV-coinfected patients, the HTLV-2 proviral load was 
significantly higher than those negative for HCV infection. This finding was indicating 
that each HCV or HTLV-2 virus influenced the pathogenesis and natural history of the 
other. Despite elevated rates of HCV/HTLV coinfection, epidemiological and clinical 
features of coinfection have been overlooked.  
Therefore, we evaluated the role of HTLV-2 infection in HIV-1 infected patients 
classified by HCV infection. Interestingly, we found that among HIV-1/HCV coinfected 
patients, HTLV-2 infection significantly reduced levels of activated CD8+ T cells in 
patients with good immune recovery (CD4+ counts greater than 500 cells/mm3), levels 
of alanine transaminase and liver fibrosis, clearly indicating a further protective role of 
HTLV-2 infection in HCV-infection and liver disease, the current leading cause of death 
among HIV-1-infected individuals194. 
Further sub-studies evaluating the influence of HTLV-2 infection on microbial 
translocation and secretion of proinflammatory cytokines among HIV-1/HCV coinfected 
patients showed that HTLV-2 infection significantly decrease levels of LPS in plasma of 
HIV-1/HCV coinfected individuals. And, by contrast, levels of IFN-γ and IL-17A were 
significantly increased in presence of HTLV-2.  
Taking all these findings together we proposed a model that supports the 
protective effect of HTLV-2 infection in the previously described HIV-1 disease 
progression, and moreover, HCV infection.  
HTLV-2 infection in HIV-1/HCV coinfected individuals seemed to increase the 
secretion of IL-17A from Th17 cells. This interleukin-17A was reported to enhance 
epithelial regeneration in the GALT and defend against microbial translocation by 
recruiting neutrophils to clear microbial products130-132. According to its potential role on 
mucosa recovery, we found significantly lower levels of LPS in the HTLV-2 infected 
individuals.  
Microbial translocation was suggested as one possible contributor to chronic 
inflammation and fibrosis in chronic HCV monoinfection199-202. Strikingly, in parallel to 
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decreased levels of LPS, we found significantly lower levels of both ALT, specifically 
released when hepatic injury276 and hepatic fibrosis in presence of HTLV-2 infection.  
Liver fibrosis is influenced by the Th2 response being associated with more 
active fibrogenesis277-278. Th2 response was also associated to HIV-1 disease 
progression243. The pattern of HTLV-2 infection may indeed contribute to induce a 
protective Th1 response upregulating IFN-γ secretion as observed in these HIV-1/HCV 
coinfected individuals and previously described237, which can also inhibit CCR5 
expression and is involved against invading pathogenes240. 
We are unable to ensure correlation between bacterial products and immune 
activation due to the small size of patients analyzed for microbial translocation. 
However, we observed significantly reduced levels of activated CD8+ T cells in 
coinfected patients with good immune recovery (CD4+ counts superior to 500 
cells/mm3), and elevated levels of CD8+ T cells.  
A vicious circle was reported in which inflammatory and fibrogenic cells were able 
to stimulate each other during hepatic fibrogenesis in coinfected patients279. HTLV-2 
infection may disrupt this circle delaying HCV-disease progression and liver disease. 
To end up, we performed another sub-study in which we evaluate the effect of 
treatment intensification with an integrase inhibitor, raltegravir, on HTLV-2 pVL in well-
suppressed HIV-1-infected patients.  
Up today, there is no effective treatment for the HTLV infection. However, given 
the similarities between HIV-1 and HTLV-1 integrase, raltegravir, was thought to be 
effective against HTLV-1. Supporting this idea, a decrease in HTLV-1 pVL in vitro and 
also ex vivo was detected in presence of raltegravir252. Furthermore, in vitro studies 
showed that raltegravir prevented the integration of HTLV-1 in both cell-free and cell-to-
cell infection253. 
Despite these promising in vitro results, no decrease on HTLV-1 pVL was 
reported in the unique in vivo study on five infected patients254. The lack of any 
beneficial effect on HTLV-1 viral replication was attributed to the virus infection 
transmission mainly maintained through cell division instead of through new rounds of 
viral replication255. 
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We observed a transient increase on HTLV-2 pVL in HTLV-2/HIV-1 co-infected 
patients when cART was intensified with raltegravir and no changes on HTLV-2 pVL in 
the HIV-1/ HTLV-2 coinfected patients on suppressive regimen without raltegravir.  
This transient increase could be due to the activation and clonal expansion of the 
CD8 lymphocytes infected with HTLV-2280-281, explaining the subsequent return to 
baseline proviral load levels by the CTL response that would rapidly eliminate infected 
cells once they start to express viral proteins. Nevertheless, this possible transient 
clonal expansion was not reflected on CD8 count or frequency that remained stable 
along the follow up studied. 
On the other hand, it is also possible that a transient increase of episomal HTLV-
2 2-LTR DNA circles might occur as seen in HIV-1 patients intensified with raltegravir 
110
. This possibility implies an increase on HTLV-2 replication and a subsequent 
accumulation of episomal HTLV-2 2-LTR DNA circles due to raltegravir effects.  
Two important limitations of this study were the limited amount of DNA sample 
from each patient to test these two given possibilities, and the small number of patients 
included for the analysis forcing to take these results with caution. Unfortunately, there 
is limited experience using specific antiretroviral drugs in these HTLV-2-infected 
patients and no treatment recommendations can be given.  
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CONCLUSIONS 
 
1. Treatment intensification decreases immune activation in well-suppressed HIV-1 
infected patients. However, parallel decrease was not found in microbial 
translocation which, in fact, increases within individuals who intensified with 
maraviroc. Effects on immune activation or microbial translocation during the 
intensification follow-up period were reverted after intensifying drug 
discontinuation. 
2. Dynamics of microbial translocation are in parallel with expression of gut homing 
β7 receptor on T cells favoring the idea of T cells recruitment from the periphery 
to the GALT to recover gut mucosa. 
3. The quantification of LPS, LBP and sCD14 are good measurements of microbial 
translocation and can be used interchangeably. However, poor association 
between microbial translocation and immune activation was found in long-term 
suppressed individuals. 
4. Leishmaniasis is a factor that strongly contributes to increase the severity of 
immunodeficiency caused by HIV-1, with worse immunological characteristics 
than those observed in patients with discordant response to cART, showing 
increased levels of CD8+ T cell activation, IL-6, sCD14 and activated CD8+ T-cell 
senescence. 
1. Protective role of HTLV-2 infection on HIV-1 infected individuals was 
corroborated in this study, with reduced plasma HIV RNA levels before starting 
antiretroviral therapy despite similar nadir CD4+ T cell count, and higher levels of 
CD8+ T cell count in HIV-1/ HTLV-2 coinfected individuals compared to HIV-1 
monoinfected patients. 
2. Further protective role of HTLV-2 role on HCV infection and liver disease was 
observed in HIV-1/HCV-coinfected individuals. HTLV-2 infection significantly 
reduced levels of activated CD8+ T cells in patients with good immune recovery 
(CD4+ counts above 500 cells/mm3), levels of alanine transaminase and liver 
fibrosis. 
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3. Sub-study from these patients further contribute to the protective role of HTLV-2 
in HIV-1/HCV coinfected individuals, showing increased levels of IFN-γ (Th1 
response) and IL-17 (Th17) in parallel with reduced levels of LPS.  
4. A transient increase on HTLV-2 proviral load was found during raltegravir 
intensification. 
 
Further investigations will be needed to prevent or attenuate microbial 
translocation and generalized immune activation in order to reduce the risk of 
developing non-AIDS defining comorbidities associated to HIV-1 related immune 
dysfunction and inflammation during antiretroviral treatment. Besides, further studies 
on the immunological interactions between HTLV-2 and HIV-1 or HCV would be useful 
to understand the mechanisms underlying the potencial protective effect of the HTLV-2 
infection on other viral infections, such as HIV-1 and HCV. 
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DISCUSIÓN 
 
INTENSIFICACIÓN DEL TRATAMIENTO ANTIRETROVIRAL 
 
La intensificación de la terapia antirretroviral se ha evaluado como una estrategia 
para la erradicación de VIH-1. Numerosos estudios han defendido la intensificación de 
tratamiento como estrategia efectiva para reducir los niveles de replicación viral 
residual y la consecuente infección de nuevas células diana256-258.  
Uno de los estudios muestra una asociación entre la intensificación de 
tratamiento con raltegravir y una disminución de los niveles de ADN proviral en el 
tejido linfoide asociado a mucosas108. Otro estudio sostiene unos menores niveles de 
ARN no procesado en células CD4+  procedentes del íleo259. Sin embargo, ninguno de 
ellos mostró cambios en la viremia residual. La hipótesis que sostienen para entender 
los resultados obtenidos, es que la intensificación de tratamiento tiene su efecto en 
determinados lugares anatómicos como la mucosa intestinal, donde el tratamiento no 
alcanza niveles inhibitorios esperados, con el consecuente establecimiento de zonas 
donde el virus continuaría replicando e infectando nuevas células260.  
Los niveles de células CD8+ activadas se ven significativamente mermados 
durante la intensificación de tratamiento, independientemente del fármaco utilizado. 
Esta reducción podría ser causada por el reclutamiento de células  CD8+ activadas 
hacia el intestino, pero parece una opción poco probable teniendo en cuenta que la 
cantidad de linfocitos T permanecen estables durante el periodo de seguimiento. 
Por otro lado, los niveles de activación inmune no se correlacionan con los 
niveles de translocación bacteriana. Por el contrario, aquellos individuos que 
intensifican su terapia con maraviroc, muestran un aumento de los niveles de 
lipopolisacáridos bacterianos a pesar de recibir tratamiento antirretroviral261. 
Sin embargo, cabe destacar que los niveles de translocación bacteriana varían 
paralelamente con la expresión de receptores β7 en la membrana de linfocitos T 
activados, ofreciendo evidencias de un posible reclutamiento de células T activadas 
como un mecanismo de recuperación de la integridad de la mucosa, para disminuir en 
consecuencia el proceso de translocación bacteriana e inflamación en el intestino163-
164
.  
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Se puede observar una fuerte correlación entre las células T activadas 
expresando el receptor β7 y los niveles de lipopolisacáridos al final del periodo de 
intensificación (48 semanas), momento en el que el proceso de translocación 
bacteriana es máximo.  
El mayor inconveniente en este estudio es el número reducido de pacientes que 
se someten a tratamiento de intensificación. 
Si se analizan simultáneamente todas las determinaciones obtenidas de los 
pacientes incluidos en el estudio a lo largo del seguimiento, se observa una correlación 
positiva entre las diferentes técnicas para medir la translocación bacteriana, 
incluyendo lipopolisacáridos, proteínas de unión a lipopolisacáridos y CD14 soluble263, 
con la excepción de los niveles de ADN de la subunidad 16 ribosomal264.  
La translocación bacteriana se ha propuesto como un mecanismo 
desencadenante de la elevada activación inmune de los individuos infectados por VIH-
1 a pesar del tratamiento. Sin embargo, no se ha detectado correlación alguna entre 
los niveles de translocación bacteriana y la activación inmune. Esta ausencia de 
correlación se le ha atribuido a la propia naturaleza de los pacientes analizados, todos 
ellos con muy buena recuperación inmunológica y en tratamiento por largo periodo de 
tiempo.   
 
 
INDIVIDUOS COINFECTADOS CON LEISHMANIA EN 
COMPARACIÓN CON INDIVIDUOS CON RESPUESTA 
DISCORDANTE A TRATAMIENTO 
 
 
Los individuos infectados por VIH-1 con leishmaniasis visceral se caracterizan 
por una elevada activación inmune respecto a los individuos monoinfectados por VIH-
1, más parecido su estado inmunológico a aquellos individuos infectados por VIH-1 
con respuesta inmunológica discordante al tratamiento antirretroviral. 
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De este modo, los individuos coinfectados por VIH-1/Leishmania tienen menores 
niveles de células CD4+, comparables a los niveles observados en individuos con 
respuesta inmunológica discordante al tratamiento antirretroviral.  
Los niveles plasmáticos de CD14 solubles detectados en individuos infectados 
con leishmania visceral eran significativamente mayores que los niveles detectados en 
individuos monoinfectados. De todos modos, el parásito infecta monocitos, a los que 
activa pudiendo alterar los niveles de sCD14 liberados. Es posible que en este tipo de 
pacientes coinfectados, fuera más riguroso la utilización de una técnica alternativa 
para medir los niveles de translocación bacteriana.  
Se han detectado mayores niveles de inflamación y activación de células T CD8+ 
en individuos coinfectados con Leishmania en comparación con individuos 
inmunodiscordantes. La activación inmune elevada se asociaba con una mayor 
senescencia celular, a pesar de no haber diferencia de edades entre los grupos 
analizados. 
 
COINFECCIÓN POR HTLV-2 Y HCV                                                                 
EN INDIVIDUOS INFECTADOS VIH-1 
 
 
Las coinfecciones por HTLV-2 en individuos HIV-1 positivos, son relativamente 
frecuentes en usuarios de droga vía intravenosa. En el Hospital Ramón y Cajal, en 
Madrid, la prevalencia de infección por HTLV-2 que encontramos en este colectivo 
ascendió a un 8.5%.  
Numerosos estudios han remarcado el posible papel protector que la infección 
por HTLV-2 ejerce en la infección por VIH-1 y progresión a SIDA234-235. Nuestros 
resultados corroborarían la ralentización de la progresión de la enfermedad en 
individuos coinfectados que tienen una menor carga proviral previo inicio del 
tratamiento antiretroviral, a pesar de contar con niveles similares de células CD4+ T 
nadir. Además, los individuos coinfectados poseen mayores niveles de linfocitos T 
CD8+ en comparación con individuos monoinfectados por VIH-1. 
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Existen pocos estudios, sin embargo, que estudien la influencia del virus HTLV-2 
en la infección por VHC y el desarrollo de enfermedades hepáticas, a pesar del gran 
número de individuos VIH-1/HCV coinfectados en este sector.  
Se propuso pues profundizar en las características inmunológicas y virológicas 
de estos pacientes para evaluar los efectos de HTLV-2. De este análisis se observó 
que la infección por HTLV-2 conduce a una reducción de los niveles de activación 
inmune de las células T CD8+ y menores niveles de la enzima alanina transaminasa, 
indicadora de daño hepático, y de los niveles de fibrosis hepática. 
Un sub-estudio realizado en estos pacientes VIH-1/HCV coinfectados, muestra 
además una menor translocación bacteriana en individuos HTLV-2+, y un aumento de 
la secreción de la interleucina-17, precisamente encargada de la reparación de la 
mucosa intestinal.  
Teniendo en cuenta los resultados obtenidos, la infección por HTLV-2 no sólo 
tendría un papel beneficioso en la infección por VIH-1, sino además ralentizaría 
además la aparición de enfermedades hepáticas asociadas a infección por VHC. 
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CONCLUSIONES 
 
1. La intensificación de tratamiento disminuye activación inmune en individuos 
infectados por VIH-1 virológicamente suprimidos. Sin embargo, nose observó 
una disminución paralela con la translocación bacteriana, de hecho, estos 
niveles se incrementan en los individuos que intensificaron con maraviroc. Los 
efectos de la intensificación sobre la activación inmune y la trnanslocación 
bacteriana se revierten durante el periodo de desintensificación. 
2. El proceso de translocación bacteriana varía paralelamente con la expresión del 
receptor β7 en la superficie de células T, favoreciendo el reclutamiento de 
linfocitos hacia la mucosa intestinal para restablecer su integridad. 
3. Las técnicas para evaluar el proceso de translocación bacteriana, incluyendo 
niveles de LPS, LBP y sCD14 se correlacionan entre sí, permitiendo su 
utilización como marcadores intercambiables de translocación bacteriana. Sin 
embargo, no detectamos correlación entre translocación bacteriana y activación 
inmune, al menos en individuos suprimidos durante un largo periodo de tiempo. 
4. La leishmaniasis visceral agrava severamente la inmunodeficiencia generada por 
VIH-1. Las características inmunológicas de los pacientes coinfectados por 
Leishmania son peores que las observadas en individuos monoinfectados con 
respuesta discordante a tratamiento. Entre estas características destacan una 
elevada activación de células T CD8+, unos mayores niveles de inflamación, y 
sCD14 que puede explicar la deficiente respuesta inmunológica en estos 
individuos. 
5. La función protectora de la infección por HTLV-2 en individuos VIH-1-positivos se 
ha corroborado en este estudio, con una reducida carga viral VIH-1 previa al 
comienzo de tratamiento a pesar de tener el mismo nadir CD4 con respecto a 
pacientes no infectados, y con un aumento de los niveles de células T CD8+. 
6. La función protectora de HTLV-2, se extiende a la infección por  HCV  y 
enfermedades hepáticas mediante la disminución de los niveles de activación de 
células T CD8+ en individuos con niveles de CD4+ superiores a 500 cells/mm3, 
así como los niveles de enzima alanina transaminasa y de fibrosis hepática.  
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7. Un sub-estudio de estos pacientes coinfectados por HIV-1/HCV corrobora la 
función protectora de HTLV-2, mediante un aumento de la expresión de las 
citoquinas IFN-γ (Th1) y IL-17A (Th17) en paralelo con una disminución de los 
niveles de LPS.  
8. Se ha observado un incremento transitorio de la carga proviral HTLV-2 durante la 
instensificación de tratamiento con raltegravir. 
 
Posteriores investigaciones serían necesarias para desarrollar estrategias que 
puedan prevenir o atenuar la translocación bacteriana y activación inmune 
generalizada en individuos infectados por VIH-1, para lograr, si no su erradicación, una 
calidad de vida más próxima a individuos no infectados por VIH-1. Además, el 
entendimiento de los mecanismos que subyacen la ralentización de la progresión a 
SIDA y de enfermedades hepáticas en individuos coinfectados por HTLV-2 sería 
fundamental para reducir el riesgo de morbilidad y mortalidad en individuos infectados 
por VIH-1.  
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BASIC AND TRANSLATIONAL SCIENCE
Correlation Between Different Methods to Measure
Microbial Translocation and Its Association With
Immune Activation in Long-Term Suppressed
HIV-1–Infected Individuals
María Abad-Fernández,* Alejandro Vallejo, PhD,* Beatriz Hernández-Novoa,* Laura Díaz,†
Carolina Gutiérrez,* Nadia Madrid,* María Ángeles Muñoz,† and Santiago Moreno*
Introduction: Microbial translocation (MT) has been proposed as
one of the triggering mechanisms of persistent immune activation
associated to HIV-1 infection. Our objectives were to determine the
correlation between different measurements of MT in suppressed
HIV-1–infected individuals and to evaluate its correlation with
immune activation.
Methods: Eighteen suppressed HIV-1–infected patients with CD4+
T-cell count above 350 cells per cubic millimeter and undetectable
plasma viral load, included in antiretroviral treatment intensiﬁcation
clinical trials, were evaluated. Samples obtained at baseline and at
established time points during the trials were analyzed. Lipopolysac-
charide (LPS), lipopolysaccharide binding protein (LBP), soluble
CD14 (sCD14), and bacterial 16S ribosomal DNA (16S rDNA),
and markers of immune activation were determined.
Results: We analyzed 126 plasma samples from the 18 patients. LPS
signiﬁcantly correlated with sCD14 (P , 0.001, r = 0.407) and LBP
(P = 0.042, r = 0.260). Also, a signiﬁcant correlation was found between
sCD14 and LBP (P = 0.009, r = 0.325) but not between bacterial 16S
rDNA and LPS, sCD14, or LBP (P = 0.346, P = 0.405, and P = 0.644).
On the other hand, no signiﬁcant correlation was found between LPS,
sCD14, or LBP and CD4+ (P = 0.418, P = 0.619, and P = 0.728) or
CD8+ T-cell activation (P = 0.352, P = 0.275, and P = 0.124). Bacterial
16S rDNA correlated with activated CD4+ T cells (P = 0.005, r = 0.104)
but not with activated CD8+ T cells (P = 0.171).
Conclusions: There is a good correlation in the quantiﬁcation of
LPS, sCD14, and LBP levels, but not with bacterial 16S rDNA, as
measurements of MT. We are unable to ensure that MT directly
triggers T-cell immune activation at least among these patients with
relatively good immune recovery and under treatment intensiﬁcation.
Key Words: microbial translocation, LPS, sCD14, LBP, 16S rDNA,
immune activation
(J Acquir Immune Deﬁc Syndr 2013;64:149–153)
INTRODUCTION
The mucosal damage associated to HIV-1 infection
leads to translocation of microbial products from the intestinal
lumen into the bloodstream.1–5 Levels of microbial transloca-
tion (MT) in plasma of HIV-1–infected patients have been
frequently determined by the quantiﬁcation of the plasma
levels of lipopolysaccharide (LPS), soluble CD14 (sCD14),
lipopolysaccharide binding protein (LBP), or bacterial 16S
ribosomal DNA (16S rDNA).
Increased MT has been proposed as one of the main
trigger mechanisms for persistent immune activation in HIV-
1–infected patients,6–9 a strong predictor for disease progres-
sion.10–14 Several studies have reported the association
between MT and immune activation in the ﬁrst years of
chronic HIV-1 infection or in the most advanced stages of
HIV/AIDS.15–17 However, the dynamics of MT and immune
activation in patients with high CD4+ T-cell counts and unde-
tectable plasma viral load are still poorly deﬁned.
The aim of our work was to determine correlations
between different techniques employed to measure MT in
plasma of HIV-1–infected individuals under suppressive anti-
retroviral therapy (ART). For this purpose, we analyzed levels
of bacterial products as LPS and 16S rDNA and sCD14
marker of monocyte activation and plasma LBP. As a second-
ary objective, we evaluated the correlation between MT and
CD4+ and CD8+ T-cell activation.
MATERIALS AND METHODS
This study was performed within 2 pilot open-label
phase II intensiﬁcation clinical trials conducted at the
Hospital Ramón y Cajal in Madrid, Spain, from 2008 to
2012.18,19 The 18 patients included in this study had a median
age of 46 (41–50) years and most were male (88%), with
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a median time on ART of more than 8 years (Table 1). The
median CD4 count was 675 cells per cubic millimeter, and all of
them had CD4+ T-cell count above 350 cells per cubic millime-
ter and prolonged viral suppressive ART (,40 HIV-1 RNA
copies/mL). Nine patients incorporated a CCR5 antagonist
(maraviroc, provided by Pﬁzer, Inc., New York) to their current
suppressive regimen, whereas the other 9 patients intensiﬁed
their ART with an integrase inhibitor (raltegravir, provided by
Merck Sharp and Dhome, Whitehouse Station, NJ).
The 7 time points included in this study were as follows:
baseline, before the inclusion of intensifying drugs; weeks 12,
24, 36, and 48 after the inclusion of the intensifying drugs; and
weeks 12 and 24 after discontinuation of intensifying drugs.
All these 126 samples from the 18 patients at the different time
points were analyzed altogether.
MT was measured in plasma by 3 commercial kit
assays according to the manufacturer’s protocol. Plasma bac-
terial LPS was measured using QCL-1000 Limulus Amebo-
cyte Lysate (Lonza, Basel, Switzerland), plasma sCD14 was
quantiﬁed using the Quantikine Human sCD14 Immunoassay
(R&D Systems, Minneapolis, MN) and plasma LBP was
measured by LBP soluble ELISA kit (Enzo Life Sciences,
Farmingdale, NY). All the samples were run in duplicate.
To perform the bacterial 16S rDNA quantiﬁcation, DNA
was extracted from 200 mL of plasma using QIAamp DNA kit
(Qiagen, Hilden, Germany). A standard curve was generated
using 10 to106 copies of a recombinant plasmid containing 16S
gene fragment (171 bp) for quantiﬁcation purpose. The ampli-
ﬁcation reaction was carried out in duplicate using LightCycler
2.0 (Roche Diagnostics, Manheim, Germany) in a total volume
of 20 mL containing LightCycler FastStart DNA Master PLUS
HybProbe 5X (Roche Diagnostics), 200 ng of DNA, 50 pmol
of each primer, 16S-F (59-AGGTCGCTTCTCTTTGTATGC)
and 16S-R (59-ATGCGCCATTGTAGCACGTGTGT), along
with 2 pmol of the following ﬂuorescent probe: 59-[6FAM]-
AAGTCCCGCAACGAGCGCAACCCT-[BQH1]. The cycling
parameters included a hot start at 95°C for 10 minutes and
continued with 40 cycles of denaturation at 95ºC for 5 seconds,
annealing at 55ºC for 10 seconds and extension at 72ºC for
15 seconds.
Fresh ethylenediamine tetraacetic acid anticoagu-
lated whole blood was used to analyze CD4+ and CD8+
T-cell activation with the following antibody combination:
CD3-allophycocyanin-Cy7, CD4-peridinin chlorophyll protein
complex, CD8-phycoerythrin-Cy7, CD38-phycoerythrin, and
HLA-DR-allophycocyanin. Antibodies were from BD (Becton
Dickinson, Franklin Lanes, NJ), and an unstained control was
performed for all samples. Brieﬂy, 100 mL of blood were lysed
with 200 mL of FACS Lysing Solution (Becton Dickinson) for
30 minutes at room temperature, incubated with the antibodies
during 20minutes at 4°C,washed, and resuspended in phosphate-
buffered saline containing 1%of azida.Cellswere analyzed using
a Gallios ﬂow cytometer (Beckman-Coulter, Brea, CA). At least
40,000 CD3+ cells were collected for each sample and analyzed
withKaluza software (Beckman-Coulter) initiallygating lympho-
cytes according to morphological parameters. The gating was
always the same between different time points.
LPS and sCD14 levels and immunological parameters
were assessed every 12 weeks during the 48 weeks of
treatment intensiﬁcation and also at weeks 12 and 24 after
maraviroc and raltegravir removal. However, 16S rDNA
levels were determined during the period of treatment
intensiﬁcation (baseline, 12, 24, 36, and 48 weeks during
intensiﬁcation), and LBP levels were assessed at baseline, at
week 48 of treatment intensiﬁcation, and at weeks 12 and 24
after discontinuation of intensifying treatment.
Statistical Analysis
Continuous variables were expressed as the median and
interquartile range and discrete variables as percentages. The
t test for independent samples was used to compare normally
distributed continuous variables and the Mann–Whitney test to
compare nonnormally distributed continuous variables. Cate-
gorical variables were described as proportions. The association
between categorical variables was evaluated using the x2 test.
The Spearman correlation test was used. Statistical analysis was
performed using SPSS software 21.0 (SPSS, Inc, Chicago, IL).
RESULTS
Good Correlation Between MT
Measurements Except for 16S rDNA
We analyzed the associations among MT measurements
performed on 126 determinations from 18 patients, altogether.
Plasma LPS determinations positively correlated with levels
of sCD14 and LBP (P , 0.001 and P = 0.042, respectively)
(Figs. 1A, B). Similarly, high levels of sCD14 were associ-
ated with high levels of LBP (P = 0.009) (Fig. 1C). No
TABLE 1. Baseline Characteristics of the Patients
Number of determinations 126
Patients 18
Age (yrs) 46 (41–50)
Gender (male) 88%
CD4+ count (cells/mm3) 675 (570–775)
CD8+ count (cells/mm3) 693 (521–952)
Risk factors (%)
MSM 50
IDU 28
HTx 22
Time on ART (mo) 99 (52–146)
Antiretroviral regimen (%)
NRTIs 11
NRTIs + NNRTI 39
NRTIs + PI 50
CD4+ T-cell activation (CD38+ HLA-DR+) 2.05 (1.44–2.95)
CD8+ T-cell activation (CD38+ HLA-DR+) 2.8 (1.6–4.08)
sCD14 (·106 pg/mL) 1.4 (1.2–1.6)
LPS (pg/mL) 31.7 (18.4–50.9)
LBP (ng/mL) 34.9 (31.2–37.9)
16S rDNA (copies/mL) 5.4 (3.8–8.9)
IDU, intravenous drug users; HTx, heterosexual men; MSM, men who have sex
with men; NNRTI, nonnucloeoside reverse transcriptase inhibitor; NRTI, nucleoside
reverse transcriptase inhibitor; PI, protease inhibitor.
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correlation was found, however, between bacterial 16S rDNA
either with LPS, sCD14, or LBP levels (Figs. 1D–F; P =
0.346, P = 0.405, and P = 0.644, respectively).
16S rDNA Level Correlated With Activated
CD4+ T Cells, While No Correlation With CD8+
T-Cell Activation Was Evident
We also analyzed the associations between MT and
CD4+ and CD8+ T-cell activation, CD4+ and CD8+ T-cell
count, and the CD4+/CD8+ ratio. No signiﬁcant correlation
was found between plasma levels of LPS, sCD14, or LBP
and activated CD4+ T cells (P = 0.418, P = 0.619, and P =
0.728, respectively) (Fig. 2A) or activated CD8+ T cells (P =
0.352, P = 0.275, and P = 0.124, respectively) (Fig. 2B). How-
ever, high levels of bacterial 16S rDNA correlated signiﬁcantly
with high levels of activated CD4+ T cells (P = 0.005) (Fig. 2A)
but not with activated CD8+ T cells (P = 0.171) (Fig. 2B).
No association between MT measurements and CD4+
or CD8+ T-cell count or CD4+/CD8+ ratio was observed (data
not shown). Similarly, T-cell immune activation showed no
signiﬁcant correlation either with CD4+ or CD8+ T-cell count
or CD4+/CD8+ ratio.
DISCUSSION
In HIV-1–infected patients, elevated LPS in circulation
binds the CD14 toll-like receptor 4 (TLR 4) through plasma
LBP and triggers the activation of monocytes and macrophages
that increase secretion of sCD14 and proinﬂammatory
cytokines.20 Several studies have reported the correlation
between LPS and sCD14 levels in HIV-1 immune depressed
patients6,20,21 and in patients with undetectable HIV-1 viral
load.22 Besides, a correlation between LPS and both LBP and
sCD14 levels was found and was associated to HIV-associated
dementia in AIDS patients.23
We have observed a signiﬁcant correlation between
plasma LPS, LBP, and sCD14 levels in patients with optimal
CD4+ T-cell response (.350 cells/mm3) during prolonged
viral suppressive ART (,40 HIV-1 RNA copies/mL), in
agreement with previous studies.24 Nevertheless, no correla-
tion between 16S rDNA and the other measurements of MT
was found in our study, although this correlation has been
reported by other authors who evaluated both treatment-naive
and -experienced patients.25,26 The fact that our study
included only patients on long-term ART who were virolog-
ically suppressed and with good immunological recovery may
explain the discrepancy between our results and those of the
other studies, including mixed populations.
According to our data, and in this particular group of
patients, these 3 markers (sCD14, LPS, and LBP) are suitable to
measure MT. Nevertheless, each marker has limitations: sCD14
can be induced by different factors other than LPS in unsup-
pressed HIV-1 infection27; LPS is only present in Gram-negative
bacteria and there are inherent technical difﬁculties in its mea-
suring, that is, plasmas have to be stored in apyrogenic tubes
and handled with care to prevent contamination. On the other
hand, although 16S rDNA is present in both Gram-negative and
FIGURE 1. Correlation between different measurements of MT. Significant positive correlation between A, plasma LPS levels and
sCD14; B, LBP and sCD14 levels; and C, LPS and LBP levels. No correlation between D, 16S rDNA and LPS levels; E, 16S rDNA and
sCD14; and F, 16S rDNA and LBP. Only significant data (P , 0.05) are showed with regression lines and correlation coefficients.
The Spearman correlation test was used.
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Gram-positive bacteria, it has been technically hampered due to
DNA contamination.
MT has been proposed as a possible driver mechanism
of immune activation in HIV-1 infection,28–30 supported by
the correlation between LPS levels and circulating CD8+
T cells expressing CD38+ and HLA-DR+ observed in chron-
ically infected HIV-1 patients, elite controllers, and naive
patients.31 Another group has found a correlation between
16S rDNA and CD8+ T-cell activation (P = 0.047), but only
when aviremic- and viremic-treated patients were analyzed
together.25 On the other hand, other studies failed to show
this correlation during treatment interruption32 or in patients
undergoing raltegravir treatment intensiﬁcation.33 After the
scenario of treatment intensiﬁcation, no correlation between
the levels of LPS, LBP, or sCD14 with immune activation
was found. Surprisingly, a signiﬁcant correlation between
levels of 16S rDNA and CD4+ T-cell activation was found.
We do not have a good explanation for this ﬁnding, but the
type of patients and the fact that they had been in a treatment
intensiﬁcation scenario could account for this correlation.
Considering these data, we are unable to ensure that
MT directly triggers T-cell immune activation, at least among
these patients with relatively good immune recovery and
under treatment intensiﬁcation, although this process is
clearly an important component of innate immune inﬂamma-
tion associated to HIV-1 infection.
We cannot discard that treatment intensiﬁcation might
affect MT and subsequent correlation with immune activation
in different ways depending on the intensifying drug. To
discard this possibility, we analyzed individuals who intensiﬁed
with maraviroc separately from individuals who intensiﬁed with
raltegravir, obtaining similar results. The discrepancies found
in our study compared with others may be attributable to the
good immunological characteristics of our cohort undergoing
treatment intensiﬁcation after at least 2 years of antiretroviral
treatment maintaining HIV-1 viremia undetectable and high
levels of CD4+ T cells (.350 cells/mm3).
In conclusion, the quantiﬁcation of LPS, LBP, and sCD14
are good measurements of MT and can be used interchangeably,
taking into account the technical difﬁculties in performing each
measurement. On the other hand and studying this particular
type of patients, long-term suppressed individuals, a poor
association between MT and immune activation, was found
because only a single correlation between activated CD4+ T cell
and 16S rDNA was found. Further studies focusing on the
restoration of the gut mucosa in HIV-1 infection would help
to clarify the role of MT in HIV-1–associated immune activa-
tion and the subsequent immune recovery.
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HTLV-2b Among HIV Type 1-Coinfected
Injecting Drug Users in Spain
Marı´a Abad,1 Fernando Dronda,2 Ester Dominguez,1 Santiago Moreno,2 and Alejandro Vallejo1
Abstract
Human T cell lymphotropic virus type 2 (HTLV-2) infection is endemic in the American Indian population and
Pygmy tribes in Africa. Nevertheless, HTLV-2 infection has been predominantly detected in U.S. and European
injecting drug users (IDU). Noteworthy is that the HTLV-2a subtype is the main circulating variant in North
America and Eastern Europe whereas the HTLV-2b subtype is mainly found in Western Europe, particularly in
Italy and Spain where coinfection with HIV-1 is frequent. Twelve Spanish subjects infected with HTLV-2 were
recruited for the study. All of them were IDUs coinfected with HIV-1. Molecular epidemiology was done by
sequencing the LTR, env, and tax regions and by generating phylogenetic trees. The present study showed that
all the sequences belonged to the HTLV-2b subtype and were closely related to other Spanish and Portuguese
reported sequences, clearly differentiated from those belonging to the HTLV-2a subtype from Eastern Europe.
Therefore, infection with HTLV-2b remains prevalent in Spain based on previous studies.
The human T cell lymphotropic virus type 2 (HTLV-2)was initially identified and isolated from a patient with
atypical hairy cell leukemia in 1981.1 However, at present
there is still no clear evidence that HTLV-2 causes any human
disease, although it has been occasionally linked to neuro-
logical and lymphoproliferative disorders.2 HTLV-2 infection
is endemic in some American Indian populations and Pygmy
tribes in Africa.3 Nevertheless, HTLV-2 has been widely dis-
tributed in injecting drug users (IDUs) in the United States
and Western Europe.4
Molecular epidemiological studies have distinguished
three main HTLV-2 subtypes geographically dispersed. Sub-
type HTLV-2a is the main circulating variant in North
America and Eastern Europe, while subtype HTLV-2b can be
found in native Central and South American Indians as well
as in Western Europe, particularly in Italy and Spain5,6 where
coinfection with HIV-1 is very frequent. Some Brazilian iso-
lates clustered within subtype HTLV-2a but diverged by
coding a 25 amino acid longer Tax protein. This diversity
conceived as amolecular variant of HTLV-2a7 was considered
by some to indicate another subtype (HTLV-2c).8 Finally,
subtype HTLV-2d has been detected among African tribes.9
Data from the Spanish HTLV national registry showed that a
total of 717 HTLV-2-infected individuals had been diagnosed
in Spain up to December 2009.10 Despite of the continuing
immigration from HTLV-2 endemic areas, most of the newly
infected cases reported in Spain were native former drug
users coinfected with HIV-1.10
In the present study, 12 HTLV-2-infected Spanish individ-
uals (58% male) with a history of intravenous drug use and
coinfected with HIV-1 were phylogenetically analyzed
through three viral genes and compared with other reported
isolates. The individuals analyzed were diagnosed between
2003 and 2009. All the selected samples were obtained from
epidemiologically unlinked individuals from the Hospital
Ramon y Cajal, located in Madrid, Spain.
Plasma samples from these individuals showed a complete
positive HTLV western blot (WB) pattern (Bioblot HTLV,
Genelabs, Singapore) with the exception of three samples that
showed an indeterminate WB pattern, according to HTLV
European Research Network criteria.11 These indeterminate
samples were later confirmed by HTLV-2-specific PCR. DNA
was extracted from cryopreserved peripheral blood mono-
nuclear cells (PBMCs) using the QIAamp DNA kit (Qiagen
GmbH, Hilden, Germany) according to the manufacturer’s
protocol. Partial LTR, env, and tax genes were amplified by
nested polymerase chain reaction (PCR).
All reaction mixtures were performed in a total volume of
25ml containing PCR Buffer II (AccuPrime Taq High Fidelity,
Bioline, London, UK), 0.5U Taq polymerase (AccuPrime Taq
High Fidelity, Bioline), 200 ng of genomic DNA, and 20 pmol
of each primer, HT2-1 (TAAAGGCTCTGACGTCTCC-30) and
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HT2-2 (GCAGCAAGGGCTAGGGCT-30) for LTR, Ev-2 (GTT
CCAATAGCAGTGAGCCTTGT-30) and Ev-3 (AAAGCTG
CATGCCCAAGAC-30) for the env gene, and Tx-3 (CTGG
TCTCCTAACGGCAATCTC-30) and Tx-4 (CAAGTAAA
GGCTCTGACGTCT-30) for the tax gene. Thirty-five cycles of
denaturation at 948C for 15 s, annealing at 588C for 15 s, and
extension at 688C for 20 s were used. After the first PCR
reaction, 2ml of the amplified products was used for a sec-
ond PCR run in the same amplification conditions. Primer
HT2-1 (TAAAGGCTCTGACGTCTCC-30) and HT2-4 (AAC
GAAACCTCAACGCCGCC-30), Ev-3 (AAAGCTGCATGCC
CAAGAC-30) and Ev-4 (ATTGCTACCAACCTCGCCTAC
-30), and Tx-3 (CTGGTCTCCTAACGGCAATCTC-30) and
Tx-6 (CAGACCGTCTCACACAAACAATC-30) were used for
the amplification of 390 bp (nt 153–541) of the LTR fragment,
777 bp (nt 5180–5956) of the env region, and 993 bp (nt 7213–
8205) for the tax region, respectively. The sequence positions
are listed according to the Mo isolate (GenBank accession
number M10060).
Purified PCR products were sequenced in a final volume of
15 ml by using the ABI Big Dye Terminator v3.1 cycle se-
quencing reaction kit (Applied Biosystems, Foster City, CA)
and processed with the ABI 310 Genetic Analyzer (Applied
Biosystem). Sequences were edited using SeqMan II Software
version 5.0.1 (DNASTAR, Madison, WI) and aligned with
MEGA software v4.0.2 together with reference sequences of
the HTLV-2a subtype (Mo) and HTLV-2b subtype (G12 and
NRA). Phylogenetic trees were generated using the unweight
pair group method with arithmetic mean (UPGMA) by
Clustal W v5.8 and MEGA v4.0.2. The neighbor-joining
method was also used to corroborate them. The topology of
the trees was supported by 1000 bootstrap replicates. Genetic
distance was estimated by Kimura’s two-parameter method.
Some reported sequences from GenBank listed below were
used in this study for comparison purpose, and the simian
T cell lymphotropic virus type 2 (STLV-2) was used as the
outgroup.
Within the LTR fragment (nt 153–541), the NF-kB binding
site was highly conserved when compared to NRA except for
the insertion of an A at position 183 in the MA_CGO,
MA_DGE, andMA_JSR sequences. Another Awas inserted at
position 258 in the MA_MSC and MA_SPG sequences. All
sequences showed a transition from G to A at position 305
except MA_GRO and MA_CAS, and two contiguous trans-
versions from TC to GG at positions 323 and 324, respectively
(data not shown). Similarity values when compared to pro-
totypes NRA (HTLV-2b) and Mo (HTLV-2a) are shown in
Table 1.
The splicing site within the beginning of the env fragment
was conserved. This site is essential to generate the double-
spliced messengers encoding the regulatory tax protein.9 The
nucleotide sequences were well conserved when compared to
NRA, with high similarity values (Table 1). A total of 11 point
mutations were found at positions 5231, 5358, 5827, 5832,
5945, and 5949 in MA_BMJ, MA_VMM, MA_SPG, MA_CAS,
MA_ROL, and MA_FRM sequences, and at positions 5359
and 5413 in all sequences. The remaining three nucleotide
point mutations at 5185, 5209, and 5437 were found in the
same subject MA_VMM. Six of these mutations were related
to an amino acid change in the coded protein at positions 10,
18, 59, 218, 256, and 257 in the MA_VMM, MA_BMJ,
MA_MSC, MA_CAS, MA_ROL, and MA_FRM sequences,
respectively (Fig. 1A).
Almost the complete tax region (nt 7213–8205) was ana-
lyzed. The percentage of nucleotide similarity with regard to
both Mo and NRA prototypes is shown in Table 1. A total of
10 point mutations were found when compared to the HTLV-
2b NRA prototype at positions 7400 in MA_GRO, 7475 in
MA_ROL, 7824 and 8045 in MA_CGO, 7915 in MA_VMM,
8007 and 8030 in MA_MSC, 8010 in MA_JSR, and finally 8144
and 8182 in all sequences except in MA_MSC for the last
position indicated, respectively. Generally, the amino acid
sequences were well conserved, especially the nuclear loca-
tion signal (NLS), nuclear export signal (NES), and the di-
merization domain that remained unchanged for subtype b.12
Nevertheless, six of the nucleotide mutations generated an
amino acid substitution at positions 63, 88, 235, 273, and 278,
in MA_GRO, MA_ROL, MA_VMM, MA_MSC, and MA_
CGO sequences, respectively. All the sequences shared the
amino acid change at position 323 except MA_MSC, which
remained intact with regard to NRA prototype (Fig. 1B). The
amino acid identity compared to Mo and NRA sequences is
also shown in Table 1.
The phylogenetic tree for LTR showed that Spanish sam-
ples clustered with other reported sequences from Spanish
(BF, AA, JA, DP, 130, 324, RVP, SPAN129, and SPAN130) and
Portuguese (PortNn, PortHl, and PortVs) IDUs. Together
these formed a subgroup closely related to sequences from
Italian IDUs (I-GI, I-OV, I-OG, and I-OV Gu), and more dis-
tantly with sequences from American Indian (WYU1 and
G12) and African (Gab) sequences. All these sequences clus-
tered in the HTLV-2b subtype sustained by a bootstrap value
of 85%. Subtypes 2a and 2d formed other two genetically
distant clusters (Fig. 2).
Similar results were found for env gene analysis where
Spanish sequences were highly related to reported sequences
from Italian IDUs (I-OV). Together with sequences from
Amerindian (WY100, G12, and G2) and African (Gab) indi-
viduals, these formed the HTLV-2b subtype supported by a
bootstrap value of 99%. The MA_MSC and MA_VMM se-
quences were the most divergent sequences among the
Spanish samples (Fig. 2).
Table 1. Comparison of HTLV-2 Nucleotide and Amino Acid Sequences of the Spanish Patients
with HTLV-2Mo (2a) and NRA (2b) Prototypes
Nucleotide identity (%) Amino acid identity (%)
LTR env tax Env Tax
Mo (2a) 99.941–99.931 99.955–99.951 99.962–99.960 99.969–99.965 99.976–99.973
NRA (2b) 99.990–99.982 99.999–99.995 99.998–99.996 99.996–99.992 99.997–99.994
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Finally, the analysis of tax region showed three well-
differentiated groups for HTLV-2a, HTLV-2b, and HTLV-2d
subtypes, supported by high bootstrap values. The 2b sub-
group included reported sequences from Italian (PR-46) and
American (FUC and PAR) IDUs closely related to the Spanish
sequences and the reported sequences from the Gabonese
(Gab) and the American Indian prototypes (G12 and G2).
Among Spanish samples, MA_CGO and MA_MSC were the
most divergent (Fig. 2).
With respect to HTLV-2 infection, most of the cases re-
ported in Spain were native IDUs and coinfected with HIV-
1.13 It has been speculated that HTLV-2 originated from the
Amerindians and was introduced to European IDUs in at
least two separate periods: one for the 2a subtype in Eastern
Europe and another one for the 2b subtype in Western Eur-
ope.14 During the 1980s and 1990s, HTLV-2 spread expo-
nentially among Spanish intravenous drug users because of
needle-sharing practices. The prevalence of HTLV-2 infection
has been one of the highest in Europe, estimated at 18%
among IDUs in prisons and at 1–5% outside the prison set-
ting.15 In the past decades, many injecting drug users have
changed the route of drug usage, thus the number of new
injecting drug users has decreased. Therefore, it is estimated
that the number of new cases of HTLV-2 infection might be
very low.13
The present study of 12 infected IDUs from Spain coin-
fected with HIV-1 showed that HTLV-2b remains the preva-
lent subtype in Spain. They also continue to be closely related
to Italian and Portuguese IDUs, clearly differentiated from
those belonging to the HTLV-2a cases from Eastern Europe.
Sequence Data
The following GenBank accession numbers for previously
published HTLV-2 gene fragments were used in this study:
Mo (M10060), G12 (L11456), G2 (AF07965), NRA (L20734),
Gab (Y13051), Efe-2 (Y14365), STLV-2 (U90557). For the LTR
analysis: NAV.DS (U10257), SMH2 (Y09148), PH230PCAM
(Z46838), LA8A (U10256), KAY73 (L42509), BRAZ.A21
(U10253), ATL18 (U10252), Dub805 (AF175467), AA (L7738),
DP (L7737), JA (L7739), BF (L77236), SPAN129 (U10265),
SPAN130 (U10266), RVP (L77244), 130 (L77242), 324 (L77243),
PortHl (AY622977), PortNn (AY622978), PortVs (AY622979),
Gu (X89270), I-GI (Y09153), I-OV (Y09155), I-OG (Y09154),
WYU1 (U12792), BBD_3126 (FJ911656), BBD_2278 (FJ911644),
BBD_2766 (FJ911652), BBD_2286 (FJ911645). For the env anal-
ysis: WY100 (S69268), Gu (X89270), SP-WV (AF139382), RP329
(AF326583), K96 (AF326584), AF412314. For the tax analysis:
SMH2 (Y09148), Gal (AF292002), SP-WV (AF139382), RP329
(AF326583), K96 (AF326584), KAY1 (U32874), KAY2 (U32875),
A
B
FIG. 1. Alignment of Env (A) and Tax (B) amino acid sequences compared to prototypes HTLV-2a (Mo) and HTLV-2b (G12
and NRA).
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SP1 (U32873), SP2 (U32872), PR-46 (DQ022075), FUC (U32882),
PAR (U32880). Sequences from the samples studied in this
work have been submitted to GenBank under the following
numbers: LTR: MA_CPE (GU433203), MA_DGE (GU433204),
MA_FRM (GU433205), MA_MSC (GU433206), MA_JSR
(GU433207), MA_CGO (GU433208), MA_GRO (GU433209),
MA_SPG (GU433210), MA_ROL (GU433211), MA_VMM
(GU433212),MA_BMJ (GU433213),MA_CAS (GU586121). env:
MA_BMJ (GU586109), MA_DGE (GU586110), MA_FRM
(GU586111), MA_MSC (GU586112), MA_JSR (GU586113),
MA_CGO (GU586114), MA_GRO (GU586115), MA_SPG
(GU586116), MA_ROL (GU586117), MA_VMM (GU586118),
MA_CPE (GU586119), MA_CAS (GU586120). tax: MA_BMJ
(GU591294), MA_CGO (GU591295), MA_CPE (GU591296),
MA_DGE (GU591297), MA_FRM (GU591298), MA_GRO
(GU591299), MA_JSR (GU591300), MA_MSC (GU591301),
MA_ROL (GU591302), MA_SPG (GU591303), MA_VMM
(GU591304), MA_CAS (GU591305).
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Abstract 
 
Background: HIV-1-infected individuals progressively loss CD4+ T cells leading to 
immunosuppression. CD8+ T-cells play an important role in the immune response 
against virus infections through their TCR. 
Objective: To evaluate the CD8-TCR repertoire and immunologic markers in HIV-1-
infected patients. 
Study design: Ten chronic HIV-1-infected individuals on prolonged effective ART were 
analyzed before treatment interruption (TI), after at least one year of TI and after at 
least one year from ART resume. Twenty-four TCR-Vβ gene families were analyzed by 
a modified CDR3 spectratyping method in isolated CD8+ T-cells. Immune activation, 
exhaustion and subpopulation markers were analyzed by flow cytometry.  
Results: Expansion of Vβ10, Vβ14 and Vβ15 families during TI that was associated 
with low cell activation and stable exhaustion markers. Moreover, an increment of 
effector memory cells was found. Besides, depletion of Vβ20, Vβ28, and Vβ29 families 
during TI was associated with an increase in cell activation and exhaustion markers. 
These alterations seemed to be more pronounced in patients who had longer time from 
diagnosis. ART seemed to restore altered CD8+ T-cell repertoire and most of the 
immunologic markers. 
Conclusions: Increased and depleted CD8+ T-cell repertoire was related to increased 
or decreased levels of cell activation and exhaustion marker, respectively. 
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1. Background 
HIV-1-infected individuals progressively loss CD4+ T-cells leading to 
immunossuppression and raising the risk of opportunistic infections.1 Factors that are 
critical for the function of the immune system include the frequency of naïve T-cells, 
premature T-cell senescence, cell exhaustion2-4, as well as the effector function of 
these cells through the repertoire of T-cell receptors (TCR). 
 
TCR repertoire alterations have been observed in HIV-1-infected subjects, reflecting 
vigorous but not fully effective virus-specific cytotoxic T lymphocyte responses.5-11 HIV-
1 infection induces alterations in TCR repertoire during acute infection, as clonal 
expansion and exhaustion of HIV-1-specific T-cell clones12-14, and also in chronic or 
progressive HIV-1 infection.15 Although there is some controversy, some studies have 
observed that altered TCR repertoire is not fully reconstituted by the effect of an 
effective antiretroviral therapy.12,16-21  
 
2. Objectives 
In the present study, we examined the evolution of the CD8+ T-cell receptor repertoire 
by CDR3-spectratyping technique in HIV-1-infected patients who received antiretroviral 
treatment after a prolonged period of treatment interruption. We also analysed the 
relationship between this evolution and the expression of cell activation, T-cell 
exhaustion, and memory cells in CD8+ T-cells with specific TCR Vβ. 
 
3. Study design 
3.1 Patients 
Up to February 2006, 55 Caucasian Mediterranean patients with plasma HIV-1 viral 
load under 50 copies/mL at least during the last 12 months, and CD4 count above 500 
cells/mm3 began a period of treatment interruption (TI). This cohort of patients has 
been described elsewhere.22 Antiretroviral treatment was resumed either when CD4 
count reached 250 cells/mm3, clinical progression, or by self-decision. Ten patients had 
available samples to perform this retrospective study and were included in this study. 
Informed consent for the collection and analysis of blood samples was obtained from 
all of the patients.  
 
Clinical characteristics of the patients are shown in table 1. CD4 count was determined 
in fresh samples by flow cytometry. Plasma HIV-1 RNA was measured by quantitative 
PCR assay (HIV MonitorTM Test Kit; Roche Molecular System, Hoffman-La Roche, 
Basel, Switzerland), according to the manufacturer´s instructions, every three months 
during the follow up. This assay has a lower detection limit of 50 HIV-1 RNA copies⁄mL. 
Twenty-four TCR Vβ gene families and T-cell subsets were analyzed in each patient in 
the three time points; after at least 12 months on effective antiretroviral treatment 
(median 90 months, baseline), at least 12 months on treatment interruption (median 22 
months, TI), and at least twelve months after treatment resume, (median 30 months, 
TR). Viral load was undetectable at baseline and at TR time point, whereas viral 
rebound was observed at TI time point, with median 4.18 log RNA copies/mL (Table 1).  
 
3.2 Isolation of CD8+ T-cell subset 
Peripheral blood mononuclear cells were isolated from heparinized whole blood by 
density gradient centrifugation (Lymphoprep, Nycomed Pharma, Oslo, Norway) and 
cryopreserved in liquid nitrogen. CD8 T-cell subset was isolated by immunomagnetic 
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separation technique (Dynabeads, Dynal, positive isolation kits, Paisley, UK) using 
monoclonal anti-CD3 and anti-CD8 antibodies for positive cell isolation, according to 
the manufacturer’s instructions. Cell fraction contained at least 1-5 x 106 cells with 
purity above 98%.  
 
3.3 Measurement of CDR3 length variation by multiplex RT-PCR  
Total RNA was extracted from CD8+ T-cell subset by using QIAamp Viral RNA Kit 
(Qiagen Diagnostics, Barcelona, Spain) following the manufacturer´s instructions, and 
RNA concentration was determined by spectrophotometry (NanoDrop ND-1000).  
 
A modified multiplex RT-PCR was used to amplify the CDR3 region of 24 TCR Vβ 
families in order to minimize the number of reactions (filed patent number 
P201132088). Several forward primers and one reverse primer labeled with two 
different fluorochromes (C1 and C2) were designed to amplify three different molecular 
size ranges for 24 Vβ families (Table 2). To avoid artificially distorted CDR3 length 
distribution caused by insufficient mRNA template, an optimization was performed with 
cord blood cells purified from a healthy donor. Gaussian distribution of the amplified 
CDR3 length repertoires was guaranteed with 100 ng RNA (Figure 1A). To normalize 
and ensure a good quality of the mRNA template, a region of the GAPDH gene was 
amplified in each reaction. Also, a missing length was repeated twice to confirm the 
results. 
 
High-temperature multiplex RT-PCR was performed in 20 µl reaction mixture 
containing 100 ng mRNA template, 1 µM dNTP, Buffer 5x, 20 U protector RNase 
inhibitor, 10 U transcriptor reverse transcriptase (Roche Applied Science), and 1 µM 
each primer (three Vβ forward primers and one C reverse primer). First cycle at 42ºC 
for 45 min, followed by inactivation step at 85ºC for 5 min, and 35 cycles consisting of 
15 s at 94ºC, 15 s at 58ºC and 30 s at 72ºC, with a final extension step of 7 min at 
72ºC. 
 
To analyze the spectrum of each Vβ family we run samples using GeneScan-based 
spectratyping (Genetic Analysis System CEQ 8000, GenomeLab, Beckman Coulter). 
The calculated area under the curve for each CDR3 length in a given Vβ family was 
extrapolated to a proportion of expression (Figure 1B). 
 
3.4 Flow cytometry analysis of T-cell subsets 
Isolated PBMC from the subjects were immunostained with the respective antibody 
combinations for 30 min in phosphate-buffered containing 2% albumin and 0.1% 
sodium azide. Cells were analyzed by multiparametric flow cytometry (Gallios, 
Beckman Coulter). The following antibodies were purchased from BD Pharmingen (BD 
Biosciences): HLA-DR-allophycocyanin (APC)-Cy7, CD38-allophycocyanin (APC)-700, 
PD-1-peridinin chlorophyll protein complex (PerCP)-Cy5.5, CD45RA-phycoerythrin 
(PE)-Cy7, CCR7-allophycocyanin (APC), CD3-eFluor 450, and CD8-Krome Orange 
(KO). 
 
The proportion of cells was determined initially gating lymphocytes according to 
morphological parameters and then gating on CD3+ T-cells. CD8+ T-cell subsets (at 
least 20,000 events were gated) were defined as follows: naïve cells, 
CD3+CD8+CD45RA+CCR7+; effector memory (EM) cells CD3+CD8+CD45RA-CCR7-; 
and central memory (CM) cells CD3+CD8+CD45RA-CCR7+. Activation levels were 
also analyzed by the co-expression of CD38 and HLA-DR, whereas PD-1 was used as 
an activation-induced inhibitory T-cell marker of exhausted T-cells. All these 
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parameters were analyzed in CD8+ T-cells bearing three different TCR families using 
the following antibodies (co-staining): Vβ14-fluorescein isothiocyanate (FITC), Vβ20-
FITC, and Vβ2-phycoerythrin (PE) (IOTest, Beckman Coulter).  
 
3.5 Statistical analysis 
Continuous variables were expressed as median and interquartile range, and discrete 
variables as percentages. The t test (paired samples) was used to compare normally 
distributed continuous variables and ANOVA test to compare non-normally distributed 
continuous variables in multiple groups. Statistical Package for the Social Sciences 
software package (SPSS 16.0, Chicago, Illinois, USA) was used. 
 
4. Results 
4.1 TCR CDR3 profile of Vβ families during the follow up 
The overall median proportion of the expression of each TCR Vβ family from all the 
patients at baseline (BL), treatment interruption (TI) and treatment resume (TR) is 
shown in figure 1C. The expression of Vβ10, Vβ14, and Vβ15 families, significantly 
increased at TI compared to baseline (p=0.017, p=0.047, and p=0.007, respectively), 
and were restored at TR, with no statistical differences compared to baseline. The 
same profile was observed for Vβ9 and Vβ11 families, although with no statistical 
significance (Figure 1C). On the other hand, the expression of Vβ20, Vβ28, and Vβ29 
families significantly decreased at TI compared to baseline (p=0.007, p=0.007, 
p=0.005, respectively), while a restoration in their expression was observed at TR, with 
no statistical difference compared to baseline (Figure 1C). A similar trend in Vβ families 
Vβ5 and Vβ24 was observed during the follow up, although with no statistical 
significance. The rest of the Vβ families showed no significant differences at TI 
compared to baseline.  
 
4.2 TCR Vβ expression according to the time from diagnosis 
Patients with longer time from diagnosis at baseline (greater than the median 105 
months) showed significant higher levels of expression of Vβ10, Vβ14, and Vβ15 
families (Figure 2A, p=0.035, p=0.034, and p=0.028, respectively) at TI compared to 
baseline, while patients with shorter time of infection at baseline (below the median 105 
months) showed no significant differences. Interestingly, a significant increase of Vβ9 
and Vβ11 families, and a significant decrease of Vβ5 and Vβ24 families were found at 
TI compared to baseline only in those patients with longer time of infection (data not 
shown). 
 
On the other hand, a significant decrease of Vβ20, Vβ28, and Vβ29 families (Figure 
2B, p=0.028, p=0.028, and 0.028, respectively) was found at TI compared to baseline, 
while patients with shorter time from diagnosis showed no significant differences. 
Again, a significant decrease of Vβ5 and Vβ24 families was found at TI compared to 
baseline only in those patients with longer time from diagnosis (not shown). 
 
No influence of the nadir CD4 cell count or viral rebound at TI was observed in the 
expression of the Vβ families with the exception of the Vβ10 family. Within this family, 
only those patients with higher viral rebound (greater than 4.18 log copies/mL) had a 
significant increase (p=0.043) in its proportion at TI compared to baseline.  
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4.3 Immunophenotyping of CD8+ T-cell subpopulations in altered Vβ families 
The proportion of CD8+ T-cell subpopulations, T-cell exhaustion, and memory cells 
within the expanded TCRVβ14 and depleted TCRVβ20 families were analyzed. As 
well, TCRVβ2 family was used as control. A comparison between the proportion of 
families Vβ14, Vβ20 and Vβ2 measured by spectratyping or by immunophenotyping 
showed no significant differences at any time point. This result validates the 
proportions obtained with this modified spectratyping method. The proportion at TI of 
CD8-Vβ14 cells significantly increased (p=0.023), while decreased in CD8-Vβ20 cells 
(p=0.04), compared to baseline. Instead, no significant difference in the proportion was 
observed in CD8-Vβ2 cells. These proportions were not different at TR compared to 
baseline with the exception of CD8-Vβ20 cells where it remains significantly lower (not 
shown). 
 
No significant increase of cell activation was found in CD8-Vβ14 cells at TI among 
patients with shorter or longer time from diagnosis (Figure 3A, p=0.068 and p=0.144, 
respectively) compared to baseline. On the other hand, an increase was observed only 
in patients with longer time from diagnosis in CD8-Vβ20 cells at TI (p=0.003). 
Interestingly, activation increased in CD8-Vβ2 cells in all the patients. However, 
activation in CD8-Vβ20 cells was higher compared to CD8-Vβ14 cells in patients with 
longer time from diagnosis (p=0.003), and showed no difference with CD8-Vβ2 cells 
(p=0.353). Activation in CD8-Vβ14 cells at TI was significantly lower than in CD8-Vβ2 
cells (p=0.018). At TR the level were restored in all patients but CD8-Vβ20 and CD8-
Vβ2 cells in patients with longer time from diagnosis. Similarly, no increase in PD-1 
level in activated CD8-Vβ14 cells at TI was found among patients with shorter or longer 
time from diagnosis (Figure 3B, p=0.461 and p=0.144, respectively). Besides, 
increased PD-1 level was observed in activated-CD8-Vβ20 cells in all the patients at TI 
(p=0.038 and p<0.001, respectively). Only patients with longer time from diagnosis 
showed increased PD-1 levels in activated-CD8-Vβ2 cells (p<0.001). Interestingly, PD-
1 level in activated-CD8-Vβ20 cells in patients with longer time from diagnosis was 
higher at TI compared to that found in either activated-CD8-Vβ20 or CD8-Vβ2 cells 
(p=0.017 and p=0.008, respectively). Finally, the proportion of effector memory cells 
increased at TI only in patients with longer time from diagnosis in CD8-Vβ14 and CD8-
Vβ20 cells (Figure 3C, p=0.046 and p<0.001, respectively), while increased in all 
patients in CD8-Vβ2 cells (p<0.001). Nevertheless, effector memory CD8-Vβ14 cells 
were lesser than either CD8-Vβ20 or CD8-Vβ2 cells (p=0.032 and 0.028, respectively). 
These levels were restored at TR in all patients. 
 
5. Discussion 
This study showed a common pattern of altered Vβ repertoire after treatment 
interruption in chronic HIV-1 infection among adults. This altered pattern consist on the 
one hand, in an increased transcript accumulation of families Vβ10, Vβ14, Vβ15, 
probably due to expansion of cytotoxic response due to the increment of either HIV 
antigens or other antigens, i.e. those produced by microbial translocation; and on the 
other hand, in a decreased transcription of families Vβ20, Vβ28, Vβ29, probably due to 
cell depletion after a direct cytolytic effect of the HIV-1 infection or the accumulation of 
other antigens. The fact that only the increase of Vβ10 family was related with the HIV-
1 viral rebound suggest that other antigens produced during the treatment interruption 
period might play an important role in the alterations of the Vβ repertoire. 
 
Previous works have reported the implication of most of these families in the response 
to HIV-1 exposure.23-27 Nevertheless, few studies have analyzed the evolution of CD8+ 
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T-cell repertoire in the treatment interruption scenario.28,29 No other previous studies 
have found a pattern of Vβ alterations similar to that found in this study maybe because 
neither of these studies analyzed the patients at three different time points, did not 
leave enough time between the studied time points or did not included enough patients 
to be able to observe a specific pattern.30-34 A limitation of our study is the low number 
of patients eligible for the study. Also, functional studies and the contribution of HIV-1 
specific responses are needed to further understand the fluctuations of Vβ families. 
 
The expansion of the Vβ10, Vβ14, and Vβ15 families during treatment interruption 
were in parallel with a low increment in cell activation and no increment in T-cell 
exhaustion markers on these activated cells. These low parameters might not only 
prevent apoptosis and subsequent cell destruction of these cells but also allow them to 
proliferate. As well, an increment of effector memory cells coming from central memory 
cells was found that could be a consequence of antigen-specific stimulation.  
 
On the other hand, the depletion of the Vβ20, Vβ28, and Vβ29 families during 
treatment interruption was in parallel with a remarkable increase in both cell activation 
and cell exhaustion markers that lead to an accelerated level of apoptosis. There is 
increasing evidence showing that up-regulation of PD-1 mediates HIV-specific CD8+ T-
cell functional exhaustion, including defective perforin and IFN-γ expression and 
impaired proliferative capability, resulting in immune deficiency of CD8+ T-cells to 
control virus replication. Thus, the accumulation of PD-1 as well as the hyper-activation 
of T-cells prevent renewal of functionally competent CD8+ T-cell repertoire.7,35 Since 
only a limited correlation between this decreased families and HIV-1 viral load was 
found in this study, other antigens may have a role inducing PD-1 expression. A good 
candidate for this could be antigens derived from the increased microbial translocation 
driven by the viral load rebound after treatment interruption.36-39 it is possible that 
microbial translocation can produce a generic stimulation of specific TRBV families that 
could account for these TRBV family-associated changes found in this study. 
Interestingly, we found that CD8+ effector memory T-cells increased after treatment 
interruption. Some studies have suggested that PD-1 up-regulation is high in HIV-
specific T effector memory cells and that may be associated with skewed maturation of 
virus-specific CD8+ T-cells.40-41 Despite an increase in cell activation was also found 
within the control Vβ2 family, the lower level of cell exhaustion determined that they 
were not depleted. A strong balance between cell activation and cell exhaustion is 
crucial to promote cell death or cell proliferation. 
 
Interestingly, these TCR-Vβ fluctuations were significant only in those patients with 
longer time from diagnosis probably because they were prolonged exposed either to 
HIV-1 and, perhaps more importantly, to increased bacterial translocation.36-39 
Antiretroviral treatment reconstituted CD8+ T-cell repertoire and most of immunologic 
markers that could be involved. Moreover, these fluctuations were not related with the 
nadir CD4.  
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Figure legends 
 
Figure 1:  A) Proportion of expression (area under the curve) for each from cord blood sample. 
B) Gaussian distribution of the amplified CDR3 length repertoires in patient 8 in the different 
time points. C) Proportion of expression of each TCRVβ family in the different time points from 
all the patients. Black arrows highlight families with significant increased proportion of 
expression at TI, while grey arrows highlight families with significant decreased proportion of 
expression at TI. 
 
Figure 2: Proportion of expression of disturbed TCRVβ families according to the time from 
diagnosis. A) Increased at TI, TCRVβ10, TCRVβ14, and TCRVβ15, and B) decreased at TI, 
TCRVβ20, TCRVβ28, and TCRVβ29. Filled boxes, patients with <105 months from diagnosis; 
empty boxes, patients with >105 months from diagnosis. Box represents interquartile range, 
black line represents median values, and also maximum and minimum values are shown. BL, 
baseline; TI, treatment interruption; TR, treatment resume. Significant when p<0.05. 
 
Figure 3: A) Cell activation (CD38+HLA-DR+), B) level of cell exhaustion (PD-1+) of activated 
cells, and C) effector memory cells (CCR7-CD45RA-) of Vβ14, Vβ20, and Vβ2 cells. Filled 
boxes, patients with <105 months from diagnosis; empty boxes, patients with >105 months from 
diagnosis. Baseline (BL), treatment interruption (TI) and treatment resume (TR). A comparison 
betweendifferent cell populations is also shown. Significant when p<0.05. 
Figure 2
Figure 3
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Dynamics of the HIV-1 latent reservoir after
discontinuation of the intensification of antiretroviral
treatment: results of two clinical trials
Carolina Gutie´rreza, Beatriz Herna´ndez-Novoaa, Alejandro Vallejoa,
Sergio Serrano-Villara, Marı´a Abad-Ferna´ndeza, Nadia Madrida,
Laura Dı´azb, Ana Morenoa, Fernando Drondaa, Javier Zamorac,
Marı´a A´ngeles Mun˜oz-Ferna´ndezb and Santiago Morenoa
Objective: Antiretroviral therapy (ART) intensification has been shown to reduce the
reservoir of latently infected CD4þ T cells. However, it is currently unknown whether
this effect is maintained after discontinuation of the intensifying drug.
Design: The effect of ART intensification during 48 weeks with maraviroc or raltegravir
in chronically HIV-1-infected patients was assessed in two previous clinical trials. In this
study, we analysed this effect at week 24 after discontinuation of the intensifying drugs,
at baseline and 48 weeks of intensification.
Methods: We measured the latently infected memory CD4þ T cells carrying
replication-competent virus, 2-long terminal repeat (2-LTR) circles and CD4þ/CD8þ
T cells activation.
Results: Fifteen patients were evaluated. After 48 weeks of intensification, HIV-1
reservoir size significantly decreased from 1.1 to 0.0 infectious units per million (IUPM)
(P¼0.004). After 24 weeks of drug discontinuation, themedian size of the reservoir was
still significantly lower than at baseline (P¼0.008). 2-LTRs were undetectable in all
individuals at baseline and after 48 weeks of intensification, continuing undetectable
in all patients except two at week 24 after discontinuation (P¼0.1). CD4þ and CD8þ
T-cell activation significantly decreased at 48 weeks after intensification, without
further increase after discontinuation.
Conclusion: The effects of ART intensification with maraviroc or raltegravir persist at
least 24 weeks after discontinuation of the drug. In a global strategy, ART intensification
should be considered as part of a combination approach to achieve a functional cure or
HIV eradication.  2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
AIDS 2013, 27:2081–2088
Keywords: 2-long terminal repeat circles, HIV-1 dynamics, HIV-1 reservoir,
immune activation, treatment intensification
Introduction
Intensification of successful antiretroviral therapy (ART)
with one or more drugs has been proposed as a potentially
useful strategy to help achieve the eradication or a func-
tional cure of HIV infection. The rationale for such inter-
vention is based on the assumption that HIV replication
persists in patients receiving effective ART [1–6].
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Indeed, a number of reports point in this direction,
including the evidence provided by treatment intensi-
fication clinical trials [7], suggesting the gut-associated
lymphoid tissue (GALT) as the site wherein HIV
replication is more likely to persist [8]. As different
intensification trials have failed to demonstrate a
reduction in residual HIV found in plasma using ultra-
sensitive methods [5,8–12], other authors have argued
against persistent replication of HIV and the utility of
treatment intensification [13–15].
We and others have shown that intensification
of antiretroviral treatment with different drug classes
(reverse transcriptase inhibitors, CCR5 antagonists,
integrase inhibitors) can lead to a reduction in the
size of the latent cellular reservoir, as measured by
the coculture assay, with no effect on residual viremia
[16–18]. The most plausible mechanism for these
findings would be the inhibition of ongoing viral
replication in sites with suboptimal efficacy of the
regimens, possibly due to subinhibitory concentrations
of some of the drugs as suggested by other studies [3,4].
It is unknown, however, whether the effect achieved
by treatment intensification persists after discontinuation
of the intensifying drug. This could be important in order
to better understand the mechanisms underlying the
persistence of the HIV-1 cellular latent reservoir as well as
for practical purposes.
To provide additional insight into the effects and
dynamics of the cellular viral reservoir after treatment
intensification, we amended two ongoing intensification
clinical trials. The intensifying drugs used during these
studies were discontinued to evaluate, after 24 weeks,
whether the cellular reservoir was replenished or,
alternatively, the reduction observed after intensification
persisted. Together with the size of the HIV-1 cellular
reservoir, we evaluated other markers of viral replication
including the changes in the HIV-1 episomal DNA with
2-long terminal repeat (2-LTR) and markers of immune
activation.
Materials and methods
Study design
We previously conducted two pilot open-label phase II
clinical trials that evaluated the effect of two intensifying
drugs [maraviroc (MVC) or raltegravir (RAL)] on the
cellular HIV-1 reservoir in patients receiving ART
[17,18]. The present study analyses the global effect after
discontinuation of the intensifying drug (MVC or RAL).
Both protocols were amended to include a measurement
after 24 weeks of drug discontinuation (Fig. 1).
Both clinical trials (NCT00795444 and NCT00807443)
were conducted at the Hospital Universitario Ramo´n y
Cajal in Madrid, Spain, between 2008 and 2011 with
an intensification period of 48 weeks, and a follow-up
of 24 weeks after drug discontinuation. MVC was
developed and provided by Pfizer, Inc, (New York,
New York, USA) and RAL by Merck Sharp and Dome,
(Whitehouse Station, New Jersey, USA).
Ethics statement
The two clinical trials were conformed according to
the principles of the Declaration of Helsinki and the
Good Clinical Practice Guidelines and were approved by
the AEMPS (Spanish Agency for Medications and Health
Products) and by the local Ethics Committee. All patients
gave their written informed consent to participate in both
trials once amended.
Patients and specimen collection
Sixteen patients (seven from MVC trial and nine from
RAL trial) completed the intensification phase of the
study; however, one individual from RAL trial declined
to participate in the follow-up after drug discontinuation,
so finally 15 patients completed the follow-up period
of 24 weeks. The inclusion criteria were identical
for the two clinical trials and included undetectable
plasma viral load (pVL) by standard commercial assays
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Enrolment
Assessed for eligibility from the
two clinical trials (n = 18)
Excluded (n = 3) [MVC group (2) and
RAL group (1)]
– Toxicity (n = 1)
– Poor adherence (n = 1)
– Negative to participate (n = 1)
Final enrolled (n = 15)
Allocation
Allocated to intervention (n = 15)
Received allocated intervention (n = 15)
Follow-up
Discontinued intervention (n = 0)
Analysis
Analyzed (n = 15)
Fig. 1. Consort flow diagram.
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(<40 copies HIV-1 RNA/ml) for at least 2 years; ART
with three or more drugs for at least 2 years; CD4þ T-cell
count> 350 cells/ml; R5 viral tropism using a phenotypic
assay (Trofile; Monogram Biosciences, San Francisco,
California, USA) in a pretreatment sample in the case
of the MVC trial, and no previous treatment with any of
the intensifying drugs (MVC or RAL). Patients were
recruited from two hospitals (Hospital Ramo´n y Cajal and
Hospital Doce de Octubre), in Madrid, Spain.
Blood samples were collected at baseline, after 48 weeks
of intensification and after 12 and 24 weeks of drug
discontinuation, apart from sampling for other determi-
nations (data not shown). A total of 300ml of heparinized
whole blood was drawn to quantify the latent HIV-1
reservoir. Fifty millilitres of whole blood with EDTA
were also drawn to isolate plasma and peripheral blood
mononuclear cells (PBMCs).
HIV-1 cellular reservoir quantification: detection
of cells carrying replication-competent HIV-1
virus
The detection of cells carrying replication-competent
virus was determined using a previously described
enhanced culture assay of highly enriched resting CD4þ
T cells that constitute the principal reservoir for the virus
[19,20] with some modifications [17,18].
Briefly, PBMCs were isolated by Ficoll density gradient
centrifugation (Lymphocytes Isolation Solution; Rafer,
S.L, Zaragoza, Spain) from 300ml of heparinized
whole blood. Resting CD4þ T cells were isolated
from these total PBMCs by a negative selection of
CD3þ/CD4þ/HLA-DR/CD25 cells using magnetic
beads according to the manufacturer’s recommendation
(Miltenye Biotec, S.L. Bergisch Gladbach, Germany).
The isolated resting cells (as minimum 63 106) yielded a
purity greater than 99%.
Cells were plated in a duplicate five-fold serial dilution
cultures from 25 106 to 320 cells. Ten-fold of allogenic
irradiated PBMC from healthy donors was added to each
culture with phytohaematoglutinin (PHA, 1mg/ml) and
recombinant interleukin 2 (IL-2, 100U/ml) for efficient
cell activation.
The maximum number of resting cells that were put into
one well of a six-well plate was 106 in a final volume of
8ml.. Two individual wells of a six-well plate were
labelled as 106 dilution plate. The 5 106 dilution was
split into five wells with 1 106 cells/well and treated as a
group, whereas the 25 106 dilution was split into 25
wells with 1 106 cells/well and again treated as a group.
Cell concentrations below 1 106 were cultured in 24-
well tissue culture plates with the appropriate number of
resting cells, that is 2 105, 4 104, 8 103, 1.6 103
and 320 in a final volume of 2ml.
Plates were placed at 378C in a humidified 5% CO2
incubator. On day 2, supernatants containing PHA were
removed from the wells and replaced with fresh culture
media (without PHA). Then, CD8þ T-cell depleted
PBMCs from healthy donors, prepared 2–3 days before in
thepresenceof PHA(1mg/ml),were addedonce aweek to
each culture. Depletion of CD8þ T cells was performed
using a positive selection method (CD8 positive selection;
MiltenyieBiotec).These cellswere obtained fromdifferent
healthy donors each week and used fresh to avoid possible
cell viability problems due to cryopreservation. Also, these
cells were tested for fully permisivity for viral infection
using amixture ofNL4-3 and IIIBHIV-1 strains. A total of
6 106 cells were added to each well of a six-well plate
and 1 106 cells to each well of a 24-well plate.
On days 15 and 21, culture supernatants were tested
for the presence of HIV-1 antigen using an HIV-1 p24
antigen assay kit (Innogenetics Diagnostica Iberia, S.L.
Tarragona, Barcelona, Spain). Infected cell frequencies
were determined using the maximum likelihood method
and expressed as infectious units per million (IUPM)
of resting CD4þ T cells, with a limit of detection of
0.023 IUPM [21].
HIV-1 episomal DNA 2-long terminal repeat
circles determination
The presence of 2-LTRcircleswas detected by a qualitative
PCR, as described previously [17,18]. To maximize the
recovery of 2-LTR circles and to overcome the lack of
sensitivity of this technique [1,22,23], enriched 2-LTR
circles were extracted selectively from approximately
5 million PBMCs using QIAprep SpinMiniprep (Qiagen,
Valencia, California, USA) following the manufacturer’s
protocol for low copy number plasmids [1].
Immune activation and lymphocyte subsets
Fresh EDTA anticoagulated whole blood was used to
analyse CD4þ and CD8þ T-cell activation using the
following antibody combination: CD3-allophycocyanin
(APC)-Cy7, CD4-peridinin chlorophyll protein com-
plex (PerCP), CD8-phycoerythrin (PE)-Cy7, CD38-
phycoerythrin (PE) and HLA-DR-APC, as previously
described [18]. T-cell activation was characterized by
HLADRþCD38þ expression. Antibodies were from
Becton Dickinson (Becton Dickinson, Franklin Lakes,
New Jersey, USA), and an unstained control was
performed for all samples. At least 105 CD3þ T cells were
isolated for each sample and analysed with Kaluza software
(Beckman-Coulter, Brea, California, USA) initially gating
lymphocytes according to morphological parameters.
Gating was similar between different time points.
Statistical analysis
Continuous variables were expressed as median and
interquartile range (IQR) and discrete variables as percent-
ages. The t-test for independent samples was used to
compare normally distributed continuous variables and
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the Mann–Whitney test to compare nonnormally
distributed continuous variables. Categorical variables
were described as proportions. The association between
categorical variables was evaluated using the chi-square
test. The Spearman correlation coefficient was used to
analyse the correlations between continuous variables.
Statistical analysis was performed using IBM SPSS
software 16.0 (IBM, Armonk, New York, USA).
Results
Patient characteristics
Baseline characteristics of patients are summarized in
Table 1. Median age was 46 years (IQR 41–50) and no
significant differences were found between CD4þ and
CD8þ T-cell counts at baseline [676 cells/ml (IQR 522–
828) and 678 cells/ml (IQR 567–1066), respectively,
P¼ 0.7] and at the end of 24-week follow-up [642 cells/ml
(IQR 552–722) and 647 cells/ml (IQR 439–886),
respectively, P¼ 0.1].
All were receiving nucleoside reverse transcriptase
inhibitor (NRTI)-containing regimens combined with
nonnucleoside reverse transcriptase inhibitors (NNRTIs)
in seven cases (46.6%), with protease inhibitors in six cases
(40%), and with one-third NRTI in two cases (13.3%).
During follow-up, no changes were made in previous
ART regimens. All individuals remained virally sup-
pressed during the period of the study.
Effect of discontinuation of the intensifying drug
on the HIV-1-cellular latent reservoir
The median size of the HIV-1-cellular latent reservoir at
baseline including the 15 patients from the two clinical
trials was 1.1 IUPM (IQR 0.023–3.2). At the end of the
48-week intensification period, the number of latently
HIV-1 infected memory CD4þ T cells decreased
significantly, with a median of 0.0 IUPM (IQR 0.0–
0.27) (P¼ 0.004). This effect in reducing the size of
the HIV-1 latent reservoir was maintained at the end
of the 24-week period after drug discontinuation, with a
median of 0.0 IUPM (IQR 0.0–0.0), with no statistical
differences with respect to the 48-week intensification
period study point (P¼ 0.9), but significantly lower than
at baseline (P¼ 0.008) (Fig. 2).
Effect of discontinuation of the intensifying drug
on episomal 2-long terminal repeat DNA circles
All individuals showed undetectable episomal 2-LTR
DNA circles at baseline and after the 48-week
intensification period. As described, a transient increase
was observed during intensification in patients in the
MVC group at week 12 and 24 (P¼ 0.037 and P¼ 0.012,
respectively, compared with baseline). After discontinu-
ation, 2-LTR circles remained undetectable in all patients
except two, without reaching a statistical significance
compared with baseline and to the end of the 48-week
intensification period (P¼ 0.1)
Effect of discontinuation of the intensifying drug
on T-cell counts and T-cell activation
Globally, no differences were observed in the total CD4þ
and CD8þ T-cell counts either after the 48 weeks of
intensification or after the 24 weeks of discontinuation
with respect to baseline.
We have previously reported a trend to decreased immune
activation after intensification with both MVC and RAL.
This effect was maintained at week 24 after discontinu-
ation,with a significant decrease inCD4þandCD8þT-cell
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Table 1. Baseline characteristics of the 15 patients included in the desintensification study, according to the intensifying drug administered.
Variable MVC (n¼7) RAL (n¼8) Total (n¼15)
Age (years) 46 [31–48] 48 [44–53] 46 [41–50]
Male (%) 85.7% 100% 93%
Risk factors (%) IDU (42.8%) IDU (25%) IDU (33.3%)
MSM (42.8%) MSM (50%) MSM (46.6%)
HSx (14.2%) HSx (25%) HSx (20%)
Previous AIDS, n (%) 14.3% 37.5% 26.7%
HIV RNA (log copies/ml)
Maximal 5.3 [4.1–5.5] 5.5 [4.8–5.6] 5.5 [4.8–5.6]
Before ART 5.3 [4.2–5.5] 4.6 [4.4–5.6] 4.8 [4.4–5.5]
At study entry <1.7 (100%) <1.7 (100%) <1.7 (100%)
Duration of ART (months) 75 [38–144] 144 [70–167] 110 [52–144]
Duration of virological suppression (months) 70 [38–132] 55 [44.7–108.2] 62 [41–109]
CD4 cell count (cells/ml)
Nadir 230 [171–416] 40 [17–297] 202 [62–317]
At study entry 711 [547–793] 655 [417–877] 676 [522–828]]
IUPM 0.41 [0.0–3.2] 1.4 [0.1–6.8] 1.1 [0.023–3.2]
Immune activation
CD38þHLADRþ CD4þ T cells (%) 3.3 [2.9–3.8] 2.4 [1.7–3.0] 3 [2.1–3.5]
CD38þHLADRþ CD8þ T cells (%) 5.3 [5.05–8.0] 3.9 [3.5–4.5] 4.7 [3.7–5.7]
Continuous variables are expressed as median and interquartile range [IQR]. ART, antiretroviral therapy; HSx, unprotected heterosexual contacts;
IUPM, infectious units per million cells; MVC, maraviroc; RAL, raltegravir.
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activation compared with baseline (P¼ 0.003 and P¼
0.042, respectively), and a significant decrease in CD4þ
T-cell activation compared with week 48 after intensi-
fication (P¼ 0.020) (Fig. 3a).
Then, we analysed the differences in immune activation
according to the intensifying drug. Although no signifi-
cant decrease in CD4þ T-cell activation was observed
at week 48 after intensification in the MVC group,
these levels were significantly lower at week 24 after
discontinuation than at baseline (P¼ 0.028). The effect
of intensification with MVC in reducing CD8þ T-cell
activation was maintained at week 12 and 24 after
discontinuation compared with baseline (P¼ 0.028
and 0.028, respectively) (Fig. 3b). In the RAL group,
no significant differences were observed in immune
activation between baseline and week 48 after intensi-
fication, but only the levels of CD8þ T-cell activation
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Fig. 2. Effect of discontinuation of the intensifying drug on
the HIV-1 cellular latent reservoir.Median size of the HIV-1
latent reservoir at baseline, after 48 weeks of intensification
and at the end of the 24-week period after drug discontinu-
ation. The HIV-1 latent reservoir remained significantly lower
after drug discontinuation than at baseline.
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Fig. 3. Effect of discontinuation of the intensifying drug on T cell counts and T-cell activation. (a) CD4þ and CD8þ T-cell
activation at baseline (BL), after 48 weeks of drug intensification (48) and after12 weeks (12d) and 24 weeks (24d) of drug
discontinuation. (b) Levels of activated CD4þ and CD8þ T cells in the MVC group at baseline (BL), after 48 weeks of drug
intensification (48) and after12 weeks (12d) and 24 weeks (24d) of drug discontinuation. (c) Levels of activated CD4þ and CD8þ
T cells in the RAL group at baseline (BL), after 48 weeks of drug intensification (48) and after12 weeks (12d) and 24 weeks (24d) of
drug discontinuation.
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were significantly lower at week 24 after discontinuation
than at baseline (P¼ 0.042) (Fig. 3c).
Discussion
To date, the pool of latently infected resting CD4þ T cells
has been the most profoundly analysed HIV-1 reservoir
and is widely recognized as one of the major barriers
to achieving eradication or a functional cure of HIV-1
[24–27]. In recent years, the absence of consensus on
the causes of the stability of the latent viral reservoir
originated a storm of controversy in relation to the
possibility that residual HIV replication in subsets of
CD4þ T cells in the lymphoid tissue may contribute to
replenishment of HIV-1 reservoir [8,13,15,28,29]. More
recently, different groups have drawn attention to the
GALTas a major HIV-1 reservoir in individuals receiving
ART, as CD4þ T-cell recovery is poorer in GALT and
viral replication remains higher with respect to peripheral
blood. This persistent viral replication in GALT probably
contributes to maintenance of the reservoir despite
peripheral viral suppression [7,8,30–32]. Therefore,
intensification of conventional ART could further reduce
the low-level ongoing viral replication and, subsequently,
the reservoir replenishment.
Herein, we provide the first evidence that ART
intensification can generate a significant and stable
reduction of latently infected resting CD4þ T cells that
is maintained after discontinuation of the intensifying
drug. Of note, in this pooled analysis of two ART
intensification clinical trials of successful ART, partici-
pants showed a small size of the HIV-1 reservoir (median
IUPM¼ 0.8 IUPM) at baseline, and low levels of CD4þ
and CD8þ T-cell activation. Thus, this population had
an optimal immunovirological status before the inter-
vention, probably driven by the long-standing virological
suppression [median 62 months (IQR 41–109)]. Even so,
ART intensification was effective in reducing the size of
the HIV-1 reservoir after 48 weeks, and strikingly, this
effect was maintained after 24 weeks of discontinuation of
the intensifying drug, with IUPM below the threshold of
detection, and with undetectable 2-LTRs circles in the
majority of patients. It could be argued that an increase in
adherence could drive most of the impact of ART
intensification on the size of the reservoir [33]. In our
opinion, this seems unlikely based in two facts. First,
in addition to long-standing virological suppression with
no clinical rebound at any time, pharmacy records of
adherence were excellent for patients included in the
two studies of intensification. Only one patient had
bad adherence during the MVC intensification clinical
trials due to serious personal problems and he developed
virological failure. Secondly, there was a clear relationship
between the intensification of ART and the decrease of
the reservoir.
Along with this efficacy in reducing the pool of latently
infected resting CD4þ T cells, a significant reduction
in immune activation was also observed at the end of
the follow-up, suggesting at least an indirect relation
between CD4þ and CD8þ T -cell activation and the
persistence of HIV-1 in the cellular reservoir.
So far, only three studies, including our clinical trials
with MVC and RAL, have evaluated the effect of
intensification strategies on the HIV-1-cellular latent
reservoir in patients with virological suppression under
ART by using the coculture method [16–18], which is
currently considered the gold-standard technique to
identify latently infected resting CD4þ T cells. Impor-
tantly, all three studies revealed a decayof the reservoir. The
fact that all three experimental strategies used drugs with
different mechanisms of action (abacavir with/without
efavirenz, MVC and RAL) imply that the reduction of
the reservoir might be a consequence of a shrinkage in the
viral replication in the anatomical reservoirs – such as the
GALT – [7] rather than be driven by a specific drug effect
of abacavir, MVC or RAL on the cellular reservoir. Thus,
the rationale for ART intensification strategies would be
an increase in drug concentrations up to inhibitory levels
in sites with suboptimal efficacy of conventional ART
regimens, as suggested previously [1–6,34].
In the light of these data, an important question remained
to be answered. The proof that intensification strategies
are effective in reducing the HIV-1 reservoir by inhibition
of residual viral replication would be a decrease in
IUPM after intensification and a subsequent rebound of
IUPM and T-cell activation after discontinuation of the
intensifying drug, due to an increase of the low-level viral
replication and a replenishment of the HIV-1 reservoir
[1–6,9–11,23]. This study was designed to provide new
insight into this question. Although we found a decrease
in IUPM and T-cell activation after intensification with
two different drugs, the reservoir persisted undetectable
and percentages of T-activated cells remained significantly
lower after discontinuation of MVC/RAL with respect
to baseline, contrarily to what we had hypothesized
and expected. These surprising results deserve some
considerations. The straightforward explanation is that
replenishment of the HIV-1 reservoir might take more
than 24 weeks after interruption of an intensification
strategy. Against this reasoning, most immunovirological
events such as plasma HIV-1 load rebound or CD4 cell
count decline occur within the first weeks after ART
interruptions [6,35]. Alternatively, intensification with
MVC/RAL could have suppressed residual HIV-1 repli-
cation in tissues to an extent that may allow the immune
response to exert some sort of control and prevent
replenishment of theHIV-1 reservoir. Themaintenance of
low T-cell activation after MVC/RAL interruption
supports this hypothesis. As IUPM and T-cell activation
declined in parallel after intensification, an increase in T-
cell activation after treatment discontinuation would have
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suggested an increase in tissue HIV-1 load. However, both
IUPM and T-cell activation remained at low levels after
intensification interruption.
The findings regarding 2-LTRs circles also merit some
considerations. These circles are episomal forms of
nonintegrated HIV DNA with a relatively short half-
life. Therefore, detection of 2-LTRs circles is generally
considered a marker of recent infection [1,22,23,36] and
do not necessarily reflect the size of the HIV-1 cellular
latent reservoir [37]. As 2-LTRs were undetectable at
baseline, after intensification and at the end of follow-up,
the findings on 2-LTRs circles cannot lead us to any
specific conclusion, other than they may indirectly reflect
the absence of residual viremia in peripheral blood [12].
Our study is subject to a series of limitations. First, the small
sample size demands a cautious interpretation; although
our results were consistent across all comparisons and
reached statistical significance, they should be reproduced
in larger clinical trials. Second, the coculture assay is a
technique of high sensitivity; however, an improvement of
the threshold of detection might have enabled us to detect
differences in the reservoir size between thedeterminations
after intensification and at the end of drug discontinuation.
Third, although we estimated that 24 weeks would
be enough to detect a rebound of IUPM, this periodmight
be insufficient to assess this outcome and future studies
in this direction should be designed with longer periods
of follow-up. The lack of a control group also limits the
strength of the conclusions. However, the intensive
laboratory work and high costs associated together with
the fact that a spontaneous decrease of the reservoir was
very unlikely made us decide not to include the control
group. As stated in a previous report, the probability
that the results be associated with hazard is really low
(P< 0.017). Even so, the comparison with a control group
would have led to more definitive conclusions.
In summary, our data provide new evidence that the
effects of ART intensification with MVC or RAL in
reducing the HIV-1 cellular latent reservoir persist at least
24 weeks after discontinuation of the drug. We believe
that despite the great controversy on this field [1–6,9–
12,23,38,39], this study shows that ART intensification
strategies can alter the dynamics of the HIV-1 reservoir
[23] and reduce its size to undetectable levels in selected
patients. Thus, ART intensification strategies should
be considered in future strategies – including the use of
antilatency agents [40,41] – to achieve a functional cure
or HIV eradication.
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Summary Objectives: HIV-infected subjects on antiretroviral therapy often fail to normalize
the CD4/CD8 ratio despite CD4 count normalization. We aimed to analyze the biological signif-
icance of this finding.
Methods: Cross-sectional analysis in 20 HIV-infected subjects on stable triple-ART, plasma HIV
RNA <40 copies/mL for at least 2 years and CD4 count >350 cells/mm3. Laboratory measure-
ments included T-cell activation (HLADRþ, CD38þ) and senescence (CD57þ), lipopolysaccharide
(LPS), sCD14 and the HIV latent reservoir (number of latently infected memory CD4 cells car-
rying replication-competent virus).
Results: CD4/CD8 ratio was positively correlated with CD4 nadir (r Z 0.468, p Z 0.038) and
accumulated ART exposure (r Z 0.554, p Z 0.0011), and negatively with viral load before
ART initiation (r Z 0.547, p Z 0.013), CD4þHLADRþCD38þ T-cells (r Z 0.428, p Z 0.086)
and CD8þCD57þ T-cells (rZ 0.431, pZ 0.084). No associations with LPS, sCD14 or HIV latent
reservoir were found. After the multivariate analyses, the CD4/CD8 ratio remained indepen-
dently associated with CD4þHLADRþCD38þ T-cells and CD8þHLADRþ T-cells.
Conclusions: In our study in subjects on suppressive ART the CD4/CD8 ratio was independently
associated with T-cell activation. Our results must be confirmed in larger studies, as this
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parameter might be a useful clinical tool to identify subjects with ongoing immune activation
despite long-term viral suppression.
ª 2012 The British Infection Association. Published by Elsevier Ltd. All rights reserved.
Introduction
Despite the dramatic success of combined antiretroviral
therapy (ART) in the natural history of HIV infection, ART
has failed in its attempt to completely restore normal
health. Although recent evidence suggests that HIV-
infected subjects with a good immunological recovery
display mortality patterns similar to those in the general
population,1 most studies in patients with long-term viral
suppression show increased morbidity and mortality,2,3 es-
sentially driven by non-infectious comorbidities,4,5 a group
of conditions generally associated to ageing, including car-
diovascular disease, renal disease, liver disease, neurocog-
nitive disorders, osteoporosis and non-AIDS
malignancies.5e10 Indeed, specific non-infectious comor-
bidities and pluripathology are more common among HIV-
infected subjects than in the general population.5,11,12
Thus, the great clinical challenge is no longer to reduce
the incidence of opportunistic infections, but the early de-
tection and management of subjects at risk of developing
non-infectious comorbidities.
Most of these non-infectious conditions have been re-
lated to ongoing immune activation and low-level systemic
inflammatory status that occurs in chronic HIV infection
despite suppressive ART.13,14 In fact, persistent immune ac-
tivation in treated HIV infection is probably the major driv-
ing force of the accelerated immunological and systemic
ageing in HIV infection.13,15 Albeit our understanding of
persistent immune activation is incomplete, different
mechanisms such as viral persistence in cellular and ana-
tomic reservoirs, increased bacterial translocation due to
a chronically injured mucosa-associated lymphoid tissue
(MALT) or asymptomatic cytomegalovirus (CMV) replication
are likely to play a major role.16e18
The majority of ART-naive patients show an inverted
CD4/CD8 T-cell ratio. In the general population, a low CD4/
CD8 ratio is considered a surrogate marker of immunose-
nescence, and has been associated with persistent cyto-
megalovirus replication and with all-cause mortality.19e22
In untreated HIV infection, the CD4/CD8 ratio has been in-
vestigated as a predictor of poor prognosis,23e26 and has
shown to independently predict immune restoration,24
AIDS-related25 and non-AIDS-related morbidities.26 How-
ever, after several years of treatment, some patients still
show an inverted ratio despite the normalization of CD4
counts, and the clinical and biological significance of this
finding remains unknown. In aviremic HIV-infected sub-
jects, the CD4/CD8 ratio has been associated with the fre-
quency of CD4þ T-cells carrying HIV-1 proviral DNA, used as
an indirect measure of the size of the latent reservoir.27,28
However, proviral DNA quantifies both replication of com-
petent and incompetent virus, and the gold-standard tech-
nique for the evaluation of the HIV latent CD4þ T-cell
reservoir carrying replication-competent virus is currently
considered the capacity of the latent CD4þ T-cells to pro-
duce infectious virus.29
In this study, we analyzed the biological significance of
the CD4/CD8 T-cell ratio, by evaluating the correlations
with immune activation, immunosenescence, bacterial
translocation and the size of the HIV latent reservoir
measuring the infectious units per million resting CD4þ T-
cells.
Methods
Study design and patients
We combined the data of two pilot open-label phase II
clinical trials to evaluate the effect of maraviroc (ERRAD-
VIH-01 (MRV): NCT00795444)30 and raltegravir (ERRADVIH-
02 (RAL): NCT00807443)31 on the HIV latent reservoir. The
studies were conducted at the Hospital Universitario Ramon
y Cajal in Madrid, Spain, between 2008 and 2010. Biochem-
ical, immunological, and virological parameters were as-
sessed at baseline and at weeks 12, 24, 36, and 48. For
the present analysis, only baseline measurements e before
ART intensification e were analyzed. Plasma viral load was
measured by quantitative RT-PCR with a detection limit of
40 copies/mL (Roche Taqman HIV-1 test, Roche Molecular
Systems), and T-lymphocyte counts were determined by
flow cytometry.
The main inclusion criteria were as follows: HIV-1-
infected adults receiving ART based on no less than three
drugs for at least two years; undetectable plasma viral load
(below 40 HIV-1 RNA copies/mL) for at least two years;
CD4þ T-cell counts above 350 cells/mm3; and no previous
experience with raltegravir or maraviroc. Patients were ex-
cluded if they had experienced virological failure or had re-
ceived any immunosuppressive or immunomodulatory
therapy. A total of 300 mL of heparinised whole blood
was drawn from each patient for quantification of the HIV
latent reservoir; 50 mL of whole blood with EDTA were
drawn for plasma collection and isolation of peripheral
blood mononuclear cells (PBMCs).
The study was carried out according to the recommen-
dations of the Declaration of Helsinki and current Spanish
legislation on clinical trials and was approved by our local
Independent Ethics Committee (Hospital Ramon y Cajal,
Madrid, Spain). All patients provided written informed
consent for participation, sample collection, and laboratory
determinations.
T-cell activation and T-cell senescence
Fresh EDTA anticoagulated whole blood was used to analyze
CD4þ and CD8þ T-cells with the following antibody combi-
nation: CD3-allophycocyanin-Cy7 (APC-Cy7), CD4-peridinin
chlorophyll protein complex (PerCP), CD8-phycoerythrin-
Cy7 (PE-Cy7), CD38-phycoerythrin (PE), HLA-DR-
allophycocyanin (APC) and CD57-fluorescein isothiocyanate
(FITC). Antibodies were from Becton Dickinson (Becton
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Dickinson, New Jersey, USA), and unstained controls were
performed for all samples. Briefly, 100 mL of blood was
lysed with FACS Lysing Solution (Becton Dickinson) for
30 min at room temperature, incubated with the antibodies
for 20 min at 4 C, washed, and resuspended in phosphate-
buffered saline containing 1% azide. Cells were analyzed
using a Gallios flow cytometer (Beckman Coulter, Califor-
nia, USA). At least 105 CD3þ T-cells were collected for
each sample and analyzed with Kaluza software (Beckman
Coulter), by initially gating lymphocytes according to mor-
phological parameters, to quantitate CD4þ and CD8þ T-cells
expressing markers of activation (CD38þ, HLADRþ or both)
and senescence (CD57þ). Data on CD38þ, HLADRþ and
CD57þ lymphocytes were expressed as the percentage of
T-cells expressing these markers.
Bacterial translocation
Two commercial assays were used to evaluate bacterial
translocation from plasma samples. Plasma bacterial lipo-
polysaccharide (LPS), gram-negative bacteria endotoxin, was
measured using QCL-1000 Limulus Amebocyte Lysate
(Lonza, Basel, Switzerland) according to themanufacturer’s
protocol. The plasma level of soluble CD14 (sCD14) was quan-
tified using the Quantikine Human sCD14 Immunoassay (R&D
Systems,Minneapolis,Minnesota,USA), according to theman-
ufacturer’s instructions. All samples were run in duplicate.
Estimation of the HIV latent reservoir
The HIV-1 latent reservoir was determined using a modified
co-culture assay of highly enriched CD4þ T-cells, as previ-
ously described.30,31 Briefly, PBMCs were isolated by Ficoll
density gradient centrifugation (Lymphocytes Isolation So-
lution, Rafer, S.L., Zaragoza, Spain) from 300 mL of hepari-
nised whole blood. Resting CD4þ T-cells (CD3þ/CD4þ/
HLADR/CD25) were then isolated and purified using mag-
netic beads according to the manufacturer’s recommenda-
tions (Miltenyi Biotec GmbH., Bergisch Gladbach,
Germany). Isolated resting CD4þ T-cells (purity greater
than 99%) were plated in serial limiting dilution cultures
with allogenic irradiated PBMCs from healthy donors in
the presence of phytohemagglutinin (PHA). To maintain
cell cultures, CD8þ T-cell depleted PBMCs from healthy do-
nors were added once a week. On days 15 and 21, culture
supernatants were tested for HIV-1 replication using an
HIV-1 p24 antigen assay (Innogenetics Diagnostica Iberia,
S.L. Barcelona, Spain). Infected cell frequencies were de-
termined using the maximum likelihood method and ex-
pressed as infectious units per million (IUPM) of resting
CD4þ T-cells, with a limit of detection of 0.012 IUPM.
Statistical analysis
Continuous variables were expressed as median and inter-
quartile range, and categorical variables as counts and
percentages. Given the sample sizes and the non-normal
distribution of some of the variables, non-parametric
statistical tests were used. CD4/CD8 ratio was categorized
by tertiles (0.8, 1.2) and patients were classified according
to their CD4/CD8 ratio in two groups: low CD4/CD8 ratio
(<0.8, first tertile) and normal CD4/CD8 ratio (0.8,
second and third tertiles). ManneWhitney tests were used
for independent two-group comparisons and Spearman
correlation coefficient was used to analyze the correlation
between continuous variables. A series of multivariate
linear regression models were built to explore simultaneous
associations of any of the different phenotypes of activated
and senescent T-cells, as dependent variables e CD38þ,
HLADRþ, CD38þHLADRþ and CD57þ, in CD4þ and CD8þ T-
cells e with the CD4/CD8 ratio, adjusting by a limited sub-
set of independent variables. Assumptions for this analysis
were checked by exploring regression residuals. All statisti-
cal analyses were performed using SPSS software 15.0 (SPSS
Inc., Chicago, Illinois, USA).
Results
General characteristics
Median age was 45 years, median CD4 count 677 cells/mm3
and median CD4 nadir 238 cells/mm3. All patients displayed
a CD4/CD8 ratio increase from baseline measurements be-
fore ART initiation (median, 0.5), with a median CD4/CD8
ratio at the inclusion in the study of 1.0. Median accumu-
lated ART exposure was 73 months, with long-standing un-
detectable viral load (median, 60 months). Percentages of
CD4þ and CD8þ T-cells with coexpression of HLADR and
CD38 were low (3% and 4.5%, respectively), as well as the
size of the HIV latent reservoir (median IUPMZ 1.2). All pa-
tients were receiving nucleoside reverse transcriptase in-
hibitor (NRTI)-containing regimens, combined with non-
nucleoside reverse transcriptase inhibitors (NNRTI) in eight
cases (40%), with protease inhibitors (PIs) in ten cases (50%)
and with a third NRTI in two cases (10%). Six subjects (30%)
were coinfected by HCV. Table 1 summarizes the general
characteristics of the 20 patients in the study.
CD4/CD8 ratio relations with therapy and
immunovirological variables
CD4/CD8 ratio showed a positive correlation with CD4 nadir
(r Z 0.468, p Z 0.038), accumulated ART exposure
(rZ 0.554, pZ 0.0011) and a negative correlation with the
peak of viral load (rZ0.547, pZ 0.013). Despite the asso-
ciation with the accumulated ART exposure, no association
was observed between the CD4/CD8 ratio and the time since
HIV diagnosis (rZ 0.347, pZ 0.133). Importantly, the CD4/
CD8 ratio correlated with CD8þ T-cell count, but not with
CD4þ T-cell count (r Z 0.710, p < 0.001; r Z 0.314,
pZ 0.177, respectively) (Fig. 1). Thus, we explored the asso-
ciations of CD8þ T-cell count with CD4 nadir, accumulated
ART exposure and the peak of viral load. CD8þ T-cell count
only showed a statistically significant correlation with accu-
mulated ART exposure (rZ 0.612, pZ 0.004).
CD4/CD8 ratio, immune activation and
immunosenescence
A negative correlation with border-line statistical signifi-
cance was found between the CD4/CD8 ratio and the
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percentages of CD4þHLADRþCD38þ T-cells (r Z 0.428,
p Z 0.086) and CD8þCD57þ T-cells (r Z 0.431,
p Z 0.084). No significant correlations were found with
other T-cell phenotypes of activation, or between the dif-
ferent phenotypes of activated T-cells and the CD4/CD8 ra-
tio at ART initiation or the CD4/CD8 ratio increase from
baseline (data not shown). Then, we analyzed the associa-
tions with the CD4/CD8 ratio categorized by tertiles (Fig. 2)
with the percentages of the different T-cell phenotypes ex-
pressing markers of activation and senescence. Overall,
subjects in the lowest tertile (CD4/CD8 ratio < 0.8) showed
higher percentages of activated (Fig. 2A, B, DeF) and sen-
escent CD4þ and CD8þ T cells (Fig. 2G, H, respectively).
However, these differences only reached statistical signifi-
cance for the percentage of CD4þHLADRþCD38þ T-cells
(p Z 0.049) (Fig. 2A), with border-line statistical signifi-
cance for the percentage of CD8þCD38þ T-cells
(pZ 0.079) (Fig. 2D). Given the strong negative correlation
between the CD4/CD8 ratio and CD8þ T-cell count, we also
explored the associations between CD8þ T-cell count and
CD4þ activated T-cells. CD8þ T-cells did not correlate
with the percentage of CD4þHLADRþCD38þ T-cells
(r Z 0.396, p Z 0.115), CD4þHLADRþ T-cells (r Z 0.137,
p Z 0.599) or CD4þCD38þ T-cells (r Z 0.076, p Z 0.772).
CD4/CD8 ratio and bacterial translocation
No associations were found between the CD4/CD8 ratio and
markers of bacterial translocation (LPS: r Z 0.192,
p Z 0.445; sCD14: r Z 0.044, p Z 0.861). Similarly, we
did not detect any association between these two variables
and the two categories of CD4/CD8 ratio according to the
CD4/CD8 ratio cut-off of 0.8 (Fig. 3). LPS and sCD14
correlated neither with the CD4/CD8 ratio before ART initi-
ation (r Z 0.071, p Z 0.811 and r Z 0.042, p Z 0.887,
respectively) or with the CD4/CD8 ratio increase from base-
line (r Z 0.090, p Z 0.759 and r Z 0.235, p Z 0.418,
respectively).
CD4/CD8 ratio and HIV latent reservoir
Seven (35%) patients had an undetectable HIV-1 reservoir
(IUPM < 0.012). No association between the size of the HIV
latent reservoir and the CD4/CD8 ratio was observed in the
correlation analysis (r Z 0.322, p Z 0.166) (Fig. 4). The
median values of IUPM were higher in subjects with CD4/
CD8 ratio <0.8 compared to individuals with CD4/CD8 ratio
0.8; however, these differences did not reach statistical
significance. IUPM correlated neither with the CD4/CD8 ra-
tio before ART initiation (r Z 0.269, p Z 0.314) or with
the CD4/CD8 ratio increase from baseline (r Z 0.335,
p Z 0.204).
Multivariate analyses
A series of multivariate linear models were built to explore
the associations between the different phenotypes of
activated and senescent T-cells (dependent variables) and
the CD4/CD8 ratio, adjusting for those variables most likely
to exert confounding effects (Table 2). Thus, given the find-
ings in the univariate analyses, the models were adjusted
by CD4 nadir and accumulated ART exposure. After the mul-
tivariate analyses, both CD4 (HLADRþCD38þ) and CD8
(HLADRþ) T-activated cells were independently associated
with the CD4/CD8 ratio.
Discussion
Our results suggest that the CD4/CD8 ratio may provide
relevant information in treated and virologically suppressed
HIV-infected subjects, as it correlated positively with vari-
ables that summarize the immunological background e CD4
nadir and accumulated ART exposure and negatively with
activation markers in CD4 and CD8 T-cells. No association
with markers of bacterial translocation or the size of the
HIV latent reservoir was observed.
Although failure to normalize the CD4/CD8 ratio despite
peripheral CD4 count restoration is a common observation
in clinical practice, few studies have addressed the bi-
ological or the clinical significance of this phenomenon. The
outstanding importance of the viral load and the CD4 count
as surrogate markers of ART efficacy in the global manage-
ment of HIV-infected subjects could have led to overlook
the significance of the CD4/CD8 ratio. Studies before the
introduction of the highly active ART in 1996, recognized
the CD4/CD8 ratio as a predictor of AIDS, providing similar
prognostic information to that of CD4 count.32 More re-
cently, a low CD4/CD8 ratio at initiation of ART was found
to be a predictor of Hodgkin lymphoma in the Swiss Co-
hort.26 Remarkably, in a caseecontrol study in aviremic
subjects, the CD4/CD8 ratio was independently associated
with subclinical atherosclerosis,33 which in turn has been
related to immune activation.34 To our knowledge, no stud-
ies have addressed specifically the biological or clinical
Table 1 Characteristics of the study population (NZ 20).
Variable
Age (years) 45 (43e48)
Male, %/female, % 19 (95)/1 (5)
CD4 count (cells/mm3) 676 (548e892)
CD8 count (cells/mm3) 715 (626e1023)
CD4 nadir (cells/mm3) 238 (79e358)
CD4 count at initiation of ART
(cells/mm3)
246 (160e378)
CD4/CD8 ratio 1.0 (0.7e1.6)
CD4/CD8 ratio before ART initiation 0.5 (0.2e0.8)
CD4/CD8 ratio increase from baseline 0.6 (0.2e0.9)
CD4þHLADRþCD38þCD4þ T-cells 3 (2.4e3.3)
CD8þHLADRþCD38þ T-cells 4.5 (3.6e5.5)
Time on ART (months) 73 (49e143)
Time with viral suppression (months) 60 (40e107)
Time since HIV diagnosis (years) 9 (5e14)
HIVeHCV coinfection 6 (30%)
Risk factors MSM 10 (50%)
HSx 7 (35%)
IDU 3 (15%)
All values are expressed as median and interquartile range, un-
less otherwise specified.
MSM, men who have sex with men; HSx, heterosexual; IDU, in-
travenous drug users.
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significance of the CD4/CD8 ratio in HIV-infected subjects
on suppressive ART. Most studies on this field have been
conducted in the general population, where the CD4/CD8
ratio has been proposed as a surrogate marker of the im-
mune risk profile, which entails a collection of immune-
related defects that defines immune immunosenes-
cence.20,22 The immune risk profile was associated with
all-cause mortality in two European cohorts21,35,36 and is
characterized by an increase in the number of CD8þCD28
T-cells that result in a low CD4/CD8 ratio and it is associ-
ated to CMV-specific T-cells19 or CMV seropositivity.35 Re-
markably, some of these immunological alterations
accumulated with age in the elderly are similar to those
that take place in HIV-infected subjects.36 In fact, HIV in-
fection is associated with expansion of CMV-specific T-cells,
and CMV-specific T-cells are associated with atherosclero-
sis.37 In our study, the CD4/CD8 showed a strong correlation
with CD8 count, but not with CD4 count. The study design
itself, which excluded patients with CD4 count
<350 cells/mm3 may explain this finding. While hallmarks
of uncontrolled HIV infection are low CD4 count, high CD8
count and consequently a low CD4/CD8 ratio, subjects on
ART usually display an increase of CD4 count and a decrease
of CD8 count, to different extents. Thus, in individuals with
successful CD4 count recovery we must assume that the
CD4/CD8 ratio essentially depends on the CD8 count. In
our view, a higher CD8 count among virally suppressed pa-
tients with CD4 count restoration might imply oligoclonal
expansion of CD8þ T-cells, reflecting an underlying immu-
nosenescence.19 Of note, we did not detect significant as-
sociations with the CD4/CD8 ratio before ART initiation or
the CD4/CD8 ratio increase from baseline. This finding sug-
gests that rather the total increase CD4/CD8 ratio due to
ART, the homeostasis of absolute T-cell counts at a thresh-
old between 0.8 e as suggested by our data, or 1 e as sug-
gested by previous studies in the general population,21,22
might correlate with immune activation and immunosenes-
cence in HIV-infected patients.
Figure 1 CD4/CD8 correlations with therapy and immunovirological variables.
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Figure 2 CD4/CD8 ratio, immune activation and immune senescence.
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The activated phenotype correlating with the CD4/CD8
ratio was different for CD4þ and CD8þ T-cells. While CD4þ
T-activated cells associated with the CD4/CD8 ratio showed
coexpression of HLADR and CD38, only CD38þCD8þ T-cells
correlated with the CD4/CD8 ratio. Although both markers
are reliable surrogates of immune activation and are stron-
ger predictors of disease progression than a viral load,38 the
coexpression of HLADR and CD38 is usually observed as the
paradigm of late immune activation. Interestingly, recent
evidence supports a different significance of the isolated
expression of these activation markers. For example, pa-
tients with an inefficient response to ART display higher fre-
quencies of HLADRþ CD4þ and CD8þ T-cells39 and the sole
expression of CD38 has recently been shown to identify
a subset of a hypoproliferative CD4þ T-cells that does not
fit into existing na€ıve and memory cell paradigms.40 Be-
sides, the association between the CD4/CD8 ratio and im-
mune activation in HIV infection has a straightforward
biological explanation and is in keep with what is known
on the CD4/CD8 ratio. Considering that this parameter
has been previously associated with immunological and sys-
temic ageing, together with the fact that immunosenes-
cence is considered to be driven by chronic immune
activation,41 we suggest that CD4/CD8 ratio might be a sur-
rogate marker of immunosenescence also in HIV infection.
Consequently, a point of paramount importance to be ex-
plored is if the persistence of a low CD4/CD8 ratio despite
suppressive ART could also identify HIV-infected individuals
with accelerated systemic ageing.
It is worth noting that, to our knowledge, only two
studies have reported data on the association between the
CD4/CD8 and the magnitude of the HIV latent reservoir,
suggesting that failure to normalize the CD4/CD8 ratio in
subjects on effective ART is explained, at least in part, by
persistent, low-level, ongoing viral replication.27,28 Re-
markably, although there was a trend towards a higher
size of the HIV latent reservoir at lower CD4/CD8 ratios,
the difference did not reach statistical significance. The
fact that a considerable proportion of patients (35%)
showed an undetectable HIV latent reservoir, together
with the small sample size makes these data difficult to in-
terpret, preventing us from drawing conclusions on these
particular data.
The lack of association between CD4/CD8 ratio and
markers of bacterial translocation merits also some consid-
erations. Since the CD4/CD8 ratio predicted T-cell activa-
tion, we would have expected to find an association with
bacterial translocation. Importantly, both sCD14 and LPS
levels were clearly lower to those in a HIV treatment-na€ıve
control group already published elsewhere,30 suggesting
that the long-term virally suppressed subjects of this study
might have experienced a certain degree of reconstitution
of the MALT, resulting in decreased bacterial translocation.
Again, given the small sample size and the low levels of
bacterial translocation we cannot rule out an association
between CD4/CD8 ratio and bacterial translocation; this as-
sociation should be explored in larger studies in HIV-
infected subjects with higher bacterial translocation.
Figure 3 CD4/CD8 ratio and bacterial translocation.
Figure 4 CD4/CD8 ratio and HIV latent CD4þ T cell reservoir.
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Our study is subject to a series of limitations. First, the
sample size demands a cautious interpretation of the data.
Only three independent variables could be included in the
multivariate model, and we were forced to exclude other
potential confounders as the time since HIV diagnosis.
Second, we only measured the expression of CD57 in T-
cells as a marker of immunosenescence. Increased expres-
sion of CD57 in T-cells reflects a state of replicative
immunosenescence, an inability to proliferate and
antigen-induced death of CD8þ T-cells.43 However, we did
not quantify CD28 T-cells, which is an important limitation
in the analysis of immunosenescence in our study. The lack
of CD28 expression in CD57þ T-cells is considered to identify
the highly differentiated end-stage senescent cells, dis-
playing shrinkage in the T-cell repertoire and a shortening
of telomere lengths.41 Third, we did not explore the rela-
tionship between CMV-specific T-cells and CD4/CD8 ratio.
It would have been of great interest to analyze the relations
between CD4/CD8 ratio, immune immunosenescence and
CMV-specific T-cells in light of the evidence of an associa-
tion in the general population.19,20,22 Thus, our results war-
rant confirmation in larger studies in HIV-infected subjects
on suppressive ART specifically designed to investigate the
usefulness of the CD4/CD8 ratio as a marker of immune ac-
tivation and immune immunosenescence.
In conclusion, our results suggest that the CD4/CD8 ratio
in HIV-infected subjects on effective ART could be a surro-
gate marker of immune activation and possibly of immu-
nosenescence. Since chronic immune activation seems to
drive non-infectious associated mortality and morbidity in
treated HIV infection,34,42 subjects with higher immune ac-
tivation despite ART might be the target of strategies aim-
ing to prevent the development of these non-infectious
conditions. Although these findings need to be confirmed
in larger studies, the CD4/CD8 ratio merits further atten-
tion as this parameter, easily calculated in daily clinical
practice, could help to identify subjects with ongoing im-
mune activation despite long-term viral suppression.
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The effect of intensification with raltegravir on the
HIV-1 reservoir of latently infected memory CD4 T
cells in suppressed patients
Alejandro Vallejoa,M, Carolina Gutierreza,M,
Beatriz Hernandez-Novoaa, Laura Diazb, Nadia Madrida,
Marı´a Abad-Fernandeza, Fernando Drondaa, Marı´a J. Perez-Eliasa,
Javier Zamorac, Eduardo Mun˜ozd, Marı´a A. Mun˜oz-Fernandezb and
Santiago Morenoa
Objectives: The stability of the reservoir of latently infected memory CD4þ T-cells may
be associated with continuous replenishment from residual HIV-1, not completely
eliminated by otherwise successful antiretroviral therapy (ART). Treatment intensifica-
tion could help to control residual virus and to modify the latent reservoir. The objective
of this work is to assess the effect of intensifying therapy with raltegravir on the HIV-1
cell reservoir.
Design: A pilot open-label phase-II clinical trial was performed to analyze ART
intensification with raltegravir after 48 weeks in chronically HIV-1-infected patients
on stable ART.
Methods: Wemeasured the number of latently infected memory CD4þ T cells, residual
viremia, 2-long terminal repeat circles, CD4þ/CD8þ T-cell activation, lymphocyte
subpopulations, gut homing receptor, and bacterial translocation.
Results: A significant decay of HIV-1 latent reservoir was observed after intensification
in the nine patients included (P¼0.021). No variation was found in either residual
viremia or 2-long terminal repeat circles, whereas CD8þ T-cell activation decreased at
week 36 (P¼0.028). No differences were found in naive T-cell or effector memory cell
counts, and the frequencies of gut homing receptor on activated or effector memory
CD8þ T cells. Bacterial translocation was stable, with the exception of a late decrease in
lipopolysaccharide levels.
Conclusions: In this pilot noncomparative trial, treatment intensification with ralte-
gravir significantly decreased the latent cellular HIV-1 reservoir and CD8þ T-cell
activation. Despite the limitations inherent to trial design, our results suggest that
ART intensification should be considered as an adjuvant strategy to eradicate HIV-1
infection.  2012 Wolters Kluwer Health | Lippincott Williams & Wilkins
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Introduction
Successful antiretroviral therapy (ART) can reduce plasma
viremia to below the limit of detection, leading to
adequate immune recovery and clinical stability in most
HIV-1-infected patients [1]. However, despite its well
known benefits, lifelong ART is associated with
important clinical problems. First, life expectancy may
not be fully restored, and morbidity and mortality arising
from non-AIDS events are increasingly frequent in
patients with controlled viremia [2,3]. Second, successful
lifelong ART is hampered by drug toxicity, resistance
mutations, adherence, and cost, as well as limited access to
treatment in the most affected developing countries [4].
Consequently, major efforts are being made in the search
for new strategies to eradicate or cure HIV-1.
The main barrier to eradication of HIV-1 is virus persis-
tence despite suppressive ART, which leads to pretherapy
viremia levels when ART is interrupted [5,6]. The source
(or sources) of the residual virus in patients receiving ART
continues to be a matter of debate. Although nobody
questions the importance of the pool of latently infected
memoryCD4þTcells [7,8], thepossibilityof ongoingviral
replication resulting from incomplete inhibitory activity or
penetration ofART in sanctuary sites remains controversial
[9,10]. If the residual virus can replenish cell reservoirs, any
attempt to eliminate these reservoirs should be preceded by
complete inhibition of infection by the virus.
Intensification of treatment seems to be the most logical
approach to eliminating residual HIV-1 replication. Previ-
ous studies using various drugs have shown conflicting
results, possibly due to methodological differences in
quantification of the latent reservoir, timing of adminis-
tration of intensifying drugs (acute vs. chronic infection),
baseline patient characteristics, duration of viral suppres-
sion, and sampling time. The emergence of new antiretro-
viral drugs with different mechanisms of action, such as
integrase inhibitors and CCR5 antagonists, provide new
opportunities in attempts to eradicate the latent reservoir
[11–14].
We performed a pilot prospective open-label phase II
clinical trial in chronically HIV-1-infected patients on
suppressive ART in order to assess the effect of intensifying
therapy with raltegravir on the HIV-1 cell reservoir. The
main outcomemeasurewas the numberofmemoryCD4þ
Tcells thatwere latently infected byHIV-1with replicative
capacity. The secondary outcome measures were residual
viremia, episomal 2-long terminal repeat (LTR) circles,
immune activation, and bacterial translocation.
Methods
Study design and patients
We performed a pilot open-label phase II clinical trial to
evaluate the effect of raltegravir (developed and provided
by Merck, Sharp and Dohme, Whitehouse Station, New
Jersey, USA) on the HIV-1 latent reservoir. The study was
conducted at the Hospital Universitario Ramo´n y Cajal
in Madrid, Spain between 2008 and 2010. Biochemical,
immunological, and virological parameters were assessed
at baseline and at weeks 12, 24, 36, and 48. Plasma viral
load was measured by quantitative RT-PCR with a
detection limit of 40 copies/ml (Roche Taqman HIV-1
test; Roche Molecular Systems), and T-lymphocyte
counts were determined by flow cytometry.
The main inclusion criteria were as follows: HIV-1-
infected adults receiving ART based on no less than three
drugs for at least 2 years; undetectable plasma viral load
(pVL) (below 40 copies HIV-1RNA/ml) for at least two
years; CD4þ T-cell count above 350 cells/ml; and no
previous experience with raltegravir. Patients were
excluded if they had experienced virological failure,
received any immunosuppressive or immunomodulatory
therapy, were or planned to become pregnant, or planned
to interrupt treatment for any reason. A total of 300ml of
heparinized whole blood was drawn from each patient for
quantification of the HIV-1 latent reservoir; 50ml of
whole blood with ethylenediaminetetraacetic acid
(EDTA) was drawn for plasma and isolation of peripheral
blood mononuclear cells (PBMCs).
The study was carried out according to the recommen-
dations of the Declaration of Helsinki and current Spanish
legislation on clinical trials. It was approved by the
AEMPS (Spanish Agency for Medications and Health
Products) and our local Independent Ethics Committee
(Hospital Ramo´n y Cajal, Madrid, Spain). All patients
provided written informed consent for participation,
sample collection, and laboratory determinations.
Quantification of latently infected resting CD4 T
cells carrying replication competent virus
The quantification of latently HIV-1-infected cells was
determined using a previously described enhanced
culture assay of highly enriched resting CD4þ T cells
that represent the major long-term reservoir for the virus
[15,16]. Briefly, PBMC were isolated by Ficoll density
gradient centrifugation (Lymphocytes Isolation Solution;
Rafer, S.L., Zaragoza, Spain) from 300ml of heparinized
whole blood. Resting CD4þT cells were then isolated by
negative selection of CD3þ/CD4þ/HLA-DR/CD25
cells using magnetic beads according to the manufac-
turer’s recommendations (Miltenyi Biotec, S.L. Bergisch
Gladbach, Germany). Flow cytometry was next used to
test the isolated resting cells that usually yielded a purity
greater than 99%. A minimum of 63 106 resting CD4þ
T cells is needed to perform this assay. Cells were plated in
duplicate five-fold serial dilution cultures from 25 106
cells to 320 cells. For efficient-cell activation, 10-fold
allogenic irradiated PBMC from healthy donors, pre-
pared the same day, were added to each culture in the
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presence of phytohemagglutinin (PHA, 1mg/ml) and
recombinant interleukin 2 (IL-2, 100U/ml).
The limiting dilution assay with five-fold serial dilution
was set up as follows: The maximum number of resting
cells that were put into one well of a 6-well plate was 106.
Also, 107 irradiated PBMCwere added to each well. Two
individual wells of a 6-well plate were labeled as 106
dilution plate. Each of these wells had complete culture
media (RPMI1640, 10% heat-inactivated fetal bovine
serum, 20U/ml penicillin, 20mg/ml streptomicin), PHA
and IL-2 in a final volume of 8ml. The 5 106 dilution
were split into five wells with 1 106 cells/well and
treated as a group, whereas the 25 106 dilution were
split into 25 wells with 1 106 cells/well and again
treated as a group. To prevent contamination of virus from
one well into another, wells were separated by an empty
well. Cell concentrations below 1 106 were cultured in
24-well tissue culture plates. Each well was set up with
2.5 106 irradiated PBMC and the appropriated number
of resting cells, that is, 2 105, 4 104, 8 103,
1.6 103, and 320, in a final volume of 2ml. Plates
were placed at 378C in a humidified 5% CO2 incubator.
On day 2 supernatants containing PHA were removed
from the wells and replaced with fresh culture media
(without PHA).
Then, CD8þ T-cell-depleted PBMC from healthy
donors, prepared 2–3 days before in the presence of
PHA (1mg/ml), were added once a week to each culture.
Depletion of CD8þ T cells was performed using a
positive selection method (CD8 positive selection;
Miltenyi Biotec). These cells were obtained from
different healthy donors each week and used fresh to
avoid possible cell viability problems due to criopreserva-
tion. Also, these cells were tested for fully permisivity for
viral infection using a mixture of NL4–3 and IIIB HIV-1
strains. A total of 6 106 cells were added to each well of
a 6-well plate and 1 106 cells to each well of a
24-well plate.
On days 15 and 21, culture supernatants were tested for
the presence of HIV-1 antigen using an HIV-1 p24
antigen assay kit (Innogenetics Diagnostica Iberia, S.L.
Tarragona, Barcelona, Spain). Infected cell frequencies
were determined using the maximum likelihood method
and expressed as infectious units per million (IUPM) of
resting CD4þ T cells, with a limit of detection of 0.023
IUPM [17].
Residual viremia
Residual viremia was measured using internally con-
trolled ultrasensitive quantitative real-time RT-PCR
(Single Copy Assay, SCA), as reported elsewhere [18].
Briefly, using improved nucleic acid isolation and
purification techniques, as well as larger plasma volumes,
the limit of detection was less than one HIV-1 RNA copy
per ml, depending on the volume of plasma tested.
When 5–7ml of plasma is used the detection limit is
0.3 copies/ml. A median volume of 6.5ml (interquartile
range 4.6–7) was used for each patient; hence the limit of
detection was 0.3 copies/ml in most patients.
Episomal 2-long terminal repeat circles
The presence of HIV-1 episomal 2-LTR circles was
detected using in-house qualitative nested PCR. To
maximize the recovery of 2-LTR circles and overcome
the low sensitivity of this technique, enriched 2-LTR
circles were extracted selectively from 5 106 PBMCs
using QIAprep Spin Miniprep (Qiagen, Valencia,
California, USA) following the manufacturer’s protocol
for low-copy-number plasmids, as previously described
[19]. In the first round, 5 to 20ml of episomal DNAwere
amplified in a 50ml reaction with the following primers:
forward, 50-TAAGATGGGTGGCAAGTGGTCA; and
reverse, 50-TCTACTTGTCCATGCATGGCTT. The
second round was performed using 1–2ml of the first
reaction product and primers spanning the unique
junction formed by ligation of 50 and 30 LTR sequences,
as follows: forward, 50AATCTCTAGCAGTACTGG
AAG; reverse, 50GCGCTTCAGCAAGCCGAGTCCT.
GCGCTTCAGCAAGCCGAGTCCT. PCR products
were analyzed on 1% agarose gel stained with GelRed
(Biotium, Hayward, California, USA).
T-cell activation, cell subsets, and gut homing
receptor
Fresh EDTA anticoagulated whole blood was used to
analyze CD4þ and CD8þ T cells with the following
antibody combination: CD3-allophycocyanin-Cy7
(APC-Cy7), CD4-peridinin chlorophyll protein com-
plex (PerCP), CD8-phycoerythrin-Cy7 (PE-Cy7),
CD38-phycoerythrin, HLA-DR-allophycocyanin
(APC), CD45RA-phycoerythrin (PE), CCR7-allophy-
cocyanin (APC), and b7-APC. Antibodies were from
Becton Dickinson (Becton Dickinson, Franklin Lanes,
New Jersey, USA), and unstained control was performed
for all samples. Briefly, 100ml of blood was lysed with
Lysing Solution (Becton Dickinson) for 30min at room
temperature, incubated with the antibodies for 20min at
48C, washed, and resuspended in phosphate-buffered
saline containing 1% azide. Cells were analyzed using a
Gallios flow cytometer (Beckman Coulter, Brea,
California, USA). At least 105 CD3þ T cells were
collected for each sample and analyzed with Kaluza
software (Beckman Coulter) by initially gating lympho-
cytes according to morphological parameters. Gating was
always the same between the different time points. T-cell
subsets (at least 20 000 events were gated) were defined as
follows: naive cells, CD3þCD4þ(CD8þ)CD45RAþ
CCR7þ; effector memory cells CD3þCD4þ(CD8þ)
CD45RACCR7; central memory cells CD3þCD4þ
(CD8þ)CD45RACCR7þ; and transitional memory
cells TEMRA CD3þCD4þ(CD8þ)CD45RAþCCR7.
Cell activation levelswere analyzed by the co-expression of
CD38 and HLA-DR.
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Bacterial translocation
Two commercial assays were used to evaluate bacterial
translocation from plasma samples. Plasma bacterial
lipopolysaccharide (LPS), an endotoxin of gram-negative
bacteria, was measured using QCL-1000 Limulus
Amebocyte Lysate (Lonza, Basel, Switzerland) according
to the manufacturer’s protocol. The plasma level of
soluble CD14 was quantified using the Quantikine
Humans CD14 Immunoassay (R&D Systems, Minnea-
polis, Minnesota, USA), according to the manufacturer’s
instructions. Samples were run in duplicate.
Statistical analysis
The frequency of latently infected cells was calculated
using the parametric maximum likelihood method for
limiting dilution experiments, as described elsewhere
[16]. Continuous variables were expressed as median and
interquartile range, and discrete variables as percentages.
The t test for independent samples was used to compare
normally distributed continuous variables; the Wilcoxon
test was used to compare non-normally distributed
continuous variables. The association between categori-
cal variables was evaluated using the chi-square test. The
Spearman correlation coefficient was used to compare
nonrelated variables. Statistical analysis was performed
using SPSS software 16.0 (SPSS Inc., Chicago, Illinois,
USA).
Results
Patient characteristics
NineHIV-1-infected patients under suppressiveARTwere
included in this pilot study, and their baseline characteristics
are summarized in Table 1. The patients were predomi-
nantly male with a long history of ART (median 12 years).
Median CD4 cell count was 655 cells/ml and median CD8
cell count was 636 cells/ml. Only two patients were co-
infected with HCV (RAL8 and RAL9, 22%). All patients
were receiving nucleoside reverse transcriptase inhibitors
combined with nonnucleoside reverse transcriptase
inhibitors in five cases (55%) and with protease inhibitors
in four cases (44%). Raltegravir waswell tolerated by all the
patients during the study.
Decreased frequency of latently HIV-1-infected
cells
From each patient and time point at least 63 106 resting
CD4þ T cells were retrieved, with the exception of
patients RAL5 and RAL6 at week 24 when the amount
of resting cells were not enough to perform the assay.
When the amount of resting cells allowed it, more than
two wells of dilutions below 1 106 were put into
culture, that is, a total of 20 wells were put into culture in
each of the five next dilutions. All patients showed
detectable IUPM at baseline including two with a value
equal to the limit of detection of the assay (0.023 IUPM,
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patients RAL6 and RAL2). As shown in Fig. 1a, six
patients showed a stable decline of IUPM during the
follow-up, including three with only one positive time
point (patients RAL4, RAL8, and RAL6). Two of the
patients, RAL5 and RAL4, had a big decay of IUPM
from basal to week 12. Patients with unstable decay of
IUPM during the follow-up are shown in Fig. 1b
(patients RAL3 and RAL2). Finally, only one patient
showed a positive result after 48 weeks of treatment
intensification (1.6 IUPM, RAL1, Fig. 1c).
We assume that this technique has some variability in
culture recovery and to try to minimize it we always
performed the assay with a minimum of 63 106 resting
cells, added more than two wells in dilutions below
1 106 when possible, tested the permissibility of
infection of the CD8þ T-cell-depleted PBMC used to
feed the cultures, and tested the viability of the cultures
during the assay.
The decrease of IUPM during the follow-up was
significant at week 12 [median 0.12 (0.0–0.51) IUPM,
24 median 0.0 (0.0–0.0), 36 median 0.0 (0.0–0.26), and
48 median 0.0 (0.0–0.22)] (Wilcoxon, P¼ 0.025, 0.028,
0.008, and 0.021, respectively). Assuming that the
variation in the size of the cellular latent reservoir follows
a binomial distribution, with parameter P¼ 0.5, the
probability of such an observation, that is, spontaneous
event, is as low as 0.017.
No effect of intensification on plasma residual
viremia or 2-long terminal repeat circles
We measured plasma residual viremia by SCA at baseline
and after 12 weeks of intensification with raltegravir. At
baseline, residual viremia [median 0.4 copies RNA HIV/
ml (0.3–1.4)] was detected in only three patients; at week
12, residual viremia [median 1.4 copies RNA HIV/ml
(0.4–3.5)] was detected in five patients. Nevertheless,
although there was a trend to an increase, it was not
significant compared with baseline (P¼ 0.08) (Table 2).
Episomal 2-LTR circles were undetectable in all patients
at baseline and remained undetectable after 2 weeks of
intensification (table 2). Subsequently, 2-LTR circles
could be transiently detected in four patients (44.5%); two
at week 12, two at week 24, and one at week 36. Only
one patient had detectable 2-LTR circles at two
consecutive time points. 2-LTR circles were undetectable
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Fig. 1. Latently infected HIV-1 memory CD4R T cells after intensification with raltegravir (log infectious units per million cells,
IUPM). All patients had detectable latent reservoir at baseline. (a) Patients with steady decline from higher to lower frequency of
infection; (b) Patients with unsteady decline; and (c) Patient with higher frequency of infection at week 48 compared to baseline.
Filled symbols: values above limit of detection. Open symbols: values under the limit of detection. Exact values of IUPM of each
patient and time point are shown. The limit of detection was 0.023 IUPM.
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in all patients at the end of the study. This transient
detection of 2-LTR circles during follow-up was not
significant compared with baseline.
Decrease in CD8R T-cell activation and no
variation in T-cell subsets or gut homing receptor
CD4þ T-cell activation remained stable during intensi-
fication with raltegravir. Nevertheless, CD8þ T-cell
activation decreased after intensification, the difference
being statistically significant at week 36 (P¼ 0.028), with
a clearly decreasing trend at week 48 (P¼ 0.093)
compared with baseline. The slight waning effect at
week 48 was due to the increase of cell activation in only
three patients (Fig. 2a and b).
No differences were found in CD4 cell count (median
655, 610, 714, 755, and 703 cell/ml at baseline, 12, 24, 36,
and 48 weeks, respectively) or CD8 cell count (636, 549,
522, 585, and 573 cells/ml at baseline, 12, 24, 36, and
48 weeks, respectively). The naive CD4 cell count
(median 42.8, 41.8, 42.3, 38.2, and 43.2%, at baseline, 12,
24, 36, and 48 weeks, respectively) and the naive CD8 cell
count (median 42.4, 36, 44.9, 42.3, and 45.9% at baseline,
12, 24, 36, and 48 weeks, respectively) were similar
during the follow-up period (P> 0.05 at all time points in
both cases). No significant differences were observed in
the counts of either central, effector memory, or
transitory CD4þ and CD8þ T cells (not shown). The
proportions of activated CD8þ T cells and effector
memory CD8þ T cells bearing gut homing b7 receptor
did not vary significantly during the follow-up period
(Fig. 2c and d, respectively).We also found no consistence
differential effect between patients on nonnucleoside
reverse transcriptase inhibitors vs. protease inhibitor.
Late decrease in bacterial translocation
At baseline, sCD14 and LPS levels were significantly
lower than those of treatment-naive HIV-1-infected
patients. Whereas sCD14 levels were stable during
intensification, LPS levels decreased after 48 weeks of
intensification (P¼ 0.008) (Fig. 3a and b).
Discussion
The results of this pilot clinical trial show that 48 weeks of
intensification with raltegravir reduced the HIV-1
reservoir in latently infected memory CD4þ T cells.
However, this reduction was not associated with a
reduction in residual viremia. The only associated finding
was a decrease in CD8þ T-cell activation, with no effect
either on naive or memory T-cell counts or on gut
homing receptor. A late decrease in a marker of bacterial
translocation was observed as well.
The impact of intensifying ART on the HIV-1 latent
reservoir in suppressed HIV-1-infected patients has been
evaluated, and findings seem to support an effect of
intensification on the latent reservoir. Only three studies,
including the present one, have evaluated the impact of
intensification by quantifying the number of IUPM in
chronically HIV-1-infected patients using the coculture
method [20,21]. All three studies revealed accelerated
decay of the reservoir. As treatment was intensified with
different drugs (abacavir with/without efavirenz,
maraviroc, and raltegravir), the effect seems to be
nonspecific and not related to a specific drug class. It
must be noted that a different study showed no effect of
intensification with raltegravir or efavirenz on the size of
the latent reservoir [22]. However, some differences in the
trial design could explain the different results. Although
the enrolment criteria were similar to ours, the
intensification included valproic acid either alone, or
in combination with the intensifying drugs, and was
administered during a shorter period of time.
The role of intensification in reducing residual replication
and cell infection by the replicative virus is further
supported by other findings. A comparative controlled
clinical trial found a transient yet significant increase in
2-LTR circles in patients who had treatment intensifica-
tion with raltegravir. This was interpreted as a clear sign of
inhibition of residual replication [23]. Another study
showed that intensification with raltegravir was associated
with a significant decrease in proviral DNA in gut-
associated lymphoid tissue (GALT) [24] and a decrease in
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Table 2. Effect of raltegravir intensification on residual viremia and episomal 2-long terminal repeat circles.
Patient
Single copy assay Episomal 2-long terminal repeat circles
BL w12 BL w2 w12 w24 w36 w48
RAL1 <0.9 <0.4 Negative Negative Negative Negative Positive Negative
RAL2 <0.3 <0.5 Negative Negative Negative Negative Negative Negative
RAL3 2.0 1.4 Negative Negative Positive Negative Negative Negative
RAL4 <0.3 4.0 Negative Negative Negative Positive Negative Negative
RAL5 <0.3 <0.3 Negative Negative Positive Positive Negative Negative
RAL6 <0.3 3.0 Negative Negative Negative Negative Negative Negative
RAL7 0.4 2.4 Negative Negative Negative Negative Negative Negative
RAL8 <0.6 <0.5 Negative Negative Negative Negative Negative Negative
RAL9 6 11 Negative Negative Negative Negative Negative Negative
pM 0.08 1 0.1 0.1 0.3 1
MStatistical significance compared to baseline (significant when P<0.05).
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unspliced HIV-1 RNA in CD4þ T cells obtained from
the terminal ileum [25], whereas no significant effect was
observed on residual viremia. The preliminary results of
an ongoing study show that ART may not reach
inhibitory levels in tissues (lymph node and GALT),
with the result that HIV-1 can replicate and infect cells,
thus, increasing the possibility of replenishing the
reservoirs [26].
In contrast, results from other studies have been
interpreted as evidence against ongoing viral replication.
No intensification study has been able to show any
significant impact on residual viremia, as measured by
SCA [9,27–29]. However, we feel that the lack of this
effect is not surprising and does not contradict the
potential action of raltegravir on residual replication.
Intensification could act at extra-plasma sites with little
impact on residual viremia measured in plasma. This
indicates that residual viremia might arise from several
different sources. In our study, residual viremia measured
by SCA did not decrease during intensification. There-
fore, the significant decay in the latent reservoir observed
in the present study is not associated with decreased
residual viremia, thus, implicating the long-standing cell
reservoir as the probable source of such residual viremia.
This observation is also supported by the results of studies
that show a lack of genetic evolution in the persistent
virus population [30]. The increase in 2-LTR circles have
not been confirmed in other studies, although timing in
measurements was different and could explain the
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discrepancy [22]. In our study, no significant changes
were observed in 2-LTR circles after intensification with
raltegravir at any time point, although the small sample
size could at least in part explain the results.
Additionally, no clinical study has shown the impact of
intensification on proviral DNA, which has been used to
measure the HIV-1 reservoir. However, proviral DNA
does not necessarily reflect the size of the latent reservoir,
and its usefulness and validity for this purpose remain to
be established. A final argument against the decay in the
latent reservoir after intensification of ART is seen in the
lack of an effect in patients with both acute and chronic
infection who initiated therapy [12–14,28,31]. The
discrepant results may be explained by the different
situations of patients who initiate therapy and of those
whose viral load has been suppressed for a long time. It is
possible that initiation of ART could reduce the bulk of
virions in tissues and plasma and that the effect on residual
virus cannot be demonstrated months/years after the
initial assessment.
CD8þ T-cell activation decreased during intensification
with raltegravir, as observed in other intensification
studies [21]. This effect does not seem to be due to a
dilutional effect as a result of cell trafficking from plasma
to the gut, because T-cell counts were stable during
intensification, and even T-cell subpopulations, that is,
naive, central, and effector memory and transitory cells,
were constant. We found no evidence of increased levels
of gut homing receptor b7 in activated or memory T
cells. Bacterial translocation was stable during intensi-
fication, with the exception of a late significant decrease
in lipopolysaccharide levels. This finding is important,
because we previously reported that intensification with
maraviroc increased the levels of bacterial translocation
that led to increased levels of gut homing receptor b7
in both activated CD8þ T cells and effector CD8þ
T-memory cells and a subsequent decrease in CD8þ
T-cell activation, probably as a result of trafficking to the
gut [21]. Hence, the mechanism by which CD8þ T-cell
activation decreased using either of these two drugs seems
to be different.
Our study is limited by its small sample size and the lack of
a control group. This trial was designed as a proof of
concept study, and the absence of a control group was
justified by the scarce possibilities of spontaneous decay of
the reservoir, with no intervention. Apart from the
frequency of infection within resting CD4þ T cells is
extremely stable (or decays very slowly), so any significant
decrease that could be found might be attributed to the
intervention. Another limitation of this study is the lack of
two measurements at baseline. Nevertheless, in a previous
intensification trial that we performed with a different
drug [21], two baseline measurements 3 months apart
were performed. As the values obtained in the two
determinations were nearly identical, we decided to
perform only single measurements due to resource
constraints and work overload. In fact, the probability that
this decrease was a random finding is very low. As with
any study aimed at evaluating eradication strategies, our
results are limited by the restrictions inherent to current
methodological tools and the subsequent interpretation
of results.
In summary, intensification with raltegravir can reduce
the cellular viral reservoir without affecting residual
viremia. Intensification with raltegravir or other drugs
could increase the activity of ARTand enhance inhibition
of residual viral replication at sites such as the gut, where
replication may persist due to limited penetration or
suboptimal drug levels. If there is replenishment from
low-level viremia to establish the equilibrium (or slow
1892 AIDS 2012, Vol 26 No 15
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Fig. 3. Effect of intensification with raltegravir on bacterial translocation: (a) sCD14 levels, and (b) LPS levels during the follow-
up period. A group of naive HIV-infected patients was included as comparator group.
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decay) universally observed of the frequency of infection
within resting CD4þ T cells, there must be loss of latently
infected cells at a roughly equivalent rate, Therefore, if
there is depletion of resting cell infection by a period of
raltegravir intensification as seen in this study, then the
return to the prior level of resting cell infection after
either an equal or greater period of unintensified ART
could be one of two possibilities. The other possibility is
that the level of resting cell infection is so low that the
immune system can establish a new lower set point. Yet, it
seems unlikely that intensification can eliminate HIV-1
infection, as existing cell reservoirs need to be purged.
Other strategies, such as administering HIV-1 latency
antagonists, need to be investigated as part of the work
involved in eliminating HIV-1 infection.
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Abstract
Objective: The primary objective was to assess the effect of MVC intensification on latently infected CD4+ T cells in
chronically HIV-1-infected patients receiving antiretroviral therapy.
Methods: We performed an open-label pilot phase II clinical trial involving chronically HIV-1-infected patients receiving
stable antiretroviral therapy whose regimen was intensified with 48 weeks of maraviroc therapy. We analyzed the latent
reservoir, the residual viremia and episomal 2LTR DNA to examine the relationship between these measures and the HIV-1
latent reservoir, immune activation, lymphocyte subsets (including effector and central memory T cells), and markers
associated with bacterial translocation.
Results: Overall a non significant reduction in the size of the latent reservoir was found (p = 0.068). A mean reduction of 1.82
IUPM was observed in 4 patients with detectable latent reservoir at baseline after 48 weeks of intensification. No effect on
plasma residual viremia was observed. Unexpectedly, all the patients had detectable 2LTR DNA circles at week 24, while
none of them showed those circles at the end of the study. No changes were detected in CD4+ or CD8+ counts, although a
significant decrease was found in the proportion of HLA-DR+/CD38+ CD4+ and CD8+ T-cells. LPS and sCD14 levels increased.
Conclusions: Intensification with MVC was associated with a trend to a decrease in the size of the latent HIV-1 reservoir in
memory T cells. No impact on residual viremia was detected. Additional studies with larger samples are needed to confirm
the results.
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Introduction
Antiretroviral therapy (ART) can reduce plasma HIV-1 RNA
levels to ,50 copies/ml [1]. However, low residual viremia, which
is only detectable using ultrasensitive assays, can persist despite
ART [2–4]. The origin and clinical implications of persistent low-
level viremia are uncertain. While some studies postulate that it
may be the result of virus released from latently infected cells [5–
7], others support that it could arise from ongoing viral replication,
as a consequence of incomplete inhibitory activity or penetration
of antiretroviral drugs [8–13].
Although intensification of current ART with potent drugs
could potentially decrease residual viremia and prevent replen-
ishment of viral reservoirs, prior intensification studies have not
demonstrated any impact on residual viremia [12,14–17]. Only
one study confirmed a transient increase in episomal 2LTR DNA
circles after raltegravir intensification [18] as an indicator of recent
HIV-1 replication [19–21], and another study showed a decrease
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e27864
in the frequency of episodes of intermittent viremia [22]. To our
knowlegede, only a few studies have previously evaluated the effect
of intensification of stable therapy on the latent reservoir of resting
CD4+ T cells in chronically HIV-1-infected patients with
controversial results. Ramratnam et al. found an accelerated
decay of the HIV-1 latent reservoir after intensification therapy
with abacavir with or without efavirenz [22]. Two more studies
that measured the impact on the CD4+ T cell reservoir in patients
receiving a four-drug combination as initial antiretroviral therapy
provided discordant results, namely, a reduction in the reservoir in
patients treated during acute infection [23] and no changes in
chronically infected patients [24].
Bacterial translocation and a low level of ongoing viral
replication have been associated with an increase in immune
activation in HIV-1-infected patients [25,26]. Evidence of
increased bacterial translocation from damaged intestinal tissue
was recently demonstrated in chronic HIV-1 infection [25,27]. In
acute HIV-1 infection, intestinal CD4+ T cells are rapidly depleted
and T-cell activation is high. Since monitoring intestinal cells is
difficult, expression of surrogate markers such as the mucosal
homing receptor a4b7 integrin on circulating T cells has been
proposed to correlate with loss or restoration of intestinal CD4+ T
cells and could prove helpful in monitoring the success of
therapeutic strategies [28–30]. Besides, recent studies have shown
that HIV-1 utilizes a4b7 integrin to bind to CD4+ T cells [31].
Maraviroc (MVC) is a potent new antiretroviral agent approved
for the treatment of HIV-1 infection that blocks interaction
between the virus and the CCR5 co-receptor, a crucial step in the
HIV-1 life cycle [32]. Previous clinical trials have demonstrated
the safety, tolerability, and efficacy of MVC in both treatment-
naive and treatment-experienced patients [33,34].
We performed a prospective open-label pilot phase II clinical
trial to assess the effect of MVC intensification on latently infected
CD4+ T cells in chronically HIV-1-infected patients receiving
antiretroviral therapy. We also analyzed residual viremia and
episomal 2LTR DNA to examine the relationship between these
measures and the HIV-1 latent reservoir, immune activation,
lymphocyte subsets (including effector and central memory T
cells), and markers associated with bacterial translocation. The
hypothesis was that if these factors are causally linked, altering one
of them with the intervention should result in alteration of the
others.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Study Design
We performed an open-label pilot phase II clinical trial to
evaluate the effect of MVC on the cellular HIV-1 reservoir in
patients receiving ART. The study was conducted at Hospital
Universitario Ramo´n y Cajal in Madrid, Spain between 2008 and
2010. This independent clinical trial (NCT00795444) had a follow
up of 48 weeks of intensification with MVC (developed and
provided by Pfizer, Inc.).
Ethics Statement
The study was carried out according to the recommendations of
the Declaration of Helsinki and current Spanish legislation on
clinical trials. It was approved by the AEMPS (Spanish Agency for
Medications and Health Products) and our Independent Ethics
Committee (Hospital Ramo´n y Cajal, 28034 Madrid, Spain;
ceic.hrc@salud.madrid.org). All patients provided their written
informed consent for participation, which included sample
collection and laboratory determinations.
Patients and specimen collection
Nine patients met all the following inclusion criteria: undetect-
able plasma viral load (pVL) by standard commercial assays (,50
copies HIV-1 RNA/ml) for at least two years; ART with three or
more drugs for at least two years; CD4+ T lymphocyte count .
350 cells/mm3; R5 viral tropism testing a pretreatment sample
using a phenotypic assay (TrofileH, Monogram Biosciences, C.A),
and no previous treatment with MVC. Patients were recruited
from two hospitals (Hospital Ramo´n y Cajal and Hospital Doce de
Octubre), both in Madrid, Spain.
Patient’s enrollment, allocation and follow up are described in
figure 1.
Samples were collected at baseline and after 12, 24, 36, and 48
weeks of intensification with MVC. A total of 300 ml of
heparinized whole blood was drawn to quantify the latent HIV-
1 reservoir; 50 ml of whole blood with EDTA was drawn to obtain
plasma and isolate peripheral blood mononuclear cells (PBMC).
Samples were cryopreserved in the HIV Biobank of the Spanish
AIDS Research Network (RIS) following current procedures [35].
Figure 1. Consort Flow Diagram.
doi:10.1371/journal.pone.0027864.g001
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In addition, two control groups (10 treatment-naive HIV-1-
infected patients, and 10 HIV-1-negative subjects) were also
analyzed for some measurements.
Latently HIV-1-infected memory T cells
Two baseline determinations (three months apart) were
performed to investigate the accuracy of the method and the
stability of the reservoir.
We carried out a previously described co-culture assay [36,37].
Briefly, PBMC were isolated from 300 ml of heparinized whole
blood using Ficoll density gradient centrifugation (Lymphocytes
Isolation Solution, Rafer, S.L Zaragoza, Spain). Resting CD4+ T
cells (CD4+/HLA-DR-/CD25-) were isolated and purified using
magnetic beads according to the manufacturer’s recommendations
(Miltenyi Biotec, S.L. Bergisch Gladbach, Germany). CD4+ T-cell
purity greater than 99% with less than 0.4% activation was
confirmed by flow cytometry. The isolated resting CD4+ T cells
were plated in replicate limiting dilutions and co-cultured with
allogenic irradiated PBMC from seronegative donors and
phytohemagglutinin. The activated cell culture was fed once a
week with PBMC from healthy donors after depletion of CD8+ T
cells. On days 15 and 21, culture supernatants were tested for
HIV-1 replication using the HIV-1 p24 antigen assay (Innoge-
netics Diagnostica Iberia, S.L Tarragona, Barcelona, Spain).
Infected cell frequencies were determined by the maximum
likelihood method and expressed as infectious units per million
(IUPM) resting CD4+ T cells [38]. The millions of purified resting
CD4+ T cells obtained from the total PBMCs conditioned the
number of replicates of each dilution. The assay was performed to
each point as duplicate fivefold dilution series.
From baseline to week 12 of follow-up, the limit of detection of
the assay was 0.12 IUPM resting CD4+ T cells. Thereafter, the
limit of detection decreased to 0.023 IUPM, since the total blood
extraction volume was increased after approval of the amended
protocol by the IEC.
Residual viremia
Residual viremia was measured with internally controlled an
ultrasensitive quantitative real-time RT-PCR (single copy assay),
as reported elsewhere [39]. The optimal HIV-1 RNA detection
threshold was 0.3 copies/ml when 5 to 7 ml of starting plasma was
available. We used a median of 6.5 ml (IQR: 4.6 to 7).
HIV-1 episomal 2LTR DNA circles
The presence of HIV-1 episomal 2LTR DNA circles was
detected by qualitative PCR. To maximize the recovery of 2LTR
DNA circles and overcome the lack of sensitivity of this technique
[8,18,40] enriched 2LTR episomal DNA circles were extracted
selectively from ,5 million PBMC using QIAprep Spin Miniprep
(Qiagen, Valencia, California, USA) following the manufacturer’s
protocol for low-copy-number plasmids, as previously described
[8].
A nested PCR flanking the episomal 2LTR DNA circle junction
was designed. In the first round, 5–20 mL of episomal DNA were
amplified in a 50-mL reaction with the following primers: forward,
59-TAAGATGGGTGGCAAGTGGTCA; and reverse, 59-
TCTACTTGTCCATGCATGGCTT.
The second PCR round was performed using 1 to 2 mL of the
first reaction product as the template and primers spanning the
unique junction formed by ligation of 59 and 39 LTR sequences
(forward, 59-AATCTCTAGCAGTACTGGAAG; reverse, 59-
GCGCTTCAGCAAGCCGAGTCCT). PCR products were an-
alyzed on a 1% agarose gel stained with GelRed (Biotium,
Hayward, California, USA).
Immune activation and lymphocyte subsets
Fresh EDTA anticoagulated whole blood was used to analyze
CD4+ and CD8+ T cell activation with the following antibody
combination: CD3-allophycocyanin (APC)-Cy7, CD4-peridinin
chlorophyll protein complex (PerCP), CD8-phycoerythrin (PE)-
Cy7, CD38-phycoerythrin (PE), and HLA-DR-allophycocyanin
(APC). Lymphocyte subpopulations were defined as naı¨ve
(CD45RA+CCR7+), T central memory (CD45RA-CCR7+,
TCM), T effector memory (CD45RA-CCR7-, TEM), and T
effector memory RA+ (CD45RA+CCR7-, TemRA). To analyze
lymphocyte subsets this antibody combination was used: CD3-
allophycocyanin (APC)-Cy7, CD4-peridinin chlorophyll protein
complex (PerCP), CD8-phycoerythrin (PE)-Cy7, CD45RA- phy-
coerythrin (PE), and CCR7-allophycocyanin (APC), b7-allophy-
cocyanin (APC). Antibodies were from Becton Dickinson (Becton
Dickinson, NJ, USA), and an unstained control was performed for
all samples. Briefly, 100 mL of blood were lysed with 200 ml of
FACS Lysing solution (Becton Dickinson) for 30 min at room
temperature, incubated with the antibodies during 20 min at 4uC,
washed and resuspended in PBS containing 1% azida. Cells were
analyzed in a Gallios flow cytometer (Beckman-Coulter, CA,
USA). At least 15000 CD3+ cells were collected for each sample
and analyzed with Kaluza software (Beckman-Coulter) initially
gating lymphocytes according to morphological parameters. The
gating was always the same between different time points.
Bacterial translocation
Two commercial assays were used to evaluate bacterial
translocation from plasma samples. Plasma bacterial lipopolysac-
charide (LPS) was measured using QCL-1000 Limulus Amebocyte
Lysate (LonzaH, Basel, Switzerland) according to the manufactur-
er’s protocol. This test quantifies endotoxins from the cell wall of
gram-negative bacteria. Plasma sCD14 was quantified using the
QuantikineH Human sCD14 Immunoassay (R&D Systems,
Minneapolis, Minnesota, USA), according to the manufacturer’s
instructions. Samples were run in duplicate in all cases.
Statistical analysis
This is an exploratory pilot study that is trying to prove a
concept. A treatment group of 10 patients has been considered
adequate, based on data from previous studies published by other
authors on the same subject.
Continuous variables were expressed as the median and
interquartile range and discrete variables as percentages. The t
test for independent samples was used to compare normally
distributed continuous variables and the Mann-Whitney test to
compare non-normally distributed continuous variables. Categor-
ical variables were described as proportions. The association
between categorical variables was evaluated using the chi-square
test. A Spearman correlation was used. Statistical analysis was
performed using SPSS software 16.0 (Inc., Chicago, Illinois, USA).
Results
Patient characteristics
The baseline characteristics of the patients are summarized in
table 1. The median age was 46 years and 8 patients were male.
The median baseline CD4+ and CD8+ T-cell counts were 711 and
784 cells/mm3, respectively. All patients were receiving nucleoside
reverse transcriptase inhibitor (NRTI)–containing regimens com-
bined with non-nucleoside reverse transcriptase inhibitors
(NNRTIs) in two cases (22%), with protease inhibitors (PIs) in
five cases (56%), and with a third nucleoside in two cases (22%).
The median duration of ART before study entry was 75 months.
CCR5 Antagonists and HIV-1 Reservoir
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MVC was well tolerated. Two patients interrupted the study
early. Data from these patients were included only until the study
interruption. None of them was included in the final analysis at week
48.One patient, who was coinfected with hepatitis C virus, had a
significant increase in liver enzymes after the visit at week 12; the
other discontinued all antiretroviral drugs due to poor adherence
after the visit at week 12. The remaining patients maintained an
HIV viral load ,50 copies/ml until the end of the study.
Effect of MVC intensification on latent HIV-1 reservoir
The number of latently HIV-1-infected memory CD4+ T cells
decreased after 48 weeks of MVC intensification, although the
difference was not significant (p = 0.068) (figure 2). Three patients
showed a reservoir below the limit of detection before receiving
MVC (figure 2A), and this remained undetectable after 48 weeks
despite a transient increase in two patients. The remaining
patients, all of whom had a quantifiable reservoir at study entry,
showed a decrease in the IUPM after 48 weeks of intensification
(figure 2B) or after 12 weeks of intensification (figure 2C, two
patients who discontinued the study after week 12). A mean
reduction of 1.82 IUPM was found in the 4 patients with
detectable latent reservoir at baseline after 48 weeks of
intensification with MVC.
Effect of MVC intensification on residual viremia
The impact on the cellular reservoir was not associated with
significant changes in residual viremia. At baseline, 8 of the 9
patients had undetectable residual viremia using the single copy
assay. A significant increase in residual viremia was observed after
12 weeks of MVC intensification compared to baseline (p = 0.027).
Afterwards, residual viremia decreased progressively until the end
of the study, with no significant differences compared to baseline
(p = 0.08, table 2).
Effect of MVC intensification on episomal 2LTR DNA
circles
At baseline, episomal 2LTRs DNA circles were undetectable in
all patients. However, at week 12 they were detected in 5 patients
(p = 0.037, compared to baseline) and at week 24 in all 9 patients
(p = 0.012, compared to baseline). At week 48, episomal 2LTR
DNA circles were again undetectable in all patients (table 2).
Effect of MVC intensification on T-cell activation
The level of activation of CD4+ T cells decreased significantly
after 12, 24, and 36 weeks of MVC intensification (p = 0.028,
p = 0.027, and p = 0.028, respectively), only to increase after 48
weeks, although the difference with baseline was not significant
(p = 0.6) (figure 3). Compared to HIV-negative subjects, CD4+ T-
cell activation at baseline was significantly higher (p,0.001), with
no significant differences at weeks 12 and 24 (p = 0.950 and
p = 0.181, respectively).
The level of activation of CD8+ T cells also decreased
significantly after 12 weeks and until the end of the study
(p = 0.043, p = 0.025, p = 0.028, and p = 0.046, at weeks 12, 24,
36, and 48, respectively) (figure 3). The level of cell activation at
baseline was higher than in the HIV-negative subjects (p = 0.001).
Only at week 48 was this difference not significant compared to
the HIV-negative group (p = 0.181).
Effect of MVC intensification on T-cell subsets
No differences in the absolute number or percentage of CD4+
or CD8+ T cells were found during follow-up. A significant
increase in CD8+ effector memory and TemRA T cell count was
found during the first 24 and 36 weeks after MVC intensification,
respectively. Thereafter, the differences compared to baseline were
not significant (figure 4). On the other hand, a significant decrease
in CD8+ central memory T cells was observed at week 12
(p = 0.002). The level of CD8+ naive T cells was similar during
follow-up (p.0.05 at all time points). No significant differences
were observed in any CD4+ T cell subsets during follow-up (data
not shown).
The proportion of CD8+ naı¨ve and memory T cells expressing a
b7 receptor significantly increased after 12 weeks of intensification
(p = 0.037 and p = 0.007, respectively) (figure 5A and 5B
respectively). The expression of b7 receptor also increased in
activated CD8+ T cells at week 12 compared to baseline
(p = 0.046), and a trend was observed during the rest of the follow
up (figure 5C).
Effect of MVC intensification on bacterial translocation
A significant increase in sCD14 level was observed after 24, 36
and 48 weeks of intensification with MVC compared to baseline
(p = 0.015, p = 0.028 and p = 0.028, respectively) (figure 6). These
Table 1. Baseline characteristics of the patients.
Patient ID Age (years) Gender
Risk
Factors
Viral load
(copies/ml)
CD4 count
(cells/mm3)
CD8 count
(cells/mm3)
Duration of
ART (months)
Current ART
regimen
MVC
intensification
(mg/BID)
MVC 1 49 M IDU ,50 1169 683 124 ddI+3TC+NVP 300
MVC 2 47 M MSM ,50 486 673 75 FTC+TDF+ATV/r 150
MVC 3 46 M IDU ,50 796 650 78 3TC+ABC+ATV 150
MVC 4 46 F HSx ,50 534 784 57 AZT+3TC+ABC 300
MVC 5 45 M IDU ,50 728 639 142 AZT+3TC+ABC 300
MVC 6 58 M MSM ,50 787 1109 144 FTC+TDF+LOP/r 150
MVC 7 32 M MSM ,50 694 1608 50 FTC+TDF+ATV/r 150
MVC 8 30 M MSM ,50 589 1064 42 FTC+TDF+EFV 600
MVC 9 30 M MSM ,50 1241 1414 38 TC+TDF+LOP/r 150
Median [IQR] 46 [31–48] - - ,50 711 [547–793] 784 [673–1109] 75 [38–144] - -
ddI: didanosine; NVP: nevirapine; FTC: emtricitabine; TDF: tenofovir; ATV/r: atazanavir/boosted with ritonavir; ABC: abacavir; AZT: zidovudine; LOP/r: lopinavir/boosted
with ritonavir; EFV: efavirenz; F: Female; M: Male; HSx, Heterosexual; MSM: men who have sex with men.
doi:10.1371/journal.pone.0027864.t001
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levels were significantly lower than those of naive HIV-1-infected
patients at all time points. LPS levels were also higher at weeks 24,
36, and 48 of intensification than at baseline (p = 0.006, p = 0.006,
and p = 0.021, respectively) (figure 6). The level of LPS at baseline
was significantly lower that that of treatment-naive HIV-1-infected
patients; during follow-up, these levels were no different from
those of the treatment-naive patients.
A significant direct correlation was found between sCD14 levels
and LPS levels at baseline (p = 0.035, r = 0.743) while a similar
trend was observed during the rest of the follow up. Furthermore,
Figure 2. Effect of MVC intensification on HIV-1 latently infected memory CD4+ T cells. (a) Patients who had a latent reservoir below the
limit of detection at baseline, and remained undetectable after 48 weeks of intensification. (b) Patients with quantifiable latent reservoir at baseline,
and decreased after 48 weeks of intensification, (c) patients with quantifiable latent reservoir at baseline but discontinuated the study after w12.
Square symbols: detection limit of 0.12 IUPM. Diamond symbols: detection limit of 0.023 IUPM. Open symbols: under the limit of detection.
doi:10.1371/journal.pone.0027864.g002
Table 2. Effect of MVC intensification on residual viremia and episomal DNA circles.
Patient SCA Episomal 2LTR DNA
ID Baseline w12 w24 w36 w48 Baseline w12 w24 w36 w48
MVC 1 0.3 S.F. S.F. ,0.3 ,0.3 - + + - -
MVC 2 ,0.3 ,0.3 N.D. N.D. N.D. - + N.D. N.D. N.D.
MVC 3 ,0.3 SF ,0.5 0.5 - - + - -
MVC 4 ,0.3 9.2 ,0.4 ,0.3 ,0.3 - - + - -
MVC 5 ,0.3 1.0 ,0.5 ,0.3 2.2 - - + - -
MVC 6 ,0.3 3.0 3.0 1.1 3.3 - + + - -
MVC 7 ,0.6 7.0 ,0.5 ,0.5 ,0.5 - - + + -
MVC 8 ,0.4 0.5 4.6 ,0.5 3.7 - + + - -
MVC 9 ,2.0 1.0 N.D. N.D. N.D. - + N.D. N.D. N.D.
Median 0[0–0] 1[0.5–7] 0[0–3.4] 0[0–0.2] 0.5[0–3.3]
p * 0.027 0.1 0.6 0.08 0.037 0.012
SCA: Single copy assay; S.F.: Standard failure; N.D.: Not determined; *: Statistical significance compared to baseline (significance p,0.05).
doi:10.1371/journal.pone.0027864.t002
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Figure 3. Immune activation during MVC intensification. CD4+ and CD8+ T cell activation of the patients during the follow up is shown. A
group of HIV-1 negative individuals are also shown.
doi:10.1371/journal.pone.0027864.g003
Figure 4. CD8+ T cell subpopulations after MVC intensification. The proportion of naı¨ve, central memory (TCM), effector memory (TEM), and
effector memory RA+ (TemRA) cells is shown.
doi:10.1371/journal.pone.0027864.g004
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the LPS level correlated directly with both the proportion of CD4+
T cells expressing a b7 receptor and the level of naive CD4+ T
cells expressing b7 receptor at week 24 (p = 0.047, r = 0.817).
Similarly, the level of LPS at week 36 correlated directly with that
of CD8+ effector memory T cells (p = 0.045, r = 0.818).
Discussion
In this pilot study, intensification of treatment with MVC in
patients chronically infected with HIV-1 receiving successful long-
term ART was associated with a trend to an accelerated decay in
the pool of latently infected CD4+ T cells. No impact on residual
viremia was observed.
Intensification of successful antiretroviral therapy has been
explored in two different ways. Some studies have evaluated its
role for clinical purposes, that is, to achieve better virological
control or a greater increase in CD4+ T-cell counts, or, more
recently, to reduce immune activation. With the exception of one
study that showed a decrease in HIV RNA levels after abacavir
intensification, none of the studies has been able to show
significant improvements with intensified therapy compared to
the standard three-drug regimens [11,12,14–17,41]. As a conse-
quence, most clinicians feel that no further research in this
direction is necessary. Other studies have evaluated intensification
as a strategy to help to eradicate HIV. The rationale for this
approach is that suppression of putative replication could reduce
residual viremia and replenishment of cellular reservoirs leading to
a decrease in the total latent reservoir [8–18,41]. The results of all
the studies are uniform in that no single group has shown a
significant reduction in plasma HIV RNA as a result of
intensification. This finding could be interpreted as confirmation
of the lack of residual viral replication, thus supporting the
hypothesis that residual viremia is the result of viral release from
stable reservoirs and not the consequence of new rounds of viral
replication [5–7]. An alternative hypothesis would be that the
effect of intensification takes place mainly outside plasma sites and,
therefore, the measurement of plasma viral load only could not
detect this effect. Some of the studies that included measurements
other than plasma HIV RNA seem to support this hypothesis [42–
44].
We observed a reduction in the size of the latent reservoir after
intensification of treatment with MVC, although this reduction
was not significant, probably due to the small sample size. This
finding is consistent with other studies that included patients with
different baseline characteristics [22,23], although some authors
do not support it [24]. The decline in the latent reservoir that we
Figure 5. Proportion of CD8+ T cells expressing b7 receptor. A) naı¨ve T cells, B) memory T cells, and C) activated T cells.
doi:10.1371/journal.pone.0027864.g005
Figure 6. Bacterial translocation. Levels of sCD14 and LPS during the follow up are shown. The levels of a group of HIV-1 positive naı¨ve for ART
are also included.
doi:10.1371/journal.pone.0027864.g006
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found does not appear to be secondary to a decrease in residual
viral replication in plasma, since there were no detectable changes
in the measurements of residual viremia. It has been suggested that
a dilutional effect could account for the reduction observed, but
the lack of an increase in the absolute count and the percentage of
both CD8+ and CD4+ T cells strongly argues against this
possibility.
Other findings in our study may help explain the effect on the
latent reservoir. Unexpectedly, 2LTR DNA circles were transient-
ly detectable during MVC intensification. Due to its mechanism of
action, MVC is not expected to increase 2LTR DNA circles, even
when inhibiting persistent viral replication. The increase in levels
of this marker suggests that treatment with MVC in patients with
undetectable viral load may induce viral replication. Preclinical
studies showed that MVC had no agonistic activity on activated
CD4+ T cells and, therefore, could not induce viral replication
[32]. Later reports, however, have shown that the possibility of
acting as a partial agonist on CCR5 could be dependent on cell
type [45]. Therefore, MVC could activate CCR5 in resting CD4+
T cells and, through intracellular signalling, increase transcrip-
tional activation of the latent virus. As an alternative hypothesis,
CCR5 blockade by MVC could lead natural ligands or
chemokines to bind to other receptors and induce latent HIV
transcriptional activation through distinct signalling pathways.
Both hypotheses would be consistent with the reduced number of
latently infected memory T cells found in this study, the transient
increase in the number of copies of HIV RNA seen in some
patients, and the increased bacterial translocation plus migration
of a4b7 cells to the gut. This possibility is further supported by the
increased immune activation in intestinal tissue biopsies that was
observed in another MVC intensification study [46]. Finally,
trafficking of cells to peripheral blood from some other
compartment cannot be discarded to explain some of the results,
including the increase in 2 LTR circles.
Neither of the above hypotheses can account for the diminished
immune activation that we detected. MVC has been shown to
decrease immune activation in clinical trials, and it could be
assumed that a different mechanism drives the impact on immune
activation [47]. The decrease in immune activation does not
correlate with a decrease in bacterial translocation, which in fact
increased during the study, thus supporting increased viral
replication and activation in the intestine resulting from the
release of proinflammatory cytokines [48].
The transient increase in TEM and TemRA CD8+ T cell counts
parallels the increase in bacterial translocation. These increments
are balanced by a transient decrease in central memory CD8+ T cell
counts, while naive CD8+ T cell levels remain stable [49]. In
addition, the finding of increased b7 receptor levels on CD8+ T cells
and especially on activated CD8 T cells support the idea of
migration of these cells to the intestine, where bacterial translocation
takes place. This migration of activated cells to the gut could
account for the reduced immune activation observed in the
periphery. In this sense, immune events detected in peripheral
blood may not reflect what takes place in the intestine, as is the case
for the huge CD4+ T-cell destruction that occurs in the intestine of
the SIV rhesus macaque during acute infection, which is not
reflected in lymph nodes or peripheral blood [50].
Our work has a series of limitations. First, it is a pilot study with
a small sample size, thus limiting the strength of the conclusions.
Second, no control group was included. The study was designed as
a proof of concept with no guarantee of any spontaneous effect in
the sample. Finally, the methodological tools used for the different
measurements and their interpretations are still imperfect.
In summary, our study shows positive effects of MVC
intensification on latently HIV-1-infected CD4+ T cells. These
effects are not reflected in reduced residual plasma viremia and
may be associated with the activity of the drug in an anatomical
reservoir, most likely the intestine. The mechanism by which
MVC decrease the HIV-1 reservoir is under investigation. The
decrease we observed, however, is by no means large enough to
eradicate HIV. New therapeutic strategies, probably based on
anti-latency drugs, are necessary to eradicate viral reservoirs. In
this sense, complete inhibition of viral replication at all sites can be
presumed to be necessary before these new treatment strategies
can be applied. The exact role of treatment intensification in
eradication remains undefined, and a large, comparative trial with
adequate methodology is needed to provide a definitive answer to
this relevant question.
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Abstract
Background: Most of the non-B HIV-1 subtypes are predominant in Sub-Saharan Africa and India although they
have been found worldwide. In the last decade, immigration from these areas has increased considerably in Spain.
The objective of this study was to evaluate the prevalence of non-B subtypes circulating in a cohort of HIV-1-
infected immigrants in Seville, Southern Spain and to identify drug resistance-associated mutations.
Methods: Complete protease and first 220 codons of the reverse transcriptase coding regions were amplified and
sequenced by population sequencing. HIV-1 subtypes were determined using Stanford University Drug Resistance
Database, and phylogenetic analysis was performed comparing multiple reported sequences. Drug resistance
mutations were defined according to the International AIDS Society-USA.
Results: From 2000 to 2010 a total of 1,089 newly diagnosed HIV-1-infected patients were enrolled in our cohort.
Of these, 121 were immigrants, of which 98 had ethical approval and informed consent to include in our study.
Twenty-nine immigrants (29/98, 29.6%) were infected with non-B subtypes, of which 15/29 (51.7%) were CRF02-AG,
mostly from Sub-Saharan Africa, and 2/29 (6.9%) were CRF01-AE from Eastern Europe. A, C, F, J and G subtypes
from Eastern Europe, Central-South America and Sub-Saharan Africa were also present. Some others harboured
recombinant forms CRF02-AG/CRF01-AE, CRF2-AG/G and F/B, B/C, and K/G, in PR and RT-coding regions. Patients
infected with non-B subtypes showed a high frequency of minor protease inhibitor resistance mutations, M36I,
L63P, and K20R/I. Only one patient, CRF02_AG, showed major resistance mutation L90M. Major RT inhibitor
resistance mutations K70R and A98G were present in one patient with subtype G, L100I in one patient with
CRF01_AE, and K103N in another patient with CRF01_AE. Three patients had other mutations such as V118I, E138A
and V90I.
Conclusions: The circulation of non-B subtypes has significantly increased in Southern Spain during the last
decade, with 29.6% prevalence, in association with demographic changes among immigrants. This could be an
issue in the treatment and management of these patients. Resistance mutations have been detected in these
patients with a prevalence of 7% among treatment-naïve patients compared with the 21% detected among
patients under HAART or during treatment interruption.
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Background
Human immunodeficiency virus type 1 (HIV-1) is the
major pathogen responsible for the AIDS pandemic. Sev-
eral genetic variants can be recognized within HIV-1
group M, including nine subtypes (A through K), at least
43 major circulating recombinants forms (CRFs), and mul-
tiple unique recombinant forms (URFs) (http://www.hiv.
lanl.gov). The prevalence of HIV-1 subtypes varies greatly
depending on the geographic region. Subtype B is predo-
minant in North America and Western Europe, including
Spain, although is responsible for only 10% of global infec-
tions [1]. Non-B HIV-1 subtypes and its recombinants,
such as subtype C, A, CRF01_AE or CRF02_AG, are pre-
valent in Sub-Saharan Africa, Asia and Eastern Europe [2].
These subtypes cause up to 90% of the 36 million esti-
mated infections, playing an important role in the HIV-1
pandemic [3,4]. Human migration produced in the last
decade has contributed to the current spread of non-B
subtypes in developed countries [5-7].
The extensive variability of HIV-1 has a potential
impact on epidemiology, diagnosis, therapy and preven-
tion of infection. In fact, faster progression to AIDS
among individuals infected with non-B subtypes or
recombinant variants enhances the importance of identi-
fying these strains [8,9]. In addition, differences in the
sensitivity to antiretrovirals in patients infected with
non-B subtypes due to the high prevalence of poly-
morphisms in protease (PR) and/or reverse transcriptase
(RT) associated with resistance to antiretroviral therapy
has to be taken into account [10-16].
Finally, diagnostic tests, including viral load measure-
ments, might be affected by the diversity of HIV-1
strains [17,18]. Therefore, HIV-1 subtype characteriza-
tion is becoming an important aspect to adequate clini-
cal management of HIV-1-infected individuals [3]. Sub-
Saharan population in Spain has increased in recent
years. Around 10-15% of HIV-1-infected immigrants are
characterized with non-B subtype during the first medi-
cal evaluation [19-21].
Thus, the objective of this study was to analyse the
prevalence of non-B subtypes in a cohort of HIV-1-
infected immigrants in Southern Spain from 2000 to
2010, and to characterize drug resistance mutations
associated to PR and RT.
Methods
Patients
From January 2000 to December 2010 a total of 1,089
new HIV-1-infected patients were included in the
dynamic open cohort of the Infectious Diseases Service
at the University Hospital Virgen del Rocio located in
Seville, Southern Spain. Of these, 121 (11.1%) were
HIV-1 infected immigrants. For the present retrospec-
tive study, immigrant patients of any nationality with
available samples were selected. The study was approved
by the Ethical Committee of the Hospital. A total of 98
patients were included and all signed an informed
consent.
Laboratory determinations
CD4+ T cell count was determined in fresh samples by
flow cytometry. Plasma HIV-1 RNA was measured by
quantitative PCR (HIV Monitor™ Test Kit, Roche
Molecular System, Hoffman-La Roche, Basel, Switzer-
land), according to the manufacturer’s instructions. This
assay has a lower detection limit of 50 HIV-1 RNA
copies/ml.
Subtyping and drug resistance profile
For genetic analysis, in patients with detectable viral
load, HIV-1 RNA was extracted from plasma using a
viral RNA purification kit (Qiagen, Diagnostics, Barce-
lona, Spain). cDNA was synthesized by avian myeloblas-
tosis virus (AMV) reverse transcriptase. In patients with
undetectable viral load and undergoing antiretroviral
treatment at the time of the study, HIV-1 proviral DNA
from cryopreserved peripheral blood mononuclear cells
(PBMCs) isolated from heparinized blood by Ficoll den-
sity-gradient centrifugation, were used for DNA extrac-
tion (Qiagen DNA blood kit, Diagnostics, Barcelona,
Spain), following the manufacturer’s instructions.
PCR reactions were carried out in 50 μL final volumes
containing 10 mM Tris HCl pH 8.8, 50 mM KCl, 1.5
mM MgCl2, 0.1% Triton X-100, 0,2 mM of each dNTP,
0.7 units Taq polymerase (Eurotaq, Euroclone, S.p.A,
Syziano, Italy), 0.5 μM of each primer, and 1 μg purified
DNA. Cycling parameters were 94°C for 5 min followed
by 35 cycles of 94°C for 15 s, 55°C for 15 s and 72°C for
30 s, followed by a 10 min hold at 72°C. Identical condi-
tions were used for the nested PCR. Outer primers
PRF2 (5’-cagaagagagtctcaggtttggg-3’) and PRF5 (5’-tggag-
tattgtatggattttcagg-3’) for the PR-coding region, and
47RV (5’-gtattagtaggacctacacct-3’) and Pol18 (5’-agactca-
caatatgca-3’) for the RT-coding region, were used. Inner
primers Pol10 (5’-ccctcaagggcaggagc-3’) and Pol14 (5’-
gggccatccattcctgg-3’) for the PR-coding region, and A35
(5’-ttggttgcactttaaattttcccattagtcctatt-3’) and Lp2 (5’-
atcaggatgagattcataacccatcca-3’) for RT-coding region,
were used. A fragment of 450 bp encompassing the
entire PR-coding region and a fragment of 670 bp that
includes the first 220 codons of the RT-coding region
were generated by nested PCR.
Sequencing of PCR purified amplicons was performed
using Applied Biosystems 310 Sequencer and BigDye
deoxy terminator procedure as specified by the
manufacturer.
Subtyping of the PR and RT sequences was deter-
mined using the Stanford University Drug Resistance
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Database (http://hivdb.stanford.edu). Afterwards, the PR
and RT sequences were aligned together with other
HIV-1 group M reported sequences available in the
GenBank by computer software CLUSTAL W. Phyloge-
netic trees were generated using the Neighbour-Joining
method and bootstrap re-sampling of multiple align-
ments (1,000 data sets), included in the CLC DNA
Workbench software, was employed to test the tree
robustness. Drug resistance profiles in PR and RT-cod-
ing regions were defined according to the International
AIDS Society-USA.
Statistical Analysis
Continuous variables are shown as median [interquartile
range (IQR)], and categorical variables as number of
cases (percentage). Chi square test were used to analyze
differences between categorical variables. The statistical
analysis was performed using the Statistical Package for
the Social Sciences software (SPSS 16.0, Chicago, Illi-
nois, USA).
Sequence Accession Number
GenBank accession numbers for consensus sequences:
AM000054 (A); K03455 (B); AY563172 (C); DQ189088
(F); AY017457 (G); EF614151 (J); AJ249239 (K);
FM252023 (CRF01_AE); FN557324 (CRF02_AG). Pro-
tease sequences: JF338626-JF338629 (PR_SE10-
PR_SE13), JF338630-JF338633 (PR_SE15-PR_SE18),
JF338634-JF338641 (PR_SE20-PR_SE27), JF338642-
JF338653 (PR_SE29-PR_SE40), JF338653 (PR_SE40),
JF338654-JF338658 (PR_SE42-PR_SE46), JF338659-
JF338663 (PR_SE48-PR_SE52), JF338664-JF338686
(PR_SE54-PR_SE76), JF338687-JF338690 (PR_SE78-
PR_SE81), JF338691-JF338716 (PR_SE90-PR_SE115). RT
sequences: JF338717-JF338719 (RT_SE10-RT_SE12),
JF338720-JF338731 (RT_SE14-RT_SE25), JF338732-
JF338744 (RT_SE27-RT_SE39), JF338745-JF338761
(RT_SE41-RT_SE57), JF338762-JF338780 (RT_SE59-
RT_SE77), JF338781 (RT_SE79), JF338782-JF338807
(RT_SE90-RT_SE115).
Results and discussion
Patients’ characteristics
Baseline characteristics of the 98 immigrant individuals
studied are summarized in Table 1. The study popula-
tion was grouped into seven categories according to
their home countries: Central-South America (Argen-
tina, Peru, Brazil, Colombia, Cuba, Bolivia, Ecuador, El
Salvador, Guatemala, Panama, Paraguay, Dominican
Republic and Venezuela), Western Europe (France, Italy,
Portugal, Belgium, Germany and Ireland), Sub-Saharan
Africa (Nigeria, Cameroon, Angola, Uganda, Sierra
Leone, Guinea, Cote d’Ivoire), Northern Africa (Mor-
occo), Eastern Europe (Romania, Ukraine and Russia),
North America (United States), and Asia (India). The
largest immigrant group in Southern Spain was from
Central-South America (47/98, 47.9%). In most cases,
these individuals were infected with HIV-1 before mov-
ing to Spain.
The proportion of immigrants in our cohort of HIV-1-
infected patients from 2000 to 2010 is shown in Figure
1. The proportion has been rising year by year from
2.1% in 2000 to around 12% in 2010. Notably, there has
been a marked progressive increase up to 2008, which
exceeded 20% (Figure 1). Regarding risk behaviour,
injecting drug use was the most common route of trans-
mission among native Spanish patients (around 40% vs.
7% among immigrants, p < 0.001 Chi Square test), while
sexual transmission (hetero plus homosexual) was pre-
dominant (80% vs. 42% among native Spanish patients,
p < 0.001 Chi Square test) among immigrants (Figure 1).
Subtype analysis
Both PR and RT sequences were obtained for 87
patients, while only PR or RT sequences were obtained
for seven and four individuals, respectively. Twenty-nine
of the overall sequences analyzed belonged to non-B
subtypes (29.6%, Table 2). These included A, C, F, G, J,
and K subtypes, and recombinant forms, such as
CRF02_AG, as well as CRF01_AE. Besides, seven
patients harbored different subtypes for each gene,
including recombinants B/C, F/B, K/G, CRF02_AG/
CRF01_AE, and CRF02_AG/G in PR and RT respec-
tively. According to the geographical origin, the non-B
Table 1 Characteristics of the 98 HIV-1-infected
immigrant individuals studied
Male gender (%) 68 (69.4)
Age (years) 35 [30-38]
CD4+ count (cell/mm3) 321 [212-491]
HIV-1 viral load (log10IU/mL) 4.28 [1.6-4.8]
Naïve ART patients (%) 62 (63,2)
Time in treatment (months) 25.1 [14.2-48.1]
Risk factor (%)
Heterosexual 41 (41.8)
Bisexual 42 (42,8)
Injecting drug users 7 (7.1)
Others 8 (8.1)
Geographical Region (%)
Central-South America 47 (47.9)
Western Europe 14 (14,3)
Sub-Saharan Africa 19 (19.4)
Northern Africa 5 (5.1)
Eastern Europe 10 (10.2)
North America 1 (1)
Asia 1 (1)
Not determined 1 (1)
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subtype was detected in a total of 79% (15/19) of Sub-
Saharan Africans, followed by 60% Eastern Europeans
(6/10), 20% Northern Africans (1/5), 10.6% Central-
South Americans (5/47) and 7.1% Western Europeans
(1/14).
Phylogenetic analysis
Phylogenetic trees were generated based on PR and RT
sequences and included reference sequences represent-
ing different HIV-1 subtypes. All sequences clustered
within the correspondent subtype, which was concor-
dant with the data provided by Stanford University (Fig-
ure 2). Only three of the RT sequences: SE16, SE113,
and SE11 corresponding to subtype G were located
slightly apart from this subtype although within the
same branch. Noteworthy, no sub-clusters were formed
based on the geographical origin of the patients.
Sequences PR_SE15, PR_SE25, PR_SE51, PR_SE55,
RT_SE14, RT_SE15, RT_SE27, RT_SE29, RT_SE45,
RT_SE79, were excluded from the phylogenetic analysis
due to the limited length that could have influenced the
analysis.
Prevalence of resistance mutations
All patients infected with non-B HIV-1 showed at least
one polymorphic mutation in PR (Table 2). Most of
these mutations have been frequently found and
reported amongst non-B HIV-1 subtypes [14,16]. The
M36I mutation in protease was observed in all patients,
whilst K20I/R, L63P, V77I and L10V/I mutations were
present in 75%, 17.8%, 10.7% and 7.1% of patients,
respectively. However, only patient SE59 had the major
mutation L90M (1/28; 3.5%). This patient was infected
with the recombinant form CRF02_AG and had been
under HAART for at least two years.
On the contrary, only six patients showed RT muta-
tions. Three of them (SE37, SE34 and SE60) showed
major RT mutations (3/28, 10.7%, table 2). Patient SE37,
naïve for antiretroviral treatment, had A98G and K70R
major mutations associated with resistance to non-
nucleoside RT inhibitors (NNRTI), and nucleoside RT
inhibitors (NRTI), respectively. Patient SE34, in treat-
ment interruption, had L100I mutation associated with
NNRTI resistance, and finally patient SE60, receiving
HAART, had the NNRTI resistance mutation K103N.
Minor mutations or polymorphisms in RT were
observed in patients SE71, SE91 and SE111 i.e.: V118I,
E138A, and V90I mutations respectively.
Discussion
This study evaluates the prevalence of HIV-1 subtypes
and PR and RT drug resistance mutations among HIV-
1-infected immigrants living in Southern Spain. Immi-
gration had been gradually increasing since 2000, with a
peak of 22% in 2008. Since then, it has been slowly
decreasing to 11.8% in 2010. The largest immigrant
group was form Central-South America (47.9%) most of
them infected with the HIV-1 B subtype. However, up
to 25% of immigrants were from countries where HIV-1
non-B subtypes are predominant, as Sub-Saharan Africa
with 79% of HIV-1 non-B subtypes (subtypes A, G, J or
CRF02_AG), or Eastern Europe with 60% (subtypes A,
F, CRF02_AG or CRF01_AE). This marked increase in
individuals infected with non-B HIV-1 subtype in our
society may have a direct impact on the spread of these
subtypes among Spanish native individuals in addition
to the changes in appropriate treatment regimes due to
differences in genetic sequences amongst the different
HIV-1 strains. These results are similar to those found
in studies conducted in other regions in Spain, Madrid
and Canary Islands [19,20,22].
Previous studies reported a high prevalence of minor
resistance mutations in naïve patients infected with
HIV-1 non-B subtype that could facilitate the emergence
of major mutations [16,23,24]. However, the clinical
relevance of minor mutations is unclear. Our results
indicated that patients infected with HIV-1 non-B sub-
types showed a high frequency of minor PR mutations
(polymorphisms) as M36I, L63P, and K20R/I, in contrast
to the low proportion of major resistance mutations. In
fact, only one patient, subtype CRF02_AG, had L90M
mutation probably as a result of receiving antiretroviral
Figure 1 Proportion of HIV-1-infected immigrants from 2000 to
2010 in Southern Spain, and comparison of risk behavior
between native Spanish and immigrant patients. IDU, injecting
drug users; HO/BI, homosexual/bisexual; HTX, heterosexual.
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therapy during two years (1/28, 3.5%). No difference
between the number of patients with major or minor
RT mutations (3/28, 10.7% in both cases) was found.
Nevertheless, the proportion of patients with major RT
mutations was higher compared to patients with major
PR mutations.
It is of note that one treatment naïve patient, with G
subtype, showed major RT mutations associated with
resistance to NRTI (K70R) and NNRTI (A98G). This
patient might have acquired these resistance mutations
at the moment of infection. One limitation of our study
was the impossibility to test plasma samples of antire-
troviral-experienced patients before the initiation of
antiretroviral therapy to determine primary resistance
mutations.
An increasing effort has been done to characterize
the difference in antiretroviral therapy responses
within HIV-1 non-B subtypes. Although clinical
evidence remains limited, response to antiretroviral
therapy does not appear to differ significantly among
subtypes [3]. In our study, 29 patients showed HIV-1
non-B subtype in PR and/or RT. Eleven of them were
under antiretroviral therapy and had good virological
and immunological responses. Nevertheless, larger
cohorts are necessary to confirm our results. On the
other hand, 14 immigrants infected by HIV-1 non-B
subtype were naïve for antiretroviral therapy. Most of
them with viral load around 4 log HIV-1 copies/ml,
and two patients had undetectable viral load for a long
period of time (one of them at least for one year). As
previous studies have described the failure of labora-
tory techniques to detect HIV-1 non-B subtypes
[25-27], however it would be interesting to establish
whether the failure of the diagnosis may be due to a
phenotype characteristic of viral load controller in this
population.
Table 2 Characteristics of the immigrant patients infected with HIV-1 non-B subtypes (N = 29)
Patient code Origin Treatment Subtype in
PR gene
Protease inhibitor
resistance mutations
Subtype in
RT gene
RT inhibitor
resistance mutations
SE58 EE HAART A M36I, V77I N.D. N.D.
SE115 CSA Naive B M36I C None
SE71 CSA HAART C M36I C V118I
SE73 EE Naive F L10V, K20R, M36I F None
SE43 CSA HAART F M36I B None
SE99 EE Naive F K20R, M36I F None
SE108 CSA Naive F K20R, M36I F None
SE37 SSA Naive G K20I, M36I G K70R, A98G
SE103 SSA Naive G K20I, M36I G None
SE31 SSA Naive J K20I, M36I, V77I J None
SE91 SSA Naive K M36I, L63P G E138A
SE11 SSA HAART CRF02_AG K20I, M36I, L63P G None
SE16 SSA TI CRF02_AG K20I, M36I G None
SE113 N.D. Naive CRF02_AG K20I, M36I G None
SE66 WE HAART CRF02_AG K20I, M36I CRF02_AG None
SE59 NAF HAART CRF02_AG K20I, M36I, L90M CRF02_AG None
SE67 SSA HAART CRF02_AG K20I, M36I, L63P CRF02_AG None
SE49 SSA Naive CRF02_AG K20I, M36I, L63P CRF02_AG None
SE50 SSA TI CRF02_AG K20I, M36I, L63P, V77I CRF02_AG None
SE33 SSA TI CRF02_AG L10V, K20I, M36I CRF02_AG None
SE36 CSA HAART CRF02_AG K20I, M36I CRF02_AG None
SE101 SSA Naive CRF02_AG K20I, M36I CRF02_AG None
SE110 EE Naive CRF02_AG K20I, M36I CRF02_AG None
SE111 SSA HAART CRF02_AG K20I, M36I CRF02_AG 90I
SE34 SSA TI CRF02_AG K20I, M36I CRF01_AE L100I
SE96 SSA Naive CRF02_AG K20I, M36I CRF02_AG None
SE62 EE Naive CRF01_AE M36I CRF01_AE None
SE60 EE HAART CRF01_AE M36I CRF01_AE K103N
SE19 SSA HAART N.D N.D. CRF02_AG None
Protease and RT inhibitor resistance mutations.
CSA, Central-South America; SSA, Sub-Sahara Africa; EE, Eastern Europe; WE, Western Europe; NAF, Northern Africa. HAART, Highly Active Antiretroviral Therapy. TI,
treatment interruption. Bold, major resistance. N.D., not determined.
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Conclusions
The circulation of HIV-1 non-B subtypes among immi-
grants, with a prevalence of 29.6%, has significantly
increased in Southern Spain in the last decade, in associa-
tion with demographic changes. Spread of CRF02-AG, G
and F subtypes, and also some recombinant forms appear
to predominate, which is consistent with previous find-
ings [19,20,22,28]. This fact may affect the treatment and
management of these patients, and the spread of these
subtypes among native Spanish population. Furthermore,
a low percentage of the immigrants with the non-B sub-
types had major resistance mutations. Prevalence of these
resistance mutations varies from 7% among treatment-
naïve patients to 21% among patients under HAART or
during treatment interruption.
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INTRODUCTION 
 
A high percentage of CCR5+-CD4+ T cells, susceptible to HIV-1 infection, are localized 
in the gut mucosa,1,2 which is believed to be an important viral reservoir in HIV-1 
infected individuals.3-7 Intestinal damage produced in acute HIV-1 infection leads to 
translocation of microbial products from the intestinal lumen into the systemic 
circulation, and persists despite successful antiretroviral treatment,8-13 supported by the 
detection of increased levels of lipopolysaccharide (LPS) and soluble CD14 (sCD14) in 
plasma of HIV-1 infected individuals undergoing antiretroviral therapy.14-17 Elevated 
circulating LPS levels in HIV-1-infected patients bind the CD14-toll-like receptor 4 (TLR 
4) complex through plasma LPS binding protein (LBP) and trigger the activation of 
monocytes and macrophages that increase secretion of sCD14 and proinflammatory 
cytokines.18-22  
Microbial translocation and persistent low-level viremia in HIV-1 infected patients 
despite successful treatment have been proposed as triggering mechanisms of 
increased immune activation detected in HIV-1 infection.9,23-26 The ongoing and 
persistent low-level productive viral replication was expected to be reduced using 
intensification therapy with the new HIV-1 antiviral agents emerged, such as CCR5-
receptor antagonists (maraviroc) and integrase inhibitors (raltegravir). Unfortunately, 
this strategy failed to show any effect in reducing peripheral low level HIV-1 viremia, 
although it is efficient in reducing HIV-1 replication in gut mucosa.27-32  
The severe depletion of CD4+ T cells in the gut mucosa during HIV-1 infection is 
restored much slower than in peripheral blood,33-36 and studies using simian models 
have shown that T cell restoration in gut involved trafficking of CD4+ T cells from 
periphery to gut mucosa.37,38 Our previous studies of treatment intensification showed 
different behaviors of microbial translocation and the expression of gut homing β7 
receptor on T cell subsets depending on the drug used, i.e. while raltegravir 
intensification reduced the levels of either microbial translocation and gut homing β7 
receptor on peripheral T cells, the intensification with maravicoc led to an increase in 
these two parameters.39,40 Hence, we wanted to further evaluate the impact of the 
treatment de-intensification on the alteration showed during treatment intensification on 
microbial translocation, measured by the quantification of plasma LPS, sCD14, and 
LBP levels, and the expression of the gut homing receptor β7 on T cells. The second 
objective was to analyze the association of microbial translocation with T cells bearing 
β7 receptor, and the dynamic of T cell subpopulations. 
 
MATERIALS AND METHODS 
 
Patients 
 
This study was performed within two pilot open-label phase II clinical trials 
(ClinicalTrials.com NCT00795444 and NCT00807443) conducted at the Hospital 
Ramón y Cajal in Madrid, Spain, in order to evaluate the effect of treatment 
intensification with a CCR5-receptor antagonist (Maraviroc, Pfizer, Inc.) and a integrase 
inhibitor (Raltegravir, Merck Sharp and Dhome, Whitehouse Station, New Jersey, USA) 
on the HIV-1 latent reservoir. The initial intensification trial was amended to include a 
follow-up period of 24 weeks after de-intensification of maraviroc and raltegravir. 
Immunological and virological parameters were assessed at baseline, after 48 weeks 
of treatment intensification, and after 12 and 24 weeks of maraviroc and raltegravir de-
intensification. Results of the intensification trials have been published elsewhere.39,40 
Here we present the effect of de-intensification on measurements of microbial 
translocation, immune activation, and the dynamics of T cells subpopulations. 
 
For this treatment de-intensification study, a total of 15 HIV-1-infected adult individuals 
recruited for the above clinical trials, initially with CD4+ T cell count above 350 
cells/mm3 and undetectable plasma viral load (below 40 copies HIV-1 RNA/mL) for at 
least two years, remained in the trials and were analyzed. Seven patients discontinued 
maraviroc intensification, while other eight patients discontinued raltegravir 
intensification. None of them had had previous experience with any of these drugs.  
 
The study was carried out according to the recommendations of the Declaration of 
Helsinki and current Spanish legislation on clinical trials. It was approved by the 
AEMPS (Spanish Agency for Medications and Health Products) and our local 
Independent Ethics Committee (Hospital Ramon y Cajal, Madrid, Spain). All patients 
provided written informed consent for participation, sample collection, and laboratory 
determinations. 
 
Flow cytometry 
 
Fresh EDTA-anticoagulated whole blood was used to analyze CD4+ and CD8+ T cell 
subpopulations with the following antibody combination: CD3-allophycocyanin (APC)-
Cy7, CD4-peridinin chlorophyll protein complex (PerCP), CD8-phycoerythrin (PE)-Cy7, 
CD38-phycoerythrin (PE), and HLA-DR-allophycocyanin (APC), CD45RA-
phycoerythrin (PE), CCR7-allophycocyanin (APC), and β7-APC. Antibodies were from 
BD (Becton Dickinson, Franklin Lakes, NJ, USA), and an unstained control was 
performed for all samples. Briefly, 100 µL of blood were lysed with FACS Lysing 
solution (BD) for 30 min at room temperature, incubated with the antibodies during 20 
min at 4°C, washed and resuspended in PBS containin g 1% azida. Cells were 
analyzed in a Gallios flow cytometer (Beckman-Coulter, Inc, Brea CA, USA). At least 
30000 CD3+ T cells were collected for each sample and analyzed with Kaluza software 
(Beckman-Coulter, Inc) initially gating lymphocytes according to morphological 
parameters. T cell immune activation was analyzed by the co-expression of CD38 and 
HLA-DR, while T-cell subsets were defined as follows: naive cells, 
CD3+CD4+(CD8+)CD45RA+CCR7+; effector memory T cells (TEM) 
CD3+CD4+(CD8+)CD45RA-CCR7-; central memory T cells (TCM) 
CD3+CD4+(CD8+)CD45RA-CCR7+; and transitional memory T cells (TEMRA) 
CD3+CD4+(CD8+)CD45RA+CCR7-. The gating was sustained among different time 
points.  
 
Measure of soluble factors 
 
Microbial translocation was quantified in plasma by three commercial kit assays 
according to the manufacturer´s protocol. Plasma LPS was measured using QCL-1000 
Limulus Amebocyte Lysate (Lonza®, Basel, Switzerland), plasma sCD14 was 
quantified using the Quantikine® Human sCD14 Immunoassay (R&D Systems, 
Minneapolis, MN, USA) and plasma LBP was measured by LBP soluble ELISA kit 
(Enzo® Life Sciences, Farmingdale, NY, USA). All the samples were run in duplicate. 
 
Statistical analysis 
 
Continuous variables were expressed as median and interquartile range (IQR) and 
categorical variables as percentages. Mann-Whitney U test was used to compare 
medians between groups. Pearson´s χ2 was used to compare differences in 
proportions between groups considering the continuity correction or the Fisher´s exact 
test, as appropriate. The non-parametric Wilcoxon paired test was used to compare 
medians during the follow up. Correlations were analyzed with Spearman´s rank test.  
Statistical analysis was performed using SPSS software 21.0 (IBM, Chicago, IL, USA). 
Graphs were generated using GraphPad Prism 5.01 (La Jolla, CA, USA). 
 
 
RESULTS 
 
Effect of the treatment de-intensification on microbial translocation 
 
Patients´ immunovirologic characteristics at baseline (before treatment intensification) 
as well as the characteristics before treatment de-intensification (after 48 weeks of 
treatment intensification) are shown in table 1. At 48 weeks of intensification, two 
patients of the maraviroc clinical trial and one patient of the raltegravir clinical trial were 
lost for the study. During the treatment de-intensification, one patient of the raltegravir 
clinical trial decided to drop out the study.  
The effect of the treatment de-intensification on microbial translocation was different in 
patients who were intensified with maraviroc or with raltegravir. Overall, microbial 
translocation significantly increased during treatment intensification and then 
progressively decreased after drug discontinuation in patients who received maraviroc 
(Figure 1A). Hence, the levels of microbial translocation at the end of the clinical trial 
were not different from those levels found either at week 48 of intensification (LPS 
p=0.310, sCD14 p=0.892, and LBP p=0.866) or baseline (LPS p=0.091, and LBP 
p=0.846). Only sCD14 levels remained significantly increased compared to baseline 
(p=0.043).  
In contrast, while the patients who were intensified with raltegravir had stable sCD14 
and LBP levels during the treatment de-intensification, the levels of LPS significantly 
increased at week 12 and 24 of de-intensification when compared to week 48 of 
intensification (p=0.025 and p=0.036, respectively) (Figure 1B). Nevertheless, the 
significant increase in the levels of LPS during treatment de-intensification was a 
consequence of the significant decrease of these levels observed during intensification 
compared to baseline (p=0.008). Thus, at the end of the study LPS levels were not 
significantly different from baseline levels (before intensification). 
 
Expression of gut homing β7 receptor on peripheral activated T cells during the 
treatment de-intensification 
 
Again, the effect of intensification on the expression of gut homing β7 receptor on 
activated T cells was the opposite depending on the intensification treatment received. 
In patients who received maraviroc intensification, there was a significant decrease on 
activated CD8+β7+ T cells at week 24 of treatment de-intensification (p=0.028) 
compared to week 48 of intensification. However, activated CD8+β7+ T cells remained 
significantly higher at weeks 12 and 24 after treatment de-intensification compared to 
baseline (p=0.042 and p=0.043, respectively). In parallel, as observed with microbial 
translocation, the level of activated CD8+ T cells expressing β7 receptor increased 
during intensification and decreased during maraviroc de-intensification. Nevertheless, 
no changes in activated CD4+β7+ T cells were observed during the analyzed follow-up 
(Figure 2A).  
In contrast, in patients intensified with raltegravir, activated CD8+β7+ T cells were stable 
during the treatment de-intensification follow up, and no changes were observed 
compared to baseline (before intensification) (Figure 2B). However, activated CD4+β7+ 
T cells significantly increased at weeks 12 and 24 during raltegravir de-intensification 
compared to week 48 of intensification (p=0.012 and p=0.017, respectively). This 
increase was again a consequence of the decrease observed during the intensification 
period, although not significant (p=0.066).  
 
Association between microbial translocation and gut homing β7 receptor 
 
No correlation was observed between microbial translocation and gut homing β7 
receptor at baseline, before intensification. However, in patients who received 
maraviroc, a correlation was found during the treatment intensification (week 48) 
between both activated CD4+β7+ and CD8+β7+ T cells, and microbial translocation that 
was significant when LPS levels were analyzed (Figure 3). Of note, this correlation was 
lost after drug de-intensification.  
 
On the contrary, those who received raltegravir as treatment intensification showed no 
correlation between either activated CD4+β7+ and CD8+β7+ T cells with microbial 
translocation. 
  
Dynamics of T cell subpopulations during the treatment de-intensification 
 
CD4+ or CD8+ T cell counts were stable during the treatment de-intensification 
regardless the drug of intensification. Moreover, naïve CD4+ and CD8+ T cells also 
remained stable during the time-points studied regardless the drug used for treatment 
intensification, and no differences were found either in CD4- or CD8- TCM, TEM or 
TEMRA (not shown). T cell subpopulations did not correlate with microbial 
translocation (not shown).  
 
 
 
DISCUSSION 
 
We found opposite effects during de-intensification of maraviroc and raltegravir over 
the levels of microbial translocation and gut homing β7 receptor on T cells in long-term 
suppressed HIV-1-infected patients.  
 
In patients who received maraviroc as intensification treatment, activated β7+ T cells 
are probably recruited from peripheral blood to the gut tract as the major mechanism to 
recover the mucosa integrity, reducing microbial translocation and systemic 
inflammation.35,37,38 This cell recruitment during the intensification treatment is reverted 
when microbial translocation is not longer increasing, i.e. during treatment de-
intensification. In accordance with this, a strong correlation was found between both 
activated CD4+β7+ and activated CD8+β7+ T cells with LPS levels at the end of the 
intensification treatment. After the removal of maraviroc, these correlations were lost, 
as occurred at baseline (before intensification). Our study suggests that the expression 
of β7 receptor on peripheral T cells could be a good surrogate marker to monitor 
mucosal immune response. Our findings are consistent with other published maraviroc 
intensification study in which intestinal tissue biopsies were included. In this study, 
immune discordant HIV-1-infected patients were randomized to add maraviroc or 
placebo to their existing suppressive ART.41 Histological examination of intestinal 
biopsies showed increased immune activation, which could be associated with the 
increased bacterial translocation and gut homing β7 receptor on T cells, as that was 
found in our study.  
The mechanisms by which maraviroc produces such effects remain unclear. CCR5 
plays an important role in inflammatory function of several mucosal immune cell types 
(T cells, macrophage and dendritic cell subpopulations, innate lymphoid cells, etc). 
Blockade of this role is expected to interfere with mucosal immune cell functions 
required to control microbial intrusion, and indeed, these findings demonstrate 
microbial translocation, and β7 T cell activation, presumably in response to 
inflammatory activation in response to the intrusion. CCR5 blockade increase CCR5 on 
the cell membrane, increasing cell death and deteriorating the gut-associated lymphoid 
tissue, and also an increase of ligands such as MIP-1α, MIP-1β and RANTES that 
could signal through other receptors that eventually could increase gut immune 
activation. All these together could therefore increase the level of microbial 
translocation and gut homing β7 receptor.  
 
On the contrary, raltegravir intensification showed a significant decrease in microbial 
translocation (measured by LPS levels) that was related with a significant decrease of 
CD4+β7+ cells. This effect was reverted during the treatment de-intensification. These 
findings are consistent with one study of intensification with raltegravir in HIV-1-infected 
adults with CD4+ T cell count above 200 cells/mm3, in which intestinal tissue biopsies 
were included.5  No differences were shown in the gut immune activation, also 
consistent with our findings in peripheral blood. Raltegravir behaves as expected for a 
given antiretroviral drug, i.e. it did not appear to alter or tented to decrease microbial 
translocation and did not alter the level of gut homing β7 receptor on T cells, 
suggesting no alteration in the level of gut immune activation.  
On the other hand, CD4+ or CD8+ T cell counts in peripheral blood did not change 
during the entire follow up period when they were intensified with maraviroc or 
raltegravir, showing no correlations with microbial translocation and supported by 
another study that failed to show this correlation during raltegravir intensification.42 The 
fact that CD4+ T cell count in peripheral blood was constant during the follow up period 
would confirm a delayed recovery of gut CD4+ T cells compared to the CD4+ T cell 
restoration in peripheral blood.24 
 
Besides, no significant changes were observed in naïve CD4+ or CD8+ T cells, TCM, 
TEM and TEMRA during the intensification period with maraviroc or raltegravir or 
during de-intensification, with no correlation with microbial translocation or homing gut 
receptor expression. Despite the low number of patients included in this study, the 
levels of LPS, LBP and sCD14 detected in HIV-1-infected patients during maraviroc 
and raltegravir intensification, and after its discontinuation evidenced that the mucosal 
damage associated to HIV-1 infection persisted despite successful treatment allowing 
microbial translocation into the bloodstream that would cause gut immune activation 
and mucosal inflammation,43-46 as evidenced by the association between microbial 
translocation and activated T cells expressing the gut homing receptor in periphery. 
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FIGURE LEGENDS 
 
Figure 1. Effect of treatment de-intensification on microbial translocation. Levels 
of microbial translocation in both A) maraviroc and B) raltegravir groups during the 
follow up. Data related to the treatment de-intensification study are highlighted with a 
square. TI, treatment intensification; TDI, treatment de-intensification. P values were 
determined by the nonparametric Wilcoxon paired test and only significant values 
(p<0.05) are shown. 
 
Figure 2. Effect of treatment de-intensification on the expression of gut homing 
β7 receptor on activated T cells. Activated CD4+ and CD8+ T cells expressing β7 
receptor during the follow up in both maraviroc (A) and raltegravir (B) groups. Data 
related to the treatment de-intensification study are highlighted with a square. TI, 
treatment intensification; TDI, treatment de-intensification. P values were determined 
by the nonparametric Wilcoxon paired test and only significant values (p<0.05) are 
shown. 
 
Figure 3. Association of activated β7+ T cells with LPS levels. A positive correlation 
between LPS levels and either activated CD4+β7+ and CD8+β7+ T cells were found 
after 48 week of maraviroc intensification. These correlations were lost after the drug 
de-intensification. Data related to the treatment de-intensification study are highlighted 
with a square. TI, treatment intensification; TDI, treatment de-intensification. P values 
were determined by Spearman´s rank test and only significant values (p<0.05) are 
shown. 
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Abstract 
 
Numerous studies have analyzed the effects of raltegravir intensification on HIV-1 viral 
replication in infected individuals receiving suppressive combined antiretroviral 
treatment (cART). Nevertheless, there are only two studies on the effect of raltegravir 
in HTLV-1 infection, and none in HTLV-2. Hence, our objective was to study the effect 
of raltegravir on HTLV-2 infection in HIV-1-co-infected individuals. This study was a 
retrospective longitudinal study with a follow up of 48 weeks. HTLV-2 proviral load, 
CD4 and CD8 count and frequency of four HTLV-2-HIV-1-co-infected individuals who 
received raltegravir-based cART during 48 weeks and 11 HTLV-2-HIV-1-co-infected 
individuals under cART were analyzed. HTLV-2 proviral load significantly increased at 
week 24 compared to baseline among all the patients who received raltegravir 
(p=0.003), while no significant increases were found in the control group. No significant 
variation in either CD8 or CD4 counts were found during the follow up in both groups. 
Raltegravir intensification induced a transient increment on total HTLV-2 DNA proviral 
load in HTLV-2/HIV-1-coinfected individuals on suppressive cART. The period of follow 
up, nevertheless, did not permit to know whether the decrease observed at week 48 
compared to week 24 would further continue over the time or would be stabilized at 
levels comparable to baseline. Further studies with larger number of individuals under 
raltegravir intensification would be required to understand the mechanisms used by 
raltegravir to transiently increase the HTLV-2 proviral load, as an important tool for the 
eradication of HTLV-2 infection and how it would affect HIV-1 infection in co-infected 
patients.  
 
 
 
 
 
 
1. Introduction 
 
Since the isolation of human T cell lymphotropic virus type 2 (HTLV-2) from a patient 
with atypical hairy cell leukaemia in 1981 (Kalyanaraman et al., 1982), no clear 
evidence of human disease has been linked to HTLV-2 infection, except for a few 
cases of neurological and lymphoproliferative disorders (Araujo and Hall 2004; Biswas 
et al., 2009; Orland et al., 2003; Poiesz et al., 2000; Thomas et al., 2010). Even though 
HTLV-2 infection is endemic in American Indian population and Pygmy tribes in Africa 
(Switzer et al., 1995), HTLV-2 has been widely distributed in injecting drug users (IDU) 
in USA and Western Europe, including Spain where co-infection with HIV-1 is frequent 
(Abad et al., 2011; Beilke et al., 2007; Beilke, 2012; Lowis et al., 2002; Saito and 
Bangham, 2012; The HTLV European Research Network, 1996; Treviño et al., 2010; 
Treviño et al., 2012; Vallejo et al., 1996; Vallejo et al., 2003). 
 
While HIV-1 infection causes the depletion of the infected CD4+ T cells leading to 
immunosupression, HTLV-2 infection triggers the expansion of CD8+ infected T cells, 
with a possible potential to cause lymphoproliferative disorders (Simonis et al., 2012). 
Both retroviruses require the integration of the viral genome into the cell DNA as part of 
its life cycle. During chronic HTLV-2 infection, the low viral replication would drive 
infected cells to proliferate and propagate the infection via the clonal expansion with 
concomitant propagation of integrated proviral DNA (Asquith et al., 2007). The reported 
stable proviral load (pVL) over time would support a balance between virus-induced 
clonal proliferation and the immunologic control of HTLV infection (Demontis et al., 
2013; Furtado Mdos et al., 2012; Kwaan et al., 2006; Olavarria et al., 2012). On the 
other hand, HTLV-1 pVL seems to be determined by the infection route, which 
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suggests that the infectious dose at the time of infection might determine the chronic 
pVL, and/or time of infection, where carriers by vertical transmission have significantly 
higher pVL than carriers by sexual transmission (Murphy et al., 2004; Ueno et al., 
2012). It has also been reported increased HTLV-2 pVL after the initiation of 
antiretroviral treatment in HIV-1-coinfected patients (Murphy et al., 2003).  
 
Raltegravir was the first integrase inhibitor approved for HIV-infection treatment that 
blocks integration of linear viral cDNA into the host chromosomal DNA. This blocked 
cDNA subsequently circularize to form episomal DNA (2LTR DNA circles). Since then, 
numerous studies have analyzed the effects of raltegravir intensification on HIV-1 viral 
replication in infected individuals receiving suppressive combined antiretroviral 
treatment (cART) (Gandhi et al., 2010; Gandhi et al., 2012; Markowitz et al., 2006; 
Markowitz et al., 2007; Markowitz et al., 2009). For this purpose, some of them 
measured the amount of HIV-1 proviral DNA viral as reflect of viral reservoir (Chege et 
al., 2012; Nicastri et al., 2011; Delaugerre et al., 2010; Negredo et al., 2013; Buzón et 
al., 2010).  
 
There are only two studies on the effect of raltegravir in HTLV-1 (Seegulam et al., 
2011; Treviño et al., 2012). The first one is an in vitro study supporting that integrase 
inhibitors were effective in inhibiting in vitro cell-free and cell-to-cell transmission of 
HTLV-1 in lymphoid and non-lymphoid cells. The authors suggested that raltegravir 
and other integrase inhibitor could be administered as treatment for patients with 
HTLV-1-associated diseases (Seegulam et al., 2011). The other study was an in vivo 
study of five naive HTLV-1 carriers. The authors concluded that antiretroviral treatment 
with raltegravir does not result in a reduction of HTLV-1 pVL after 6 months of 
treatment (Treviño et al., 2012). No studies on the effect of raltegravir on HTLV-2 have 
been reported yet, neither in vitro nor in vivo. 
 
In this retrospective longitudinal study, our objective was to study the effect of 
treatment intensification with raltegravir on HTLV-2 pVL among HTLV-2/HIV-1-co-
infected individuals.  
 
 
2. Materials and Methods 
 
2.1 Patients 
 
This was a retrospective longitudinal study aimed to analyze the effect of the 
intensification of the cART with an integrase inhibitor (raltegravir) on the level of HTLV-
2 pVL measured at baseline, week 24 and week 48 in HIV-1-co-infected patients. Four 
HTLV-2-HIV-1-co-infected patients who received 400 mg of raltegravir twice daily were 
recruited from Hospitals Germans Trias I Pujol (Badalona, Barcelona, Spain) and 
Hospital Ramón y Cajal (Madrid, Spain) and analyzed. One of these patients was 
analyzed in two further time points, a second baseline and at week 4. Besides, a total 
of eleven HTLV-2-HIV-1-co-infected patients who did not intensify their cART with 
raltegravir were also analyzed as control group. All the patients included in this study 
had a history of intravenous drug use and have been under cART for more than one 
year with undetectable HIV-1 plasma viremia (<50 HIV-1 RNA copies/ml). The clinical 
trials from which we obtained the DNA samples were approved by the Ethics 
Committee of both Hospitals and all recruited patients signed an informed consent 
form.  
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2.2 Quantification of HTLV-2 proviral load 
 
Total HTLV-2 DNA pVL was quantified by in-house real-time PCR. DNA was extracted 
from the 106 cryopreserved peripheral blood mononuclear cells (PBMCs) using 
QIAamp DNA kit (Qiagen GmbH, Hilden, Germany). A standard curve was generated 
in each run using 5-fold dilution of 106 copies of a recombinant plasmid (TOPO TA 
cloning, Invitrogen) containing one copy of HTLV-2 tax gene fragment (171 bp). 
Besides, another standard curve was generated using 5-fold dilution of 106 copies of a 
recombinant plasmid containing one copy of human genomic GAPDH gene fragment 
(162 bp). 
 
The amplification reaction was carried out in triplicate using LightCycler 2.0 (Roche 
Diagnostics,Manheim, Germany). All reaction mixtures were performed in a total 
volume of 20 µL containing  LightCycler FastStart DNA Master PLUS HybProbe 5X 
(Roche Diagnostics), 200 ng genomic DNA, 50 pmol each primer, Tax-F 
(5´TACGGTTTTTCCCCAGG) and Tax R (5´ACTCCTGTCTCCCCCAAG) for tax gene, 
GADH-F (5´ CTGACCTGCCGTCTAGA) and GADH-R (5´GTCGTTGAGGGCAATGC) 
for GADH gene, along with 2 pmol of the following fluorescent probes:  5´-FAM-CAC 
CCG CCT TCT TCC AAT CAA TGC GAA AG-TAMRA and 5´-CAG GTG GTC TCC 
TCT GAC TTC AAC-[Flc] / 5´-LC705-CGA CAC CCA CTC CTC CAC CTT TG-[Phos]-
3´ for tax gene and GADH gene, respectively. 
 
The cycling parameters for the both amplifications begun with hot start at 95°C 10 min, 
and continued with 40 cycles of denaturation at 95ºC for 10s, annealing at 62ºC for 15s 
and extension at 72ºC for 20s for tax gene, and 40 cycles of denaturation at 95ºC for 
5s, annealing at 62ºC for 10s and extension at 72ºC for 20s for GADH gene. The 
results were expressed as HTLV-2 DNA copies per million PBMCs. 
 
2.3 Statistical analysis 
 
Continuous variables were expressed as median and interquartile range (IQR) and 
categorical variables as proportions when appropriated. The comparison of the HTLV-2 
pVL between time periods was performed using a generalized estimating equations 
(GEE) model to take into account the within patient correlation observed in the 
repeated measures. This model includes terms for time as an indicator variable with 
baseline as reference level, group (treated or control), and time-by-group interaction 
term. All statistical tests used 0.05 as significance level. Analyses were performed 
using Stata software version 12.0 (StataCorp. College Station, TX, USA) 
 
 
 
3. Results 
 
The four patients who received raltegravir-based cART were men with median age of 
51 [48-55], CD4 count of 215 [97-251] cells/mm3, and CD8 count of 819 [658-929] 
cells/mm3. The 11 patients from the control group had median age of 50 [46-56] years, 
CD4 count of 524 [307-1060] cells/mm3, CD8 count of 980 [690-1308] cells/ mm3, and 
nine of them were male (82%). 
 
The statistical GEE model found a significant interaction between HTLV-2 pVL and 
time (repeated measures) among the patients who received raltegravir (Figure 1A), 
while found no statistical significance in the control group (Figure 1B). Hence, the 
model found a p-value of <0.001 in both the increase found at week 24 compared to 
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baseline and in the decrease found at week 48 compared to week 24 among the 
patients who received raltegravir.   
 
When HTLV-2 pVL increments were analyzed, these were above 0.5 log copies/106 in 
the four patients who received raltegravir-based cART at week 24 (∆24-BL), followed 
by a significant (GEE model) decrement of HTLV-2 pVL at week 48 (∆48-24), as shown 
in figure 2A. The increment levels at ∆24-BL were significantly higher to those found at 
either ∆48-24 (p<0.001) or ∆48-BL (p=0.020), and the decrement levels found at ∆48-
24 were significantly lower compared to those found at ∆48-BL (p=0.003). Instead, 
HTLV-2 pVL increments were between ±0.5 log copies/106 in the control group at week 
24 (∆24-BL, figure 2B). Seven patients of those (63%) showed HTLV-2 pVL increments 
while the rest showed decrements. This random behavior was observed along the 
follow up, as shown in figure 2B. Thus, the increment levels in the control group were 
stable along the follow up (p>0.05 in all cases). Of note, the increment level of HTLV-2 
pVL at ∆24-BL in patients who received raltegravir was significantly higher compared to 
those found at any time point during the follow up in the control group (p<0.005). On 
the other hand, the increment level at ∆48-24 was significantly lower to those observed 
at any time in the control group (p<0.005 at each time point).  
 
Neither CD8 count nor frequency, cells that are the main but not the only target for 
HTLV-2, showed any statistical change during the follow up among patients who 
received raltegravir as shown in table 1. Among them, only one patient increased CD8 
count (Ral1) while CD8 frequency decreased in three out of four patients after 24 
weeks. Among the control group, no significant variation in either CD8 count or 
frequency was found during the follow up (not shown).  
 
Regarding CD4 T cells, other potential target for HTLV-2 infection, no significant 
variation of either counts or frequency was found. Only two patients increased either 
their CD4 counts or frequency (Ral1 and Ral3, table 1) at week 24 compared to 
baseline. Among the control group, no significant variation in either CD4 count or 
frequency was found during the follow up (not shown).  
 
 
 
4. Discussion 
 
During the last few years, the effect of raltegravir has been analyzed in several clinical 
studies in HIV-1-infected patients receiving cART. Most of them showed no significant 
changes in total or integrated HIV-1 DNA levels during the follow-up period. Moreover, 
no changes in CD4+ or CD8+ T cell counts were demonstrated. Only one study showed 
a marked HIV-1 proviral decay after 24 weeks with raltegravir-based cART (Markowitz 
et al., 2006), while another demonstrated transient increase in episomal HIV-1 DNA 
(2LTR) despite no changes in total proviral DNA in a large percentage of HIV-1-
suppressed subjects (Buzón et al., 2010). 
 
Given the similarities between HIV-1 and HTLV-1 integrases, raltegravir was thought to 
be effective against HTLV-1. Rabaaoui et al observed a decrease in HTLV-1 pVL in 
vitro and also ex vivo. However, the effects detected ex vivo were significantly lower 
than those observed in vitro. Further in vitro studies showed that raltegravir prevented 
the integration of HTLV-1 in both cell-free and cell-to-cell infection (Ratner, 2005).  
 
Despite these promising in vitro results, no decrease on HTLV-1 pVL was reported in 
the unique in vivo study on five infected patients (Treviño et al., 2012). In this report, no 
episomal DNA (2LTR) was quantified. This lack of any beneficial effect on HTLV-1 viral 
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replication was attributed to the virus infection transmission mainly maintained through 
cell division instead of through new rounds of viral replication (Pique et al., 2012).  
 
No in vivo studies on the effect of raltegravir over the HTLV-2 pVL in infected patients 
have been performed yet. Thus, this is the first study that shows that HTLV-2 pVL is 
transiently increased in HTLV-2/HIV-1 co-infected patients when cART was intensified 
with raltegravir. This increase observed at week 24 after raltegravir intensification was 
followed by a significant decrease at week 48, reaching similar levels compared to 
baseline. 
 
Since all four patients who received raltegravir behaved similarly, we wanted to discard 
two possible issues, i.e., a generic effect of the intensification treatment (regardless the 
antiretroviral used), and a random fluctuation of the proviral load over the time. For the 
first issue, we only could analyze one HTLV-2-HIV-1-co-infected patient who received 
maraviroc (CCR5 antagonist) as intensification treatment along with the initial 
suppressive cART. Since we found no significant changes on the HTLV-2 pVL during 
one year of follow up (∆w24-BL -0.16, ∆w48-w24 -0.05, and ∆w48-BL 0.23 log 
copies/106 PBMC), a generic effect of intensification seemed not to account for the 
variation observed with raltegravir. For the second issue and despite that a stable level 
of HTLV-1 pVL over the time has been reported (Demontis et al., 2013; Furtado Mdos 
et al., 2012; Olavarria et al., 2012), we analyzed a group of HTLV-2-HIV-1-co-infected 
patients who received cART without raltegravir. No significant changes were found in 
the HTLV-2 pVL during the follow-up in this group, with variations (increments and 
decrements) below 0.5 log. Again, this does not support a random fluctuation of the 
magnitude observed in the patients intensified with raltegravir. 
 
One possible explanation for the increase in the HTLV-2 pVL would be that raltegravir 
intensification interferes in the host immune response leading to the activation and 
clonal expansion of the CD8 lymphocytes infected with HTLV-2. The CD8+ T cell 
division would trigger a burst of horizontal viral replication and the consequent increase 
on the DNA proviral load (Cimarelli et al., 2012; Kannian et al. 2012). Nevertheless, this 
transient clonal expansion had to be not very large given that significant increases in 
CD8 count or frequency were not observed along the follow up. The subsequent return 
to baseline proviral load levels at week 48 would be explained by the CTL response 
that would rapidly eliminate infected cells once they start to express viral proteins as it 
has been previously described for HTLV-1 infection (Bangham, 2008). Besides this 
possible expansion of infected-CD8 lymphocytes, it is also possible that a transient 
increase of episomal HTLV-2 2LTR DNA circles might occur as seen in HIV-1 patients 
intensified with raltegravir (Buzón et al., 2010). This implies an increase of HTLV-2 
replication and a subsequent accumulation of HTLV-2 episomal 2LTR DNA circles by 
the effect of raltegravir. Unfortunately, the limited amount of DNA sample for each 
patient made it impossible to test either cellular clonality or HTLV-2 episomal 2LTR 
DNA circles quantification. On the other hand, no increase in CD4 counts was found in 
these patients suggesting that this potential cell target did not account for the increase 
of HTLV-2 pVL. 
 
One important limitation of this study is the small number of patients included for the 
analysis forcing to take these results with caution. Unfortunately, there is limited 
experience using specific antiretroviral drugs in these HTLV-2-infected patients and no 
treatment recommendations can be given.  
 
In summary, for the first time we showed that raltegravir intensification induced a 
transient increment on total HTLV-2 pVL in HTLV-2/HIV-1-coinfected individuals on 
suppressive cART. We do not know whether the decrement observed at week 48 
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compared to week 24 would further continue over the time or the level of would be 
stabilized at levels comparable to baseline. Further studies with larger number of 
individuals under raltegravir intensification would be required to understand the 
mechanisms used by raltegravir to transiently increase the HTLV-2 pVL, as an 
important tool for the eradication of HTLV-2 infection and how it would affect to the 
HIV-1 infection in co-infected patients.  
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Figure legends 
Figure 1: HTLV-2 pVL during the follow up in patients with raltegravir-based cART (A) 
and patients with cART (B). Generalized estimating equations (GEE) model was used 
for repeated measures. Only significant p values when p<0.05 are shown.    
 
Figure 2: HTLV-2 pVL increments during the follow up in both individual patients and 
mean with interquartile range under raltegravir-based cART (A), and individual patients 
and mean interquartile range under cART (B). The shadowed square represents 
increments of ±0.5 log copies/106 PBMC. Generalized estimating equations (GEE) 
model was used for repeated measures. Only significant p values when p<0.05 are 
shown.    
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Table 1: CD4 and CD8 T cell characteristics during the follow up and type of treatment of the patients who received 
raltegravir-based cART.   
  
Ral1 Ral2 Ral3 Ral4 Median [IQR] p 
CD4 count 
(frequency) 
BL 
w24 
w48 
242 (18) 
401 (21) 
241 (15) 
255 (21) 
275 (20) 
346 (21) 
188 (11) 
248 (16) 
246 (13) 
67 (3.3) 
48 (2.7)  
32 (1.9) 
215 [97-252] (14.5 [5.2-20.2]) 
261 [98-369] (18.0 [6.0-20.7]) 
243 [84-321] (14.0 [4.6-19.5]) 
 
0.246 (0.354) 
0.393 (0.605) 
CD8 count 
(frequency) 
BL 
w24 
w48 
740 (55) 
992 (52) 
866 (54) 
631 (52) 
633 (46) 
839 (51) 
940 (55) 
837 (54) 
984 (52) 
898 (45) 
795 (50) 
792 (47) 
819 [658-929] (53.5 [46.7-55.0]) 
816 [673-953] (51.0 [47.0-53.5]) 
852 [803-954] (51.5 [48.0-53.5]) 
 
0.895 (0.618) 
0.385 (0.498) 
cART  ABV, 3TC,  
ATV 
ATV, FTC,  
RTV, TDF 
3TC, LPV,  
RTV, TDF 
FTC, TNF   
Cell count in cells/mm3; cell frequency in percentage; IQR, interquartile range; Significant when p<0.05 (paired samples t test). 
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Abstract 
 
Visceral leishmaniasis (VL) in HIV-1-infected patients has been associated with poor 
immunological recovery and frequent disease relapses. The aim of this study was to 
compare the immunological profile of VL in HIV-1-infected-patients with 
immunodiscordant HIV-1-infected patients. A cross-sectional study of eight patients 
with VL with suppressive cART for at least one year, and both 14 patients with 
discordant immunological response (DR) and 15 patients with concordant 
immunological response (CR) without leishmaniasis was performed. T-cell 
subpopulations, immune activation, microbial translocation, and immunosenescence 
were analyzed. CD8+ T-cell activation was higher compared to both DR and RC 
patients, and independently associated to VL and sCD14 levels. Plasma IL-6 levels 
and sCD14 were increased and was not related to time of VL diagnosis nor the number 
of relapses. In addition, VL patients had similar level of CD4+ and higher CD8+ T-cell 
senescence compared to DR patients, and greater than the observed in CR patients, 
despite similar age of the patients. In conclusion, VL was associated with immune 
activation, microbial translocation, and immunosenescence in HIV-1-infected patients, 
higher than those observed in patients with discordant immunological response to 
cART. These data could explain the poor immunological recovery of these patients and 
the persistence of relapses. 
 
INTRODUCTION 
 
Visceral Leishmaniasis (VL) is an infectious disease caused mainly by Leishmania 
donovani and L. infantum (L. chagasi). It is a common co-infection in HIV-1-infected 
individuals in the Mediterranean basin, including Spain with a prevalence of up to 9% 
mainly among intravenous drug users with a mortality rate of up to 50% (1,2). These 
protozoans are intracellular parasites that infect macrophage cell lineages from 
lymphoid organs. The immunological response triggered after infection is directly 
associated to the clinical outcome, but the pathogenic mechanisms are still 
controversial. 
 
Leishmania and HIV-1 infections share immune-compromising mechanisms that may 
affect the parasite control by the immune system. It is demonstrated that VL 
accelerates the progression of HIV-1 disease, increasing chronic immune activation 
and accelerating T cell depletion (3). In addition, it has been shown that HIV-1 infection 
inhibits the intracellular killing of Leishmania, interfering in parasite clearance (4-7).  
 
On the other hand, the gut parasitation by Leishmania amastigotes in VL would 
accelerate the mucosal damage associated to HIV-1 infection increasing the levels of 
microbial translocation into the bloodstream causing a systemic proinflammatory 
response and increasing immune activation (8-15). It has also been observed higher 
Th2 cytokine production in PBMCs from HIV-1-Leishmania co-infection compared to 
HIV-1-infected patients, although clinical consequences remain unclear (16,17). 
 
While combination antiretroviral treatment (cART) has been shown to decrease the 
incidence of leishmaniasis in HIV-infected patients, it does not seem to prevent 
relapses (18-20). Thus, the parasite persistence may still impact the pathogenesis of 
HIV disease. 
 
Both immunological alterations could explain the high prevalence of impaired 
immunological response to cART in patients with VL, in a similar manner to that 
described with immunodiscordant patients. 
 
Our objective was to investigate how VL could impact immune activation and which 
factors could impair the immune response to control the parasite infection in 
suppressed HIV-1-infected patients, including inflammation, microbial translocation, 
and immunesenescence, in comparison with both HIV-1-infected patients with 
immunodiscordant response and with a concordant response to cART. 
 
MATERIALS AND METHODS 
Patients 
A cross-sectional, descriptive, comparative study was performed in eight HIV-1-
infected individuals with active visceral leishmaniasis (VL) from the Department of 
Infectious Diseases at the Universitary Hospital Ramón y Cajal, Madrid, Spain. All of 
them had been diagnosed for VL by parasitological diagnosis by direct visualization of 
amastigotes in bone marrow and peripheral blood, positive Leishmania-specific PCR 
on peripheral blood (21), as well as by clinical symptoms. All of them were treated with 
anti-Leismania treatment (liposomal amphotericina B, miltefosine or meglumine 
antimoniate, according to local guidelines (22)) and most of them received secondary 
prophylaxis based on monthly amphotericina B, or miltefosine ). At inclusion, all of 
them had received cART for at least one year with sustained undetectable plasma HIV-
1 RNA (<50 copies/ml).  
As comparison groups of HIV-1-infected patients, we analyzed 13 patients with 
concordant response (CR, CD4 count above 400 cells/mm3) and 14 patients with 
discordant response (DR, CD4 count below 250 cells/mm3) with no coinfection with 
Leishmania and receiving suppressive cART (HIV-1 viral load lower than 50 RNA 
copies/ml) for at least one year. 
A single blood extraction was performed in all the patients. Blood was collected in 
Vacutainer tubes (Becton Dickinson, Madrid, Spain) and processed for both plasma 
and cytometry analysis. 
This study was carried out according to the recommendations of the Declaration 
of Helsinki and current Spanish legislation on clinical trials. It was approved by the 
AEMPS (Spanish Agency for Medications and Health Products) and our local 
Independent Ethics Committee (Hospital Ramon y Cajal, Madrid, Spain). All patients 
provided written informed consent for participation, sample collection, and laboratory 
determinations. 
Analysis of inflammation and microbial translocation  
Inflammation was measured by plasma IL-6 quantification using hsIL-6 (human 
IL-6 Quantikine High Sensitivity ELISA Kit, R&D Systems). Microbial translocation was 
measured in plasma by the quantification of both lipopolysaccharide (LPS) using QCL-
1000 Limulus Amebocyte Lysate (Lonza®, Basel, Switzerland), according to 
manufacturer´s instructions, and soluble CD14 (sCD14) using the Quantikine® Human 
sCD14 Immunoassay (R&D Systems, Minneapolis, Minnesota, USA), according to 
manufacturer´s protocol. Samples were tested in duplicate. 
Flow cytometry analysis of blood samples 
Fresh EDTA-anticoagulated whole blood was used to analyze CD4+ and CD8+ T 
cell subpopulations with the following antibody combination: CD3-V500, CD4-peridinin 
chlorophyll protein complex (PerCP), CD8-phycoerythrin (PE)-Cy7. Cellular activation 
was defined as the co-expression of CD38-phycoerythrin (PE) and HLA-DR-
allophycocyanin (APC). Immunesenescence was analyzed on T cells with the 
expression of CD57-Fluorescein isothiocyanate (FITC), and the absence of CD28-
APC-H7. 
Antibodies were from Becton Dickinson (Becton Dickinson, NJ, USA), and an 
unstained control was performed for all samples. Briefly, 100 µL of blood were lysed 
with FACS Lysing solution (Becton Dickinson) for 30 min at room temperature, 
incubated with the antibodies during 20 min at 4°C, washed and resuspended in PBS 
containing 1% azida. Cells were analyzed in a Gallios flow cytometer (Beckman-
Coulter, CA, USA). At least 30000 CD3+ T cells were collected for each sample and 
analyzed with Kaluza software (Beckman-Coulter) initially gating lymphocytes 
according to morphological parameters.  
Statistical analysis 
Continuous variables were expressed as the median and interquartile range and 
discrete variables as percentages. The t test for independent samples was used to 
compare normally distributed continuous variables and the Mann-Whitney test to 
compare non-normally distributed continuous variables. Categorical variables were 
described as proportions. The association between categorical variables was evaluated 
using the chi-square test. Spearman´s rank correlation coefficient was used to analyze 
continuous variables. Statistical analysis was performed using SPSS software 16.0 
(Inc., Chicago, Illinois, USA). 
RESULTS 
Patients with VL had a median age of 45 years, similar to the age of the two 
control groups, with 62.5% of males. All but one were injecting drug users (IDUs) which 
is a different scenario compared to the risk factor of the other two control groups where 
patients with concordant response were predominantly men who have sex with men 
(MSM) (60%), and similar frequencies of IDUs and MSM were found within patients 
with discordant response (42.8% in both cases). Interestingly, while VL patients had 
significantly lower levels of CD4 count, CD4/CD8 ratio and CD4 nadir compared to CR 
patients (p<0.001, p<0.001, and p=0.001, respectively), they had higher levels of CD4 
count and CD4/CD8 ratio compared to DR patients (p=0.005 and p=0.038, 
respectively), while no significant differences were found in nadir CD4 count (Figure 
1A). On the other hand, all three groups of patients had similar duration of both cART 
and viral suppression. Most of the VL patients were infected with VHC (75%). 
Interestingly, most of the VL patients had a time of diagnosis of VL similar to the 
duration of cART (75%). Clinical and laboratory characteristics are shown in table 1. 
Immune activation 
The level of CD4 T cell activation in VL patients was similar to that found in DR 
patients (p=0.402), but significantly higher compared to CR patients (p<0.001). On the 
other hand, CD8 T cell activation is significantly higher in VL patients compared to both 
DR and RC patients (p=0.010 and p<0.001, respectively) (Figure 1B). 
We also analyzed which factors were independently associated with immune 
activation (both CD4 and CD8 T cell activation as dependent variables) to analyze 
whether VHC infection influence immune activation. As shown in table 2, CD4/CD8 
ratio and sCD14 levels were independently associated with CD4 cell activation 
(p=0.045 and p=0.025, respectively), while leishmaniasis and sCD14 levels were 
independently associated with CD8 cell activation (p=0.046 and p=0.003, 
respectively).Therefore, leishmaniasis rather than VHC greatly contributes to the hyper 
immune activation.   
Levels of inflammation and microbial translocation 
Plasma IL-6 levels were significantly increased in VL patients compared to both 
DR (p=0.035) and CR patients (p<0.001) (Figure 2A).  
While LPS levels in VL patients had significant higher levels compared to CR 
patients (p=0.001) and similar levels compared to DR patients (p=0.297) (Figure 2B), 
plasma sCD14 levels were significantly higher compared to both DR and CR patients 
(p<0.001 in both).  
Correlation between immune activation, inflammation and microbial 
translocation among VL patients 
Among VL patients, there was a significant positive correlation between both CD4 
and CD8 T cell activation and sCD14 levels (p=0.048, r=0.711 and p=0.017, r=0.801, 
respectively) (Figure 3A). On the other hand, IL-6 level correlated with LPS and sCD14 
levels (p=0.001, r=0.935 and p=0.010, r=0.833 respectively), but not with T cell 
activation. 
On the other hand, among DR patients, a significant correlation between CD4 T 
cell activation and sCD14 levels (p=0.048, r=0.553), and between IL-6 and LPS levels 
(p=0.023, r=0.601)) were found (Figure 3B). Among CR patients no correlation was 
found between immune activation and inflammation or microbial translocation. 
Nevertheless, LPS correlated with sCD14 in the three groups of patients, i.e., VL 
(p=0.011, r=0.826), DR (p=0.001, r=0.779), and CR patients (p=0.046, r=0.659).  
Immune senescence 
VL patients had similar level of CD4 T cell senescence compared to DR patients, 
but significantly higher compared to CR patients (p=0.037), despite similar age of the 
patients in each of the three groups. Similarly, VL patients had levels of activated CD4 
T cell senescence not different from those in DR patients, but again significantly higher 
compared to CR patients (Figure 4A). 
Interestingly, CD8 T cell senescence was higher in VL patients compared to DR 
patients, although not significant (p=0.059), while significantly higher levels were found 
in activated CD8 T cells compared to DR patients (p=0.005). These levels of 
senescence were significantly higher compared to CR patients (p<0.001 in both cases) 
(Figure 4B). 
DISCUSSION 
Our study demonstrates that VL patients are a subgroup of HIV-1-infected 
patients with special immunological characteristics, worse that those observed in 
patients with discordant response to cART. Thus, the increased levels of CD8+ T cell 
activation, IL-6, sCD14 and activated CD8 T cell senescence found in this group of 
patients could fairly explain the lack of immune response observed in some cases, and 
the persistence of relapses.  
 
It is known that Leishmania can persist in patients after treatment and may further 
reactivate under immunossupression (4). Immunossupressed HIV-1-infected patients 
showed inefficient T cell response compromising parasite control in Leishmania co-
infection, resulting in frequent relapses especially in VL. Even though antiretroviral 
therapy has been shown to decrease the incidence of leishmaniasis in these patients, it 
does not seem to prevent relapses (18,20,23). Leishmania infection can promote HIV-1 
replication (17) and increases the degree of immune system activation (11). 
 
Our results show that VL patients have increased levels of immune activation, 
inflammation and microbial translocation compared to HIV-1-infected patients without 
leishmaniasis despite HIV-1 viral load suppression. All these effects may impair the 
immune effector function providing a mechanism for the parasite to relapse.  
 
We found that VL patients had lower levels of CD4 T cell counts compared to CR 
patients despite similar time under suppressive cART. This may be partially explained 
by the depletion of bone marrow precursor cells caused by Leishmania in individuals 
concomitantly infected with HIV-1 leading to deficiencies in the input of new 
lymphocytes into the periphery, though these values still remain superior to DR patients 
(24,25).  
 
Another contribution for this immunosuppression is the fact that VL patients have 
elevated levels of T cell activation compared to patients without leishmaniasis that lead 
to elevated T cell depletion. This elevated immune activation was independently 
associated with CD4/CD8 ratio, leishmaniasis and sCD14 levels, but not with the 
presence of VHC infection. Thus, the contribution of leishmaniasis to cell activation is 
stronger than that observed in VHC infection. Besides, this elevated immune activation 
was associated to an increase of T cell senescence, despite similar age of the groups 
studied, which might accelerate the impairment of the immune effector function.   
 
In addition, we have found that microbial translocation correlated with 
inflammation in VL patients that was only partially found among DR patients. Moreover, 
immune activation correlated with sCD14 in VL patients and again only partially among 
DR patients. sCD14 levels seem to be an important factor that reflects an increased 
monocyte/macrophage activation, as it has been described (11), and probably it could 
not be an adequate marker of bacterial translocation in patients with VL. These findings 
are in accordance to other reported works that shown an association between cellular 
activation and LPS levels in co-infected patients (26). The overactivation of 
monocyte/macrophage lineage could impair the phagocitosis of bacterial products 
leading to the increase of LPS levels observed in VL patients which might increase 
proinflammatory response and immune activation.  
 
In conclusion, leishmaniasis is a factor that strongly contributes to increase the 
severity of immunodeficiency caused by HIV-1, despite viral load suppression. 
Compared to DR patients, VL patients also have increased levels of T cell senescence 
that accelerates the deterioration of the immune system. Also, increased levels of 
inflammation and bacterial translocation, especially sCD14 levels, contribute to the 
persistent immune activation. Therefore, VL should be considered a possible 
independent cause of bacterial translocation, immune activation and impaired immune 
response in HIV-1 infection, despite viral load suppression.  
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 cART, combination antiretroviral therapy; CR, concordant response; DR, discordant response; significant when p<0.05, comparison VL vs CR and VL vs DR. 
 
 
 
 
 
 
 
 
Table 1 
 
       
 
 
Visceral Leishmaniasis (VL) patients 
 
N=8 
 DR patients  
N=14 
 
p 
CR patients  
N=15 
 
p 
 1 2 3 4 5 6 7 8       
Age (years) 55 45 44 43 41 51 45 51 45 [43-51]  47 [41-59] 0.664 45 [32-53] 0.728 
Gender (male %) M M M F F M M F 62.5  92.8  86.6  
Risk factors (%) 
     IDU 
     MSM 
     HSx 
 
- 
- 
1 
 
1 
- 
- 
 
1 
- 
- 
 
1 
- 
- 
 
1 
- 
- 
 
1 
- 
- 
 
1 
- 
- 
 
1 
- 
- 
 
87.5 
- 
12.5 
  
42.8 
42.8 
14.3 
  
13.3 
60 
26.7 
 
CD4 count (cells/mm3) 208 204 122 144 397 451 331 336 331 [145-667]  143 [88-159] 0.006 680 [527-825] <0.001 
CD8 count (cells/mm3) 564 1449 207 455 1587 1107 1063 912 679 [546-1029]  691 [569-850] 0.815 675 [544-906] 0.776 
CD4/CD8 ratio 0.37 0.21 0.59 0.23 0.25 0.41 0.31 0.37 0.42 [0.21-0.96]  0.19 [0.09-0.32] 0.035 1.0 [0.84-1.44] <0.001 
Nadir CD4 (cells/mm3) 70 13 8 27 61 35 89 33 34 [16-68]  50 [26-99] 0.441 202 [62-317] 0.001 
cART (months) 62 200 111 205 38 177 215 168 172 [74-203]  156 [97-197] 0.799 89 [43-144] 0.065 
HIV-1 suppression 
(months) 
59 125 26 203 16 28 76 126 59 [26-125]  69 [28-102] 0.799 63 [43-110] 0.824 
HCV infection (%) No Yes Yes Yes Yes No Yes Yes 75  57  13.3  
               
VL diagnosis (months) 65 181 20 35 39 170 42 153 53 [36-165]  -  -  
Relapses of VL 2 27 2 3 3 9 1 7 3 [2-8.5]  -  -  
 Table 2 Multivariate analysis: factors independently associated with immune activation 
(dependent variables CD4 and CD8 T cell activation). 
 
 
 
 
 
 
 
 
 
CD4 T cell activation  CD8 T cell activation 
 
Coefficient (95% CI) p  Coefficient (95% CI) p 
CD4 count 
CD4/CD8 ratio  
Nadir CD4 count 
 
Leishmaniasis 
VHC infection 
 
IL-6 
LPS 
sCD14 
-0.003 (-0.009-0.002) 
-2.470 (-4.881- -0.058) 
0.009 (-0.002-0.020) 
 
-8.810 (-18.029-0.409) 
 1.093 (-1.673-3.859) 
 
0.039 (-1.120-1.198) 
-0.064 (-0.191-0.063) 
4.081 (0.546-7.617) 
0.234 
0.045 
0.105 
 
0.060 
0.424 
 
0.945 
0.308 
0.025 
 
-0.001 (-0.015-0.012) 
-5.216 (-10.817-0.384) 
0.018 (-0.008-0.044) 
 
-21.850 (-43.259- -0.440) 
-2.334 (-8.757-4.090) 
 
0.843 (-1.849-3.535) 
-0.173 (-0.468-0.122 
13.199 (4.988-21.410) 
0.838 
0.067 
0.161 
 
0.046 
0.462 
 
0.525 
0.238 
0.003 
  
 
Figure 1: Levels in VL, DR and CR patients of CD4 count and CD4/CD8 ratio (A), and 
immune activation in CD4 and CD8 T cells (B). VL, visceral leishmaniasis patients; DR, 
discordant response patients; CR, concordant response patients. Significant when 
p<0.05. 
 
 
 
 
Figure 2. Inflamation (A) and microbial translocation (B) of VL patients and control 
groups. VL, visceral leishmaniasis patients; DR, discordant response patients; CR, 
concordant response patients. Significant when p<0.05. 
 
 
 
 
 
 
  
 
Figure 3: Levels of immunosenescence in CD4+ T cells (A) and CD8+ T cells (B). VL, 
visceral leishmaniasis patients; DR, discordant response patients; CR, concordant 
response patients. Significant when p<0.05. 
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ABSTRACT 
Background: Visceral leishmaniasis (VL) in HIV-1-infected patients has been 
associated with poor immunological recovery and frequent disease relapses. The aim 
of this study was to analyze the role of changes in T cell populations, Treg cells and 
CCR5 density compared with immunodiscordant HIV-1-infected patients without 
leishmaniasis. 
 
Methods: Cross-sectional study of eight VL patients receiving suppressive cART for at 
least one year, and both 14 HIV-1-infected patients with discordant immunological 
response (DR) and 13 HIV-1-infected patients with concordant immunological response 
(CR) without leishmaniasis. T-cell subpopulations, Treg cells, and CCR5 expression 
were analyzed. 
 
Results: In VL patients, CD8 effector cells were higher compared to CR patients 
(p=0.016), and CD4 Treg cells were similar compared to DR patients, but higher 
compared to CR patients (p<0.001). Interestingly, CD4 Treg CTLA-4+ cells were higher 
compared to either DR or CR patients (p=0.048 and p<0.001). The CD4 Treg/TEM 
ratio was similar to DR patients but higher compared to CR patients (p=0.038). While 
CD4+CCR5+ T-cells was higher compared to the DR patients (p=0.087) and CR 
patients (p<0.001), CD8+CCR5+ T-cells was higher compared to CR patients 
(p<0.001). Interestingly, CCR5 density in CD4+ and CD8+ T-cells among VL patients 
were higher compared to both DR and CR patients (p<0.005 in all cases). 
 
Conclusion: Leishmania/HIV-1-co-infected patients had worse immunological profile 
than the observed in immunodiscordant patients. A lower number of naïve T-cells, 
higher Treg inhibitory activity and a higher density of CCR5 receptors could explain the 
persistence and relapses of the pathogen and the associated immunodeficiency in 
these patients. 
 
INTRODUCTION 
 
Leishmania spp are intracelular protozoan parasites which cause two common 
diseases, i.e. cutaneous leishmaniasis and visceral leishmaniasis (VL). This last 
disease is common among HIV-1-infected individuals in the Mediterranean basin, 
including Spain with a prevalence of up to 9%, mainly among intravenous drug users, 
with a mortality rate of up to 50% (1,2). These protozoans are intracellular parasites 
that infect macrophage cell lineages from lymphoid organs and frequently produce 
persistent infection. Reactivation commonly occurs under conditions of 
immunossuppression associated with HIV coinfection.  
The development of effector T cell response to leishmaniasis and how memory T 
cells are generated and maintained in humans is not fully understood. 
Naturaly occurring regulatory T (nTreg) cells play a central role in maintaining 
self-tolerance. The regulation of adaptive immune responses is indispensable for the 
effective clearance of antigen without harm to self tissues. Although the importance of 
Tregs in this process is well established, evaluation in human disease is challenging 
because of the increasing recognition of the complexity of their phenotype and function.  
Persistent infections may represent a balance between pathogen and host. While 
the host attempts to maintain a strong effector immune function, pathogens strive to 
subvert host immunity to actively promote immunossuppression and pathogen 
persistence. nTreg cells may also suppress potencially beneficial immune responses, 
such as those directed against microbial pathogens as Leishmania and HIV.   
In animal models, a definitive role of Treg cells in causing suppression of local 
effector immune response by altered ratio of Treg and effector T cells was reported 
(suffi). Moreover, studies on the Treg cells and their role in suppression of effector T 
cells response among human VL patients are limited.  
Therefore, our objective was to analyze the balance of T cell subpopulation, 
especially effector memory cells, and to understand the status of Treg cells in terms of 
their frequency and function among VL patients. Since CCR5 expression on cells, 
including Treg cells, is essential for their trafficking from peripheral lymphoid tissues 
into infected sites driven by CCR5 ligands, we wanted to analyze whether the 
frequency and density of such receptor is altered in VL patients. 
MATERIAL AND METHODS 
Patients 
A cross-sectional, descriptive, comparative study was performed in eight HIV-1-
infected individuals with active visceral leishmaniasis (VL) from the Department of 
Infectious Diseases at the Universitary Hospital Ramón y Cajal, Madrid, Spain. All of 
them had been diagnosed for VL by parasitological diagnosis by direct visualization of 
amastigotes in bone marrow and peripheral blood, positive Leishmania-specific PCR 
on peripheral blood (21), as well as by clinical symptoms. All of them were treated with 
anti-Leismania treatment (liposomal amphotericina B, miltefosine or meglumine 
antimoniate, according to local guidelines (22)) and most of them received secondary 
prophylaxis based on monthly amphotericina B, or miltefosine). At inclusion, all of them 
had received cART for at least one year with sustained undetectable plasma HIV-1 
RNA (<50 copies/ml).  
As comparison groups of HIV-1-infected patients, we analyzed 13 patients with 
concordant response (CR patients, CD4 count above 400 cells/mm3) and 14 patients 
with discordant response (DR patients, CD4 count below 250 cells/mm3) with no 
coinfection with Leishmania and receiving suppressive cART (HIV-1 viral load lower 
than 50 RNA copies/ml) for at least one year. 
A single blood extraction was performed in all the patients. Blood was collected in 
Vacutainer tubes (Becton Dickinson, Madrid, Spain) and processed for both plasma 
and cytometry analysis. 
This study was carried out according to the recommendations of the Declaration 
of Helsinki and current Spanish legislation on clinical trials. It was approved by the 
AEMPS (Spanish Agency for Medications and Health Products) and our local 
Independent Ethics Committee (Hospital Ramon y Cajal, Madrid, Spain). All patients 
provided written informed consent for participation, sample collection, and laboratory 
determinations. 
Flow cytometry analysis of blood samples 
Fresh EDTA-anticoagulated whole blood was used to analyze CD4+ and CD8+ T 
cell subpopulations and quantify CCR5 density. 
Antibodies were from Becton Dickinson (Becton Dickinson, NJ, USA), and an 
unstained control was performed for all samples. Briefly, 100 µL of blood were lysed 
with FACS Lysing solution (Becton Dickinson) for 30 min at room temperature, 
incubated with the antibodies during 20 min at 4°C, washed and resuspended in PBS 
containing 1% azida. Cells were analyzed in a Gallios flow cytometer (Beckman-
Coulter, CA, USA). At least 30000 CD3+ T cells were collected for each sample and 
analyzed with Kaluza software (Beckman-Coulter) initially gating lymphocytes 
according to morphological parameters.  
T cells were stained to define subpopulations with the following antibody 
combination: CD3-allophycocyanin (APC)-Cy7, CD4-peridinin chlorophyll protein 
complex (PerCP), CD8-phycoerythrin (PE)-Cy7, CD45RA-phycoerythrin (PE), CCR7-
allophycocyanin (APC). The different subpopulations were defined as follows: naive 
cells, CD3+CD4+(CD8+)CD45RA+CCR7+; effector memory T cells (TEM) 
CD3+CD4+(CD8+)CD45RA-CCR7-; central memory T cells (TCM) 
CD3+CD4+(CD8+)CD45RA-CCR7+; and transitional memory T cells (TEMRA) 
CD3+CD4+(CD8+)CD45RA+CCR7-.   
Regulatory T cells (Treg) and their inhibitory function were analyzed using a 
combination of CD25-APC, FoxP3-PE (Human regulatory T cell staining kit, 
eBioscience), CD3-eFluor, CD4-PerCP and CD8-V500, CTLA-4-APC-Cy7 in 
permeabilized cells. 
The frequency of T cells expressing CCR5 receptor was analyzed with CCR5-
FITC, in combination with CD3-eFluor, CD4-PerCP and CD8-V500. Also, cell surface 
CCR5 density was quantified (Quifikit, Dako) using a series of 6 bead populations 
coated with different well-defined quantities of a mouse monoclonal antibody. The 
number of this monoclonal antibody molecules ranges from 0 to 500.000. Cells are 
labeled with primary mouse monoclonal antibody (purified CCR5, BD Pharmingen)) at 
saturating concentration. Then, cells are incubated, in parallel with the beads, with 
FITC-conjugated polyclonal anti-mouse immunoglobulins at suturing concentrations. A 
calibration curve is constructed using the fluorescence intensity of the individual bead 
populations against the number of molecules on the beads. The density on the 
specimen cells is then calculated by interpolation.   
Statistical analysis 
Continuous variables were expressed as the median and interquartile range and 
discrete variables as percentages. The t test for independent samples was used to 
compare normally distributed continuous variables and the Mann-Whitney test to 
compare non-normally distributed continuous variables. Categorical variables were 
described as proportions. The association between categorical variables was evaluated 
using the chi-square test. A Spearman correlation was used. Statistical analysis was 
performed using SPSS software 16.0 (Inc., Chicago, Illinois, USA). 
RESULTS 
Patients with VL had a median age of 45 years, similar to the age of the two 
control groups, with 62.5% of males. All but one were injecting drug users (IDUs) which 
is a different scenario compared to the risk factor of the other two control groups where 
patients with concordant response were predominantly men who have sex with men 
(MSM) (60%), and similar frequencies of IDUs and MSM were found within patients 
with discordant response (42.8% in both cases). Interestingly, while VL patients had 
significantly lower levels of CD4 count, CD4/CD8 ratio and CD4 nadir compared to CR 
patients (p<0.001, p<0.001, and p=0.001, respectively), they had higher levels of CD4 
count and CD4/CD8 ratio compared to DR patients (p=0.005 and p=0.038, 
respectively), and no significant differences in nadir CD4 count. On the other hand, all 
three groups of patients had similar duration of both cART and viral suppression. Most 
of the VL patients were infected with VHC (75%). Interestingly, most of the VL patients 
had a time of diagnosis of VL similar to the duration of cART (75%). Clinical and 
laboratory characteristics are shown in table 1. 
T cell subpopulations analysis 
VL patients had significant lower levels of naïve CD4+ T cells compared to both 
DR and CR patients (p<0.001 in both cases). This loss of naïve cells was recovered by 
a significant increase of TemRA (p=0.042) and an increase of TCM, although not 
significant (p=0.059). The level of TEM cells was not different compared to both DR 
and CR patients (Table 2). 
In the same way, naïve CD8+ T cells were lower in VL patients compared to DR 
and CR patients (p=0.024 and p<0.001, respectively). This was balanced by a 
significant increase of TCM cells (p<0.001 compared to DR and CR patients). Although 
TEM cells were not different from DR patients, they were higher compared to CR 
patients (p=0.016). No differences were found in the level of TemRA cells compared to 
any of the other two groups of patients (Table 2).  
Regulatory T cells and immune inhibitory function 
VL patients had no difference of either CD4 or CD8 Treg cells compared to DR 
patients. Nevertheless, they had significant higher levels of CD4 Treg cells compared 
to CR patients (p<0.001) (Figure 1A). 
Interestingly, CD4 Treg CTLA-4+ cells were significantly higher compared to 
either DR or CR patients (p=0.048 and p<0.001, respectively) (Figure 1B). No 
significant differences were found in CD8 Treg CTLA-4+ cells compared to either DR or 
CR patients. 
The CD4 Treg/TEM ratio in VL was significantly higher compared to CR patients 
(p=0.038), but not different compared to DR patients. No differences were found in 
CD8 Treg/TEM ratio in VL compared to the other group of patients (Figure 2).  
CCR5 frequency and receptor density 
While the frequency of CD4+ T cells bearing the CCR5 receptor in the VL patients 
was slightly higher compared to the DR patients, although not significant (p<0.087), it 
was significantly higher compared to CR patients (p<0.001). There was also a 
significant difference between the frequency found in DR patients compared to CR 
patients (p=0.005), lower in this last group (Figure 3). The frequency of CD8+ T cells 
expressing CCR5 in VL patients was again similar compared to DR patients (p=0.137), 
but significantly higher compared to CR patients (p<0.001). The frequency was also 
significantly higher in DR patients compared to CR patients (p=0.046).  
Interestingly, CCR5 density in CD4+ T cells among VL patients was significantly 
higher compared to both DR patients (p=0.004) and CR patients (p<0.001). On the 
other hand, the difference of CCR5 density between DR and CR patients was not 
significant (p=0.060). CCR5 density in CD8+ T cells was significantly higher in VL 
patients compared to both DR (p=0.003) and CR patients (p<0.001). In these cells, 
CCR5 density was significantly higher in DR patients compared to CR patients 
(p=0.028). 
DISCUSSION 
The frequent relapses observed in VL/HIV-1-infected patients could be evidence 
of a reduced ability to maintain the parasite under control due to an impaired immune 
function. Despite our results showed higher levels of TEM cells compared to CR 
patients but similar compared to DR patients, VL patients had higher inhibitory activity 
exerted by Treg cells and a higher CD4 Treg/TEM ratio compared to HIV-infected 
patients without leishmaniasis.  
The lower level of naïve T cells found in VL patients may evidence a poor 
renewal of T cell repertoire that can fight against the parasite. On the other hand, this 
low level of naïve T cells could be a consequence of the infection of Leishmania into 
the bone marrow impairing the maturation or even favoring the premature death of 
stem cells.  
Compared to DR patients, the naïve T cell deep depletion found in VL patients 
were balanced with two different mechanisms in CD4 or CD8 T cells, i.e., while TemRA 
increased in CD4 T cells, TCM increased in CD8 T cells. An expected increase in TEM 
cells, since they are coinfected with another pathogen, was not found in these 
individuals. 
Other factor that could contribute to the inefficient cell immune responses to 
maintain Leishmania under control is that despite similar levels of Treg cells, VL 
patients have higher levels of CD4 Treg inhibitory activity compared to other HIV-
infected patients without leishmaniasis, according to other works (Rai AK 2012). This 
elevated inhibitory activity affects also to HIV infection deteriorating the T cell 
homeostasis since Treg suppression affects not only to CD4 T cells, but also CD8 T 
cells, B cells, and innate cells, impairing both Leismania and HIV infection. Persistent 
presence of Treg cells and their inhibitory activity may play critical role in persistence of 
residual parasite burden even after clinically effective treatment, which may result in 
the relapse of the disease. 
T cell maturation from naïve to memory cells is characterized by an increase in 
CCR5 expression. Leishmania amastigotes might avoid activating macrophages by 
mimicking apoptotic cells and, therefore, inhibit macrophage activity by exposing 
phosphatidylserine (de Freitas). CCR5 plays a significant role in the entry and 
establishment of parasite infection in monocytes/macrophages. 
CCR5 receptor is generally displayed on all types of activated T cells, and its role 
is particularly important in the recruitment of overall T cell population to in inflammatory 
sites. Furthermore, CCR5 expression results upregulated in both in vitro (Dasgupta) 
and in vivo in a number of co-infections characterized by the accelerated disease 
progression of HIV-1 infection (Nigro). The expression of CCR5 on CD4+ T 
lymphocytes of HIV-1-infected subjects has been proved to be strongly related to HIV 
viral load (Yang). Furthermore, in subjects expressing a high density of CCR5 co-
receptor on CD3+ T cells, the progression of HIV-disease is accelerated in comparison 
with patients expressing a low quantity of CCR5 (Reynes 2). In our study, despite VL 
patients have similar levels of CCR5 on T cells compared to DR patients, but higher 
compared to CR patients, CCR5 density in T cells is higher compared to patients 
without Leishmania that might contribute to accelerate the progression of HIV disease 
and favors the infection of monocyte/macrophage by Leishmania. 
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cART, combination antiretroviral therapy; CR, concordant response; DR, discordant response; significant when p<0.05, comparison VL vs CR and VL vs DR. 
 
 
 
 
 
 
 
Table 1 
 
 
       
 
 
Visceral Leishmaniasis (VL) patients 
 
N=8 
 DR patients  
N=14 
 
p 
CR patients  
N=15 
 
p 
 1 2 3 4 5 6 7 8       
Age (years) 55 45 44 43 41 51 45 51 45 [43-51]  47 [41-59] 0.664 45 [32-53] 0.728 
Gender (male %) M M M F F M M F 62.5  92.8  86.6  
Risk factors (%) 
     IDU 
     MSM 
     HSx 
 
- 
- 
1 
 
1 
- 
- 
 
1 
- 
- 
 
1 
- 
- 
 
1 
- 
- 
 
1 
- 
- 
 
1 
- 
- 
 
1 
- 
- 
 
87.5 
- 
12.5 
  
42.8 
42.8 
14.3 
  
13.3 
60 
26.7 
 
CD4 count (cells/mm3) 208 204 122 144 397 451 331 336 331 [145-667]  143 [88-159] 0.006 680 [527-825] <0.001 
CD8 count (cells/mm3) 564 1449 207 455 1587 1107 1063 912 679 [546-1029]  691 [569-850] 0.815 675 [544-906] 0.776 
CD4/CD8 ratio 0.37 0.21 0.59 0.23 0.25 0.41 0.31 0.37 0.42 [0.21-0.96]  0.19 [0.09-0.32] 0.035 1.0 [0.84-1.44] <0.001 
Nadir CD4 (cells/mm3) 70 13 8 27 61 35 89 33 34 [16-68]  50 [26-99] 0.441 202 [62-317] 0.001 
cART (months) 62 200 111 205 38 177 215 168 172 [74-203]  156 [97-197] 0.799 89 [43-144] 0.065 
HIV-1 suppression 
(months) 
59 125 26 203 16 28 76 126 59 [26-125]  69 [28-102] 0.799 63 [43-110] 0.824 
HCV infection (%) No Yes Yes Yes Yes No Yes Yes 75  57  13.3  
               
VL diagnosis (months) 65 181 20 35 39 170 42 153 53 [36-165]  -  -  
Relapses of VL 2 27 2 3 3 9 1 7 3 [2-8.5]  -  -  
Table 2 
 
 
 
VL patients                        DR patients                      CR patients                       P value 
 
N=8 N=14 N=15 VL vs DR VL vs CR DR vs CR 
CD4 T cell subpopulations      
      Naive 8,42 [6,21-11,46] 15,25 [13,21-21,70] 33,40 [27,36-40,44] <0.001 <0.001 <0.001 
      TCM 46,29 [45,88-48,30] 43,66 [24,20-46,41] 35,88 [26,35-41,86] 0,059 0.002 0.354 
      TEM 32,09 [30,64-34,90] 28,99 [25,13-50,17] 23,72 [22,09-26,71] 0,365 0.001 0.008 
      TemRA 11,51 [9,88-13,41] 9,86 [8,66-10,74] 5,20 [3,30-7,39] 0.042 <0.001 <0.001 
CD8 T cell subpopulations 
     
      Naive 10,03 [5,94-11,74] 14,56 [10,84-24,04] 26,72 [21,89-36,35] 0.024 <0.001 0.001 
      TCM 44,31 [43,68-44,89] 34,39 [29,24-37,26] 33,65 [28,51-35,23] <0.001 <0.001 0.652 
      TEM 32,90 [30,26-35,04] 35,48 [26,27-38,73] 25,46 [22,50-30,21] 0.330 0.016 0.007 
      TemRA 14,11 [12,63-14,86] 14,24 [12,41-18,54] 11,93 [7,43-16,64] 0.664 0.548 0.146 
  
 
Figure 1: Regulatory T (Treg) cells (A) and Treg inhibitory activity (B) in patients with 
visceral leishmaniasis (VL), with immunodiscordant response (DR) and with concordant 
response. 
 
 
 
 
 
Figure 2: Treg/TEM ratio in CD4+ and CD8+ T cells in patients with visceral 
leishmaniasis (VL), with immunodiscordant response (DR) and with concordant 
response. 
 
 
 
  
Figure 3: Frequency of CCR5+ T cells and receptor density in patients with visceral 
leishmaniasis (VL), with immunodiscordant response (DR) and with concordant 
response. 
